

CITATION REPORT

List of articles citing

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

DOI: 10.1038/34178
Nature, 1998, 391, 79-82.

Source: <https://exaly.com/paper-pdf/28893502/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2286	Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. <i>Nature</i> , 1998 , 393, 790-3	50.4	1015
2285	Differentiation and reversal of malignant changes in colon cancer through PPARgamma. 1998 , 4, 1046-52		867
2284	Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. 1998 , 4, 1053-7		530
2283	Interdomain communication regulating ligand binding by PPAR-gamma. <i>Nature</i> , 1998 , 396, 377-80	50.4	304
2282	Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. <i>Nature</i> , 1998 , 395, 137-43	50.4	1652
2281	Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids. 1998 , 12, 921-9		84
2280	T-lymphocytes and monocytes in atherogenesis. 1998 , 23, 168-77		41
2279	Recent advances in molecular genetics of cardiovascular disorders. 1998 , 4, 152-160		6
2278	Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. 1998 , 41, 1321-6		46
2277	Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. 1998 , 111, 1116-21		127
2276	Expression and cDNA cloning of porcine peroxisome proliferator-activated receptor gamma (PPARGamma). 1998 , 225, 89-96		51
2275	Receptor-interacting protein 140 interacts with and inhibits transactivation by, peroxisome proliferator-activated receptor alpha and liver-X-receptor alpha. 1998 , 146, 69-76		64
2274	Orphan nuclear receptors--new ligands and new possibilities. 1998 , 12, 3149-55		243
2273	The nuclear receptor PPARgamma - bigger than fat. 1998 , 8, 576-81		124
2272	PPARGamma in monocytes: less pain, any gain?. 1998 , 93, 153-5		140
2271	Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. 1998 , 93, 229-40		1560
2270	PPARGamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. 1998 , 93, 241-52		1541

2269	cis-parinaric acid is a ligand for the human peroxisome proliferator activated receptor gamma: development of a novel spectrophotometric assay for the discovery of PPARgamma ligands. 1998 , 431, 476-80	22
2268	Peroxisome proliferator-activated receptor gamma1 (PPAR-gamma1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation. 1998 , 434, 394-400	17
2267	Insulin-independent glucose transport regulates insulin sensitivity. 1998 , 436, 301-3	79
2266	A gut check for PPARgamma. 1998 , 115, 1283-5	9
2265	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 1998 , 41, 5020-36	275
2264	Induction of PPARgamma1 expression in human THP-1 monocytic leukemia cells by 9-cis-retinoic acid is associated with cellular growth suppression. 1998 , 251, 842-8	21
2263	Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. 1998 , 153, 17-23	489
2262	Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. 1998 , 153, 349-54	92
2261	Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. 1998 , 83, 1097-103	519
2260	Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. 1998 , 273, 25573-80	715
2259	Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. 1998 , 12, 1594-604	148
2258	Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent. 1998 , 273, 26652-61	45
2257	Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARgamma-expressing tissue. 1998 , 273, 30131-8	52
2256	PPARgamma: from adipose tissue to the atherosclerotic plaque. 1998 , 139, 363-4	4
2255	Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. 1998 , 273, 32833-41	425
2254	Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. 1998 , 95, 7614-9	622
2253	Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. 1998 , 95, 8806-11	694
2252	Cell proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells incubated with eicosapentaenoic acid. 1998 , 336 (Pt 2), 451-9	84

2251	PPAR γ in Adipocyte Differentiation. 1999 , 77, 16	8
2250	A role for preadipocytes as macrophage-like cells. 1999 , 13, 305-12	256
2249	Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. 1999 , 10, 245-57	319
2248	Peroxisome proliferator-activated receptor gamma activation in human breast cancer. 1999 , 15, 967-73	11
2247	Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. 1999 , 15, 1027-31	21
2246	p120 acts as a specific coactivator for 9-cis-retinoic acid receptor (RXR) on peroxisome proliferator-activated receptor-gamma/RXR heterodimers. 1999 , 13, 1695-703	23
2245	Pharmacological peroxisome proliferator-activated receptor gamma ligands: emerging clinical indications beyond diabetes. 1999 , 8, 1859-1872	17
2244	Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. 1999 , 140, 3245-54	41
2243	A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on α P2 gene expression detected using branched DNA messenger RNA quantitation. 1999 , 13, 410-7	44
2242	Corn oil rapidly activates nuclear factor-kappaB in hepatic Kupffer cells by oxidant-dependent mechanisms. 1999 , 20, 2095-100	31
2241	Peroxisome proliferator-activated receptor gamma gene locus is related to body mass index and lipid values in healthy nonobese subjects. 1999 , 19, 2940-4	28
2240	PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. 1999 , 19, 546-51	324
2239	9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. 1999 , 19, 2105-11	31
2238	Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor alpha. Importance of alpha-helical structure in the transactivating function. 1999 , 274, 35152-8	38
2237	Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. 1999 , 274, 18702-8	68
2236	Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. 1999 , 20, 1905-11	161
2235	Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. 1999 , 96, 4668-73	301
2234	Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation. 1999 , 274, 12632-41	123

2233	Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. 1999 , 179, 1485-94	133
2232	Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. 1999 , 33, 943-8	72
2231	COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. 1999 , 8, 1521-1536	46
2230	Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. 1999 , 19, 59-66	92
2229	Commentary: aging, differentiation-dependent gene expression, and fat cell function. 1999 , 54, B189-90; discussion B191	2
2228	Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. 1999 , 85, 394-402	442
2227	Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. 1999 , 274, 9116-21	416
2226	Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells. 1999 , 274, 18827-35	52
2225	Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. 1999 , 19, 2094-104	316
2224	Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. 1999 , 96, 11513-8	208
2223	Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. 1999 , 274, 10863-8	134
2222	Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. 1999 , 274, 15901-7	103
2221	Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. 1999 , 274, 17042-8	350
2220	Oxidative stress as a regulator of gene expression in the vasculature. 1999 , 85, 753-66	677
2219	Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. 1999 , 10, 564-70	168
2218	Thiazolidinediones: a new class of antidiabetic drugs. 1999 , 16, 179-92	350
2217	Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. <i>Nature</i> , 1999 , 400, 378-82	504 754
2216	Inducible cyclooxygenase may have anti-inflammatory properties. 1999 , 5, 698-701	1046

2215	Age-associated alterations in splenic iNOS regulation: influence of constitutively expressed IFN-gamma and correction following supplementation with PPARalpha activators or vitamin E. 1999 , 195, 127-36	42
2214	New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). 1999 , 160, 238-49	54
2213	An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. 1999 , 55, 932-43	152
2212	Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. 1999 , 42, 1433-8	79
2211	Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. 1999 , 55, 1535-46	90
2210	PPARgamma, the ultimate thrifty gene. 1999 , 42, 1033-49	534
2209	Analysis of beta-tubulin cDNAs from taxol-resistant Pestalotiopsis microspora and taxol-sensitive Pythium ultimum and comparison of the taxol-binding properties of their products. 1999 , 262, 857-68	16
2208	Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol. 1999 , 34, 497-502	15
2207	Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. 1999 , 100, 156-68	138
2206	Atherosclerotic plaque rupture: emerging insights and opportunities. 1999 , 84, 15J-20J	86
2205	Biphenotypic B/macrophage cells express COX-1 and up-regulate COX-2 expression and prostaglandin E(2) production in response to pro-inflammatory signals. 1999 , 29, 3793-803	38
2204	Peroxisome proliferator-activated receptors: nuclear control of metabolism. 1999 , 20, 649-88	2239
2203	Regulation of gene expression by dietary fat. 1999 , 19, 63-90	518
2202	Orphan nuclear receptors: shifting endocrinology into reverse. 1999 , 284, 757-60	427
2201	Orphan nuclear receptors: from gene to function. 1999 , 20, 689-725	564
2200	Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. 1999 , 31, 342-51	72
2199	Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. 1999 , 274, 32048-54	836
2198	Mechanisms by which Thiazolidinediones Enhance Insulin Action. 1999 , 10, 9-13	65

2197	Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. 1999 , 3, 397-403	963
2196	Loss-of-function mutations in PPAR gamma associated with human colon cancer. 1999 , 3, 799-804	438
2195	Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. 1999 , 262, 129-32	79
2194	Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. 1999 , 147, 85-92	80
2193	Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family. 1999 , 155, 51-60	25
2192	Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulinitis and diabetes. 1999 , 44, 107-14	33
2191	Medical significance of peroxisome proliferator-activated receptors. 1999 , 354, 141-8	402
2190	Cyclooxygenase-dependent signalling: molecular events and consequences. 1999 , 445, 1-5	33
2189	Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. 1999 , 452, 277-82	49
2188	Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line. 1999 , 452, 301-4	12
2187	Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. 1999 , 454, 27-30	73
2186	Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors. 1999 , 463, 205-10	7
2185	Receptors for oxidized low density lipoprotein. 1999 , 1436, 279-98	172
2184	Prostaglandin D2 and sleep regulation. 1999 , 1436, 606-15	118
2183	Ligand selectivity of the peroxisome proliferator-activated receptor alpha. 1999 , 38, 185-90	247
2182	A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. 1999 , 144, 251-61	65
2181	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. 1999 , 145, 1-15	29
2180	Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. 1999 , 254, 757-63	168

2179	Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. 1999 , 254, 582-6	193
2178	Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. 1999 , 260, 122-6	99
2177	Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. 1999 , 261, 833-7	71
2176	PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. 1999 , 261, 456-8	146
2175	15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. 1999 , 262, 579-85	107
2174	Peroxisome proliferator-activated receptor gamma1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia. 1999 , 263, 749-53	24
2173	Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. 1999 , 264, 441-8	51
2172	Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. 1999 , 19, 8182-98	481
2171	The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. 1999 , 66, 733-9	244
2170	Vessel and Inflammation. 1999 , 151-192	
2169	Fibrates, dyslipoproteinaemia and cardiovascular disease. 1999 , 10, 561-74	110
2168	Lipidology. 1999 , 10, 64	
2167	Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. 1999 , 10, 485-90	45
2166	Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. 1999 , 10, 151-9	170
2165	Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. 1999 , 13, 1561-74	448
2164	Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. 2000 , 97, 13275-80	342
2163	Role of endocytosis in the transactivation of nuclear factor- B by oxidized low-density lipoprotein. 2000 , 350, 829	15
2162	Role of endocytosis in the transactivation of nuclear factor- B by oxidized low-density lipoprotein. 2000 , 350, 829-837	33

2161	Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. 2000 , 20, 558-67	523
2160	Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. 2000 , 11, 519-28	88
2159	Bimonthly update: lipidology. Atherosclerosis: cell biology and lipoproteins. 2000 , 11, 563-5	
2158	Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. 2000 , 36, 430-5	122
2157	Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells. 2000 , 60, 328-37	61
2156	Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. 2000 , 30, 3363-70	63
2155	PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. 2000 , 20, 350-66	30
2154	Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. 2000 , 31, 101-8	177
2153	Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. 2000 , 114, 681-7	92
2152	Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. 2000 , 12, 2215-23	189
2151	Effects of peroxisome proliferators on the thymus and spleen of mice. 2000 , 122, 219-26	107
2150	Resolution of inflammation. 2000 , 22, 1131-5	104
2149	The heat shock response inhibits NF-kappaB activation, nitric oxide synthase type 2 expression, and macrophage/microglial activation in brain. 2000 , 20, 800-11	62
2148	Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. <i>Nature</i> , 2000 , 403, 103-8	50.4 1225
2147	Nuclear pore complexes in the organization of silent telomeric chromatin. <i>Nature</i> , 2000 , 403, 108-12	50.4 266
2146	Cyclopentenone prostaglandins-new allies in the war on inflammation. 2000 , 6, 137-8	41
2145	Anti-inflammatory action of type I interferons deduced from mice expressing interferon beta. 2000 , 7, 817-25	17
2144	Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. 2000 , 129, 367-73	22

2143	Peroxisome proliferator-activated receptors in the cardiovascular system. 2000 , 129, 823-34	272
2142	Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. 2000 , 35, 521-32	253
2141	CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells. 2000 , 28, 305-10	41
2140	The 15-deoxy-delta(12,14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma (PPARGgamma) is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells. 2000 , 21, 436-40	46
2139	Nonsteroidal anti-inflammatory drugs in orthodontic tooth movement: metalloproteinase activity and collagen synthesis by endothelial cells. 2000 , 118, 203-9	39
2138	Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. 2000 , 62, 1-13	44
2137	15-deoxy-Delta(12,14)PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells. 2000 , 62, 23-32	33
2136	COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?. 2000 , 62, 33-43	39
2135	PPARGgamma: observations in the hematopoietic system. 2000 , 62, 45-73	46
2134	Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures. 2000 , 106, 95-104	67
2133	Nuclear receptor binding factor-2 (NRBF-2), a possible gene activator protein interacting with nuclear hormone receptors. 2000 , 1490, 189-97	24
2132	Peroxisome proliferator-activated receptors: insight into multiple cellular functions. 2000 , 448, 121-38	357
2131	Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. 2000 , 448, 179-92	44
2130	Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. 2000 , 60, 67-75	45
2129	Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. 2000 , 60, 1245-50	170
2128	Cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. 2000 , 867, 115-21	44
2127	Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. 2000 , 401, 259-70	109
2126	The effect of activation of peroxisome proliferator-activated receptor gamma (PPARGgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1. 2000 , 16, 131-5	9

2125	Regulation of TRAIL-induced apoptosis by transcription factors. 2000 , 201, 77-82	58
2124	Prostaglandins regulate melanoma-induced cytokine production in macrophages. 2000 , 204, 143-9	34
2123	Peroxisome proliferator-activated receptors, coactivators, and downstream targets. 2000 , 32 Spring, 187-204	176
2122	PPAR-mediated diverse responses in various tissues of mouse. 2000 , 32 Spring, 205-11	2
2121	Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. 2000 , 22, 319-41	84
2120	The effect of gamma-interferon to inhibit macrophage-high density lipoprotein interactions is reversed by 15-deoxy-delta12,14-prostaglandin J2. 2000 , 35, 1239-47	11
2119	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. 2000 , 2, 327-35	67
2118	New insights into the role of COX 2 in inflammation. 2000 , 78, 121-9	99
2117	Hormonal signaling and transcriptional control of adipocyte differentiation. 2000 , 130, 3116S-3121S	226
2116	Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. 2000 , 279, G238-44	119
2115	15-Deoxy-Delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. 2000 , 58, 837-44	46
2114	Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. 2000 , 20, 6862-7	241
2113	Cytotoxic Role of Nitric Oxide in Diabetes. 2000 , 785-810	12
2112	15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes. 2000 , 279, C1859-69	19
2111	Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. 2000 , 7, 77-82	11
2110	Molecular Regulation of Inducible Nitric Oxide Synthase. 2000 , 129-156	13
2109	Fatty acids and immune responses--a new perspective in searching for clues to mechanism. 2000 , 20, 431-56	163
2108	Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. 2000 , 40, 491-518	285

2107	Transcriptional control of adipogenesis. 2000 , 20, 535-59	265
2106	Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. 2000 , 22, 226-34	51
2105	Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. 2000 , 275, 32681-7	274
2104	Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. 2000 , 87, 596-602	161
2103	Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. 2000 , 164, 1498-504	68
2102	Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. 2000 , 164, 1046-54	178
2101	Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. 2000 , 102, 1834-9	149
2100	Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. 2000 , 275, 4541-4	298
2099	Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. 2000 , 275, 14388-93	86
2098	Nuclear receptors in metabolic diseases. 2000 , 4, 377-396	4
2097	Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose : role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. 2000 , 20, 104-10	42
2096	Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. 2000 , 136, 609-16	159
2095	Structural basis of hematopoietic prostaglandin D synthase activity elucidated by site-directed mutagenesis. 2000 , 275, 31239-44	51
2094	Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. 2000 , 59, 245-54	56
2093	Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. 2000 , 14, 307-16	70
2092	Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. 2000 , 20, 4699-707	334
2091	Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. 2000 , 20, 5343-9	324
2090	Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. 2000 , 165, 6525-31	109

2089	Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques: relevance to progression of atherosclerosis. 2000 , 102, 2569-75	30
2088	Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. 2000 , 101, 235-8	472
2087	Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. 2000 , 87, 516-21	266
2086	Large scale gene expression analysis of cholesterol-loaded macrophages. 2000 , 275, 37324-32	101
2085	Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. 2000 , 20, 1692-8	249
2084	Expression and function of PPARgamma in rat and human vascular smooth muscle cells. 2000 , 101, 1311-8	408
2083	Peroxisome proliferator-activated receptors and hepatic stellate cell activation. 2000 , 275, 35715-22	368
2082	Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. 2000 , 275, 12243-50	111
2081	CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. 2000 , 101, 2411-7	374
2080	Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. 2000 , 275, 22435-41	175
2079	The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. 2000 , 164, 1364-71	407
2078	Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. 2000 , 275, 36703-7	365
2077	Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. 2000 , 97, 4363-8	133
2076	Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. 2000 , 21, 823-6	111
2075	Feedback control of cyclooxygenase-2 expression through PPARgamma. 2000 , 275, 28028-32	223
2074	Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. 2000 , 164, 6503-8	267
2073	The Function of Nitric Oxide in the Immune System. 2000 , 443-492	33
2072	Sigmund Freud's final exit: guideline for assisted suicide. 2000 , 160, 117; author reply 118	

2071	Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. 2000 , 20, 290-7	195
2070	Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. 2000 , 165, 6941-8	137
2069	Regulation of lipid and lipoprotein metabolism by PPAR activators. 2000 , 38, 3-11	184
2068	Macrophage control of mycobacterial growth induced by picolinic acid is dependent on host cell apoptosis. 2000 , 164, 389-97	56
2067	Pathophysiology and pharmacological treatment of insulin resistance. 2000 , 21, 585-618	222
2066	Peroxisome proliferator-activated receptors and skin development. 2000 , 54, 269-74	38
2065	Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. 2000 , 54, 275-80	52
2064	Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. 2000 , 275, 1241-6	143
2063	A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. 2000 , 275, 5754-9	222
2062	Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. 2000 , 378, 364-76	32
2061	Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. 2000 , 267, 345-9	203
2060	Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. 2000 , 270, 400-5	290
2059	Retinoic acid inhibits nitric oxide synthase-2 expression through the retinoic acid receptor-alpha. 2000 , 270, 846-51	40
2058	Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. 2000 , 273, 485-91	71
2057	The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. 2000 , 273, 1144-9	42
2056	Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. 2000 , 275, 406-11	49
2055	COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. 2000 , 355, 646-8	225
2054	PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. 2000 , 21, 469-74	327

2053	Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. 2000 , 1497, 148-54	67
2052	Inflammation and Alzheimer's disease. 2000 , 21, 383-421	3490
2051	Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?. 2000 , 21, 441-5; discussion 451-3	95
2050	Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. 2000 , 62, 119-27	61
2049	Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. 2000 , 35, 1232-6	41
2048	Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. 2000 , 26, 21-6	32
2047	PPAR delta functions as a prostacyclin receptor in blastocyst implantation. 2000 , 11, 137-42	81
2046	Inhibitory effects of PGD2, PGJ2 and 15-deoxy-delta12,14-PGJ2 on iNOS induction in rat mesenteric artery. 2000 , 66, 2173-82	11
2045	Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. 2000 , 67, 863-76	242
2044	Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. 2000 , 67, 2093-101	23
2043	Troglitazone and related compounds: therapeutic potential beyond diabetes. 2000 , 67, 2405-16	47
2042	Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. 2000 , 467, 259-62	33
2041	Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. 2000 , 486, 261-6	129
2040	Pathophysiology and Pharmacological Treatment of Insulin Resistance. 2000 , 21, 585-618	111
2039	Glutathione S-transferase polymorphisms and their biological consequences. 2000 , 61, 154-66	768
2038	Thiazolidinedione-induced activation of the transcription factor peroxisome proliferator-activated receptor gamma in cells adjacent to the murine skeletal muscle: implications for fibroblast functions. 2000 , 439, 288-96	8
2037	15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. 2000 , 97, 4844-9	913
2036	Prostaglandin D synthase: structure and function. 2000 , 58, 89-120	222

2035	A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. 2000 , 14, 1550-6	143
2034	Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. 2000 , 119, 466-78	351
2033	The PPARs: from orphan receptors to drug discovery. 2000 , 43, 527-50	1561
2032	Cellular and molecular mechanisms of Alzheimer's disease inflammation. 2001 , 3-49	
2031	Toll-like receptors and innate immunity. 2001 , 78, 1-56	249
2030	PPARS in inflammation, atherosclerosis and thrombosis. 2001 , 8, 187-94	26
2029	Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. 2001 , 44, 2061-4	69
2028	25-hydroxycholesterol induces lipopolysaccharide-tolerance and decreases a lipopolysaccharide-induced TNF-alpha secretion in macrophages. 2001 , 158, 61-71	34
2027	Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. 2001 , 120, 9-19	28
2026	Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. 2001 , 90 Suppl 3, 125-32	38
2025	Oxidized LDL and HDL: antagonists in atherothrombosis. 2001 , 15, 2073-84	315
2024	Peroxisome proliferator-activated receptor gamma and metabolic disease. 2001 , 70, 341-67	515
2023	Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. 2001 , 282, 717-22	39
2022	15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages. 2001 , 283, 344-6	51
2021	Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. 2001 , 284, 1065-70	33
2020	PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. 2001 , 286, 541-6	46
2019	Prostaglandin J(2) inhibition of mesangial cell iNOS expression. 2001 , 98, 337-45	52
2018	Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. 2001 , 267, 73-80	36

2017	Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. 2001 , 17, 215-21	64
2016	The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu ²⁺ ,Zn ²⁺ -superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. 2001 , 50, 3-11	251
2015	Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. 2001 , 50, 283-7	27
2014	Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. 2001 , 65, 23-9	46
2013	Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. 2001 , 39, 449-57	85
2012	Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. 2001 , 22, 937-44	154
2011	Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. 2001 , 175, 81-92	262
2010	New roles for PPARs in cholesterol homeostasis. 2001 , 22, 441-3; discussion 444	13
2009	Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. 2001 , 56, 181-212	31
2008	Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). 2001 , 7, 395-400	126
2007	Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. 2001 , 1, 803-12	88
2006	15-Deoxy-delta(12,14)-prostaglandin J2 is a negative regulator of macrophage functions. 2001 , 1, 2101-8	13
2005	A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. 2001 , 7, 161-71	1141
2004	A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. 2001 , 8, 737-47	264
2003	Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. 2001 , 496, 12-8	170
2002	15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. 2001 , 501, 24-30	74
2001	Atherosclerosis. the road ahead. 2001 , 104, 503-16	2455
2000	Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. 2001 , 15, 1-9	22

1999	Immunological aspects of alzheimer's disease: therapeutic implications. 2001 , 15, 325-37	14
1998	Opportunities for the treatment of inflammation in cardiovascular disease. 2001 , 2, 1751-63	1
1997	Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. 2001 , 345, 1515-21	1013
1996	Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. 2001 , 21, 93-8	53
1995	Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. 2001 , 166, 2018-24	399
1994	Cyclooxygenase-independent actions of cyclooxygenase inhibitors. 2001 , 15, 2057-72	642
1993	beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. 2001 , 21, 1179-88	564
1992	Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. 2001 , 281, F1036-46	60
1991	Pharmacological separation of the expression of tissue transglutaminase and apoptosis after chemotherapeutic treatment of HepG2 cells. 2001 , 59, 1388-94	7
1990	Gene Expression in Atherogenesis. 2001 , 86, 404-412	19
1989	Response of experimental retinal neovascularization to thiazolidinediones. 2001 , 119, 709-17	70
1988	Cyclooxygenase-2 downregulates inducible nitric oxide synthase in rat intestinal epithelial cells. 2001 , 281, G688-96	14
1987	Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. 2001 , 280, R1332-40	17
1986	New vistas in anti-inflammatory therapy. 2001 , 88, 289-95	1
1985	Molecular and cellular mediators of Alzheimer's disease inflammation. 2001 , 3, 131-157	42
1984	Effects of dietary conjugated linoleic acid in nursery pigs of dirty and clean environments on growth, empty body composition, and immune competence. 2001 , 79, 714-21	90
1983	Peroxisome proliferator-activated receptors in endothelial cell biology. 2001 , 12, 511-8	40
1982	Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?. 2001 , 12, 519-27	46

1981	15-deoxy-delta12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. 2001 , 12, 839-43	91
1980	Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection. 2001 , 14, 257-63	45
1979	. 2001 , 8, 187-194	62
1978	. 2001 , 8, 203-210	49
1977	Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. 2001 , 120, 1293-300	27
1976	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages. 2001 , 354, 225-32	17
1975	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor down-regulate platelet-activating-factor receptor expression in human macrophages. 2001 , 354, 225-232	24
1974	PPAR-gamma effects on the vasculature. 2001 , 49, 127-9	8
1973	Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. 2001 , 107, 135-42	1156
1972	Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. 2001 , 108, 15-23	572
1971	Potential roles of the peroxisome proliferator-activated receptor-gamma in macrophage biology and atherosclerosis. 2001 , 169, 461-4	32
1970	The pleiotropic functions of peroxisome proliferator-activated receptor gamma. 2001 , 79, 30-47	175
1969	[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells]. 2001 , 90, 470-7	3
1968	Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes. 2001 , 77, 79-85	54
1967	Peroxisome proliferator-activated receptor agonists prevent 25-OH-cholesterol induced c-jun activation and cell death. 2001 , 1, 10	12
1966	Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. 2001 , 15, 865-73	34
1965	Leukotrienes as targets in the gut. 2001 , 1, 309-312	1
1964	Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. 2001 , 60, 14-30	220

1963	Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. 2001 , 59, 1899-910	157
1962	Mécanismes d'interruption de la réaction inflammatoire et leur contrôle. 2001 , 15, 11-15	
1961	Acides gras polyinsaturés et inflammation. 2001 , 15, 172-176	3
1960	The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. 2001 , 3, 149-59	172
1959	Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. 2001 , 21, 185-210	520
1958	Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. 2001 , 54, 59-70	58
1957	Multiple role of reactive oxygen species in the arterial wall. 2001 , 82, 674-82	204
1956	Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. 2001 , 44, 595-607	185
1955	A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. 2001 , 44, 1096-104	61
1954	Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. 2001 , 31, 2857-65	196
1953	New insights into inflammatory resolution. 2001 , 9, 125-130	1
1952	Sepsis-induced immunosuppression: from bad to worse. 2001 , 24, 273-87	103
1951	Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. 2001 , 33, 91-9	101
1950	Progress in cardiovascular biology: PPAR for the course. 2001 , 7, 23-4	61
1949	Hitting the reset button for immune tolerance. 2001 , 7, 24-5	1
1948	The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. 2001 , 7, 41-7	427
1947	PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. 2001 , 7, 48-52	942
1946	PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. 2001 , 7, 53-8	956

1945	Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. 2001 , 7, 699-705	543
1944	The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells. 2001 , 115, 28-35	67
1943	Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. 2001 , 116, 40-8	173
1942	Transcriptional regulation of prostaglandin-H-synthase-1 in the amnion-derived AV3 cell line. 2001 , 63, 123-31	
1941	Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner. 2001 , 66, 165-77	51
1940	15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells. 2001 , 66, 265-82	24
1939	Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. 2001 , 62, 1587-95	107
1938	Effects of 15-deoxy-delta(12,14) prostaglandin J(2) and interleukin-4 in Toll-like receptor-4-mutant glial cells. 2001 , 411, 223-30	7
1937	Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. 2001 , 417, 77-89	44
1936	Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. 2001 , 11, 764-8	306
1935	12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. 2001 , 11, 116-24	103
1934	Transcription factors. 2001 , 15, 657-75	13
1933	Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. 2001 , 276, 33471-7	124
1932	Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. 2001 , 21, 372-7	301
1931	Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2). 2001 , 276, 34082-8	39
1930	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. 2001 , 64, 75-80	55
1929	Peroxisome proliferator-activated receptors in inflammation control. 2001 , 169, 453-9	643
1928	Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. 2001 , 24, 392-7	141

1927	Enacting Stories, Seeing Worlds: Similarities and Differences in the Cross-Cultural Narrative Development of Linguistically Isolated Deaf Children. 2001 , 44, 311-336	67
1926	15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. 2001 , 276, 48950-5	113
1925	Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. 2001 , 104, 455-60	80
1924	Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. 2001 , 193, 827-38	371
1923	Narratives in Cultural Socialization. 2001 , 44, 337-339	
1922	Transcription factor-targeted therapies in inflammatory bowel disease. 2001 , 63 Suppl 1, 68-72	13
1921	The deprivation syndrome is the driving force of phylogeny, ontogeny and oncogeny. 2001 , 12, 217-87	10
1920	Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. 2001 , 38, 909-21	49
1919	PPARgamma/RXRalpha heterodimers control human trophoblast invasion. 2001 , 86, 5017-24	99
1918	Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?. 2001 , 86, 3250-6	113
1917	Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma -dependent and -independent pathways. 2001 , 276, 38297-306	35
1916	The selenoorganic compound ebselen suppresses liver injury induced by Propionibacterium acnes and lipopolysaccharide in rats. 2001 , 7, 321-7	16
1915	PPAR-ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. 2001 , 19, 465	2
1914	Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. 2001 , 276, 12440-8	222
1913	Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. 2001 , 15, 535-44	71
1912	Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. 2001 , 37, 722-7	117
1911	15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. 2001 , 276, 34545-52	76
1910	Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update. 2001 , 29, 224-31	31

1909	Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. 2001 , 98, 2610-5	255
1908	12/15-lipoxygenase translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic cells. 2001 , 276, 19431-9	58
1907	Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4. 2001 , 166, 2342-7	59
1906	15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. 2001 , 276, 35530-6	262
1905	Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. 2001 , 24, 688-93	114
1904	PPARalpha activators inhibit tissue factor expression and activity in human monocytes. 2001 , 103, 213-9	161
1903	Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. 2001 , 276, 45888-94	139
1902	Peroxisome proliferator-activated receptor-gamma activation inhibits interleukin-1beta -mediated platelet-derived growth factor-alpha receptor gene expression via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells. 2001 , 276, 12893-7	22
1901	Antiatherogenic effects of thiazolidinediones?. 2001 , 21, 295-6	15
1900	Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. 2001 , 166, 6742-8	89
1899	Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?. 2001 , 8, 203-10	17
1898	Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. 2001 , 87, 321-7	42
1897	Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. 2001 , 104, 109-14	82
1896	Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. 2001 , 166, 7104-11	94
1895	Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. 2001 , 86, 1306-12	179
1894	PPARgamma and atherosclerosis: effects on cell growth and movement. 2001 , 21, 1891-5	146
1893	Early de novo gene expression is required for 15-deoxy-Delta 12,14-prostaglandin J2-induced apoptosis in breast cancer cells. 2001 , 276, 47131-5	56
1892	Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. 2001 , 21, 365-71	357

1891	Anti-inflammatory mechanisms in the vascular wall. 2001 , 88, 877-87	339
1890	Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. 2001 , 164, 1487-94	173
1889	PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. 2001 , 276, 37731-4	903
1888	The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. 2001 , 276, 44258-65	217
1887	Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. 2001 , 104, 1670-5	184
1886	Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. 2001 , 21, 3057-70	149
1885	Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus. 2001 , 276, 45729-39	42
1884	Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. 2001 , 50, 660-6	81
1883	Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects. 2001 , 86, 3130-3	17
1882	Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. 2001 , 142, 3125-34	169
1881	Fast decline of hematopoiesis and uncoupling protein 2 content in human liver after birth: location of the protein in Kupffer cells. 2001 , 49, 440-7	9
1880	Effect of prostaglandin-J(2) on VEGF synthesis depends on the induction of heme oxygenase-1. 2002 , 4, 577-85	75
1879	Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. 2002 , 19, 1051-64	66
1878	Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. 2002 , 91, 210-7	55
1877	Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. 2002 , 105, 2296-302	311
1876	Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. 2002 , 277, 141-7	110
1875	Vascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies. 2002 , 30, 420-6	8
1874	Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. 2002 , 277, 9676-83	72

1873	85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. 2002 , 277, 33153-63	58
1872	Activation of the mouse heme oxygenase-1 gene by 15-deoxy-Delta(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2. 2002 , 4, 249-57	124
1871	Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. 2002 , 277, 34176-81	173
1870	Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. 2002 , 277, 6838-45	124
1869	Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. 2002 , 277, 3973-8	64
1868	Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. 2002 , 168, 2508-15	263
1867	A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition. 2002 , 168, 5318-25	27
1866	Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. 2002 , 168, 4747-55	67
1865	WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. 2002 , 169, 6806-12	87
1864	15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. 2002 , 168, 3563-9	101
1863	Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. 2002 , 51, 1507-14	157
1862	15-deoxy-Delta 12,14-PGJ2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. 2002 , 168, 1372-9	70
1861	The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. 2002 , 61, 997-1007	111
1860	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. 2002 , 16, 1861-8	101
1859	Dietary modification of inflammation with lipids. 2002 , 61, 345-58	544
1858	15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. 2002 , 277, 10459-66	322
1857	Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. 2002 , 105, 1240-6	231
1856	Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma: effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone. 2002 , 87, 4667-72	69

1855	How best to counteract the enemies? By controlling inflammation in the coronary circulation. 2002 , 4, G53-G65	1
1854	A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. 2002 , 7, 343-6	35
1853	Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. 2002 , 31, 1-10	45
1852	Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. 2002 , 7, 294-9	56
1851	Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. 2002 , 7, 283-9	58
1850	Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. 2002 , 277, 16913-9	39
1849	Novel insulin sensitizers: pharmacogenomic aspects. 2002 , 3, 99-116	31
1848	Upstream signal transduction of NF-kappaB activation. 2002 , 1, 137-49	34
1847	Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. 2002 , 16, 2793-801	217
1846	DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. 2002 , 16, 1029-39	88
1845	Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. 2002 , 24, 248-68	46
1844	Biology and toxicology of PPARgamma ligands. 2002 , 21, 429-37	23
1843	Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase 2. 2002 , 50, 84-9	17
1842	PPARgamma and vascular inflammation: adding another piece to the puzzle. 2002 , 91, 373-4	14
1841	PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. 2002 , 90, 703-10	281
1840	PPAR Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells. 2002 , 90, 348-355	
1839	Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. 2002 , 106, 3126-32	233
1838	Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. 2002 , 105, 1360-7	124

1837	Dualism of oxidized lipoproteins in provoking and attenuating the oxidative burst in macrophages: role of peroxisome proliferator-activated receptor-gamma. 2002 , 168, 2828-34	56
1836	Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. 2002 , 143, 2376-84	346
1835	Becoming fat. 2002 , 16, 1-5	51
1834	Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. 2002 , 16, 1027-40	329
1833	Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. 2002 , 168, 2795-802	203
1832	Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPLA(2)-IIA expression in alveolar macrophages through NF-kappaB and PPAR-gamma-dependent pathways. 2002 , 61, 786-94	41
1831	Pretreatment with troglitazone decreases lethality during endotoxemia in mice. 2002 , 8, 307-314	11
1830	Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. 2002 , 277, 1941-8	21
1829	Improvement of asthma after administration of pioglitazone. 2002 , 25, 401	25
1828	TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. 2002 , 277, 42821-9	186
1827	Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. 2002 , 302, 18-25	64
1826	Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. 2002 , 168, 6232-43	113
1825	Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. 2002 , 169, 1228-35	166
1824	Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. 2002 , 146, 545-51	29
1823	PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. 2002 , 90, 348-55	52
1822	Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells. 2002 , 169, 6831-41	46
1821	Rôles des Peroxisome Proliferator-Activated Receptors (PPARs) dans la régulation du métabolisme des lipides et le contrôle de l'inflammation. 2002 , 196, 47-52	33
1820	Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells. 2002 , 24, 130-8	39

1819	Genetics and molecular biology: a role for adipocyte lipid-binding protein in atherosclerosis. 2002 , 13, 93-5	1
1818	A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. 2002 , 8, 395-9	123
1817	Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. 2002 , 20, 1347-54	17
1816	Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. 2002 , 24, 184-90	41
1815	Biologic aspects of vulnerable plaque. 2002 , 17, 616-25	29
1814	Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. 2002 , 13, 305-12	21
1813	PPAR agonists in health and disease: a pathophysiologic and clinical overview. 2002 , 9, 285-302	12
1812	A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and ageing immunobiology. 2002 , 61, 363-9	25
1811	Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. 2002 , 363, 157-65	53
1810	Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor E-mediated transactivation. 2002 , 363, 157-165	83
1809	The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research. 2002 , 66, 783-90	17
1808	Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. 2002 , 132, 2019-27	124
1807	Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. 2002 , 76, 1249-55	257
1806	Fatty acids and gene expression related to inflammation. 2002 , 7, 19-36; discussion 36-40	20
1805	Inhibitory effect of peroxisome proliferator-activated receptor gamma agonist on ochratoxin A-induced cytotoxicity and activation of transcription factors in cultured rat embryonic midbrain cells. 2002 , 65, 407-18	23
1804	Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929. 2002 , 277, 192-200	52
1803	PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation. 2002 , 290, 707-12	20
1802	Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. 2002 , 18, 320-8	55

1801	Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages. 2002 , 160, 11-20	45
1800	Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. 2002 , 165, 101-10	41
1799	Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. 2002 , 122, 1924-40	357
1798	The role of transcription factors in allergic inflammation. 2002 , 110, 553-64	29
1797	Metabolic and additional vascular effects of thiazolidinediones. 2002 , 62, 1463-80	222
1796	Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. 2002 , 23, 599-622	1577
1795	Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. 2002 , 91, 1103-13	413
1794	The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. 2002 , 51, 2968-74	605
1793	The dawn of the SPPARs?. 2002 , 2002, pe9	35
1792	Epidermal anti-inflammatory properties of 5,11,14 20:3: effects on mouse ear edema, PGE2 levels in cultured keratinocytes, and PPAR activation. 2002 , 1, 5	17
1791	PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines. 2002 , 13, 2223-31	61
1790	Cyclooxygenase inhibition as a strategy to ameliorate brain injury. 2002 , 19, 1-15	95
1789	Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. 2002 , 108, 227-34	13
1788	Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. 2002 , 293, 274-83	50
1787	Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. 2002 , 293, 827-31	125
1786	Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. 2002 , 294, 597-601	57
1785	Inhibitory effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of IgE heavy chain germline transcripts in the human B cell line DND39. 2002 , 295, 547-52	15
1784	Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. 2002 , 297, 193-201	21

1783	Design of a chimeric promoter induced by pro-inflammatory mediators in articular chondrocytes. 2002 , 518, 67-71	3
1782	PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. 2002 , 520, 177-81	35
1781	Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. 2002 , 525, 43-7	62
1780	Lipopolysaccharide increases resistin gene expression in vivo and in vitro. 2002 , 530, 158-62	119
1779	Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system. 2002 , 71, 2037-52	6
1778	Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. 2002 , 103, 22-33	97
1777	Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. 2002 , 36, 249-55	61
1776	Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. 2002 , 51, 998-1002	7
1775	Effect of peroxisome proliferator-activated receptor gamma on thromboxane A(2) and prostaglandin E(2) production in macrophage cell lines. 2002 , 67, 245-51	2
1774	Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages. 2002 , 67, 435-43	60
1773	Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. 2002 , 22, 1-23	168
1772	[Nociceptors and mediators in acute inflammatory pain]. 2002 , 21, 315-35	25
1771	The peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in human heart ventricles. 2002 , 56, 407-10	15
1770	Inflammation and immune responses in atherosclerosis. 2002 , 23, 535-41	95
1769	The role of PPARs in atherosclerosis. 2002 , 8, 422-30	199
1768	Cyclooxygenases and prostaglandins: shaping up the immune response. 2002 , 2, 603-30	177
1767	PPAR and immune system--what do we know?. 2002 , 2, 1029-44	84
1766	Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis. 2002 , 13, 331-5	69

1765	Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism. 2002 , 1581, 89-99	243
1764	Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. 2002 , 104, 159-69	129
1763	The mechanisms of action of PPARs. 2002 , 53, 409-35	1974
1762	Statement of the Fourth International Consensus Conference in Critical Care on ICU-Acquired Pneumonia. 2002 , 11, 667-682	0
1761	Receptores activados por proliferadores peroxisómicos y aterosclerosis. 2002 , 14, 297-308	
1760	Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. 2002 , 91, 427-33	112
1759	The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). 2002 , 9, 233-42	33
1758	Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDL Receptor-Deficient Mice and Alters Aortic Gene Expression Determined by Microarray. 2002 , 105, 1360-1367	124
1757	Modulating Cardiac Hypertrophy by Manipulating Myocardial Lipid Metabolism?. 2002 , 105, 1152-1154	28
1756	PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. 2002 , 282, C125-33	71
1755	Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. 2002 , 25, 491-8	17
1754	PPAR. 2002 , 141-158	
1753	Ciglitazone Inhibits Plasmin-Induced Proinflammatory Monocyte Activation via Modulation of p38 MAP Kinase Activity. 2002 , 88, 274-281	24
1752	15-Deoxy- $\Delta^{12,14}$ -Prostaglandin J2 Inhibits Tissue Factor Expression in Human Macrophages and Endothelial Cells: Evidence for ERK1/2 Signaling Pathway Blockade. 2002 , 88, 524-532	33
1751	Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. 2002 , 10, 100-8	73
1750	Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. 2002 , 10, 673-9	69
1749	Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. 2002 , 10, 792-8	82
1748	15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. 2002 , 10, 845-8	43

1747	Colonic anti-inflammatory mechanisms of conjugated linoleic acid. 2002 , 21, 451-9	120
1746	Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. 2002 , 436, 7-13	43
1745	PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. 2002 , 448, 231-8	96
1744	Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. 2002 , 453, 149-58	39
1743	A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. 2002 , 90, 27G-33G	116
1742	Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. 2002 , 95, 47-62	83
1741	Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. 2002 , 54, 1627-56	108
1740	Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. 2002 , 63, 1-10	95
1739	Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. 2002 , 63, 1183-9	60
1738	UVB light suppresses nitric oxide production by murine keratinocytes and macrophages. 2002 , 64, 1469-81	15
1737	Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. 2002 , 924, 229-36	70
1736	Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. 2002 , 941, 1-10	126
1735	Vascular protective effects by activation of nuclear receptor PPARgamma. 2002 , 16, 46-9	34
1734	Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. 2002 , 16, 108-14	20
1733	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. 2002 , 16, 401-15	58
1732	Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. 2002 , 30, 1020-8	40
1731	Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?. 2002 , 14, 573-83	117
1730	Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. 2002 , 46, 598-605	29

1729	Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. 2002 , 46, 494-506	27
1728	Bisphenol a diglycidyl ether (BADGE) suppresses tumor necrosis factor-alpha production as a PPARgamma agonist in the murine macrophage-like cell line, RAW 264.7. 2002 , 26, 235-41	27
1727	Pivotal role of G-protein-coupled adenosine A2a receptors in protection of the liver against inflammation and ischemia-reperfusion injury. 2002 , 36, 1009-1011	1
1726	Hepatic stellate cells as a target for TZD: Can we treat liver fibrosis and type II diabetes at the same time?. 2002 , 36, 1011-1013	2
1725	PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. 2002 , 191, 310-9	42
1724	Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. 2002 , 51, 58-62	102
1723	Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. 2002 , 37, 487-94	32
1722	Orphan nuclear receptors find a home in the arterial wall. 2002 , 4, 213-21	21
1721	Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. 2002 , 4, 77-81	7
1720	Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. 2002 , 4, 514-21	27
1719	Peroxisome proliferator-activated receptor gamma and atherosclerosis. 2002 , 4, 71-7	21
1718	Statins: the new aspirin?. 2002 , 59, 1771-86	72
1717	Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides. 2002 , 17, 223-32	25
1716	Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. 2002 , 110, 458-68	76
1715	Prostaglandin and PPAR control of immune cell function. 2002 , 105, 20-2	16
1714	Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. 2002 , 118, 94-101	140
1713	Régulation redox de l'expression des gènes et contrôle par les nutriments. 2002 , 16, 240-247	2
1712	Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. 2002 , 82, 615-24	291

1711	15-Deoxy-Delta12,14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. 2002 , 61, 1957-67	45
1710	Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. 2002 , 62, 455-64	29
1709	Ciglitazone, Ligand of Peroxisome Proliferator-Activated Receptor- γ Inhibits Vascular Endothelial Growth Factor Activity. 2002 , 34, 127-130	7
1708	Role of Peroxisome Proliferator-Activated Receptor γ Ligands in the Vessel Wall. 2002 , 34, 121-126	
1707	Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. 2002 , 129, 379-84	27
1706	Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. 2002 , 32 Suppl 3, 24-34	199
1705	PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?. 2002 , 4, 239-48	17
1704	15-Deoxy-D12,14-prostaglandin J2 inhibits CX3CL1/fractalkine expression in human endothelial cells. 2002 , 80, 531-6	21
1703	Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. 2002 , 9, 513-26	53
1702	Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. 2002 , 9, 842-55	271
1701	Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. 2002 , 3, 59-70	192
1700	Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. 2002 , 21, 2171-80	96
1699	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. 2002 , 8, 1281-7	202
1698	Emerging roles of PPARs in inflammation and immunity. 2002 , 2, 748-59	722
1697	Anti-inflammatory lipid mediators and insights into the resolution of inflammation. 2002 , 2, 787-95	672
1696	15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. 2002 , 87, 1396-403	49
1695	Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. 2002 , 232, 95-126	423
1694	Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. 2002 , 277, 36076-84	71

1693	Genes involved in atherosclerosis. 2002 , 10, 150-63	9
1692	Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. 2002 , 26, 121-7	42
1691	Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. 2002 , 74, 155-65	72
1690	Analysis of tissue-specific and PPAR-dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method. 2002 , 239, 165-172	14
1689	NF-kappaB and breast cancer. 2002 , 26, 282-309	57
1688	Extensive plasma cell infiltration with crystal IgG inclusions and mutated IgV(H) gene in an osteoarthritis patient with lymphoplasmacellular synovitis. A case report. 2002 , 198, 45-50	7
1687	Nutrition impact of conjugated linoleic acid: A model functional food ingredient. 2002 , 38, 241-246	6
1686	Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. 2002 , 32, 7-22	41
1685	Induction and repression of peroxisome proliferator-activated receptor alpha transcription by coregulator ARA70. 2003 , 21, 139-46	9
1684	PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. 2003 , 79, 63-74	126
1683	Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. 2003 , 48, 2005-17	27
1682	Novel pituitary ligands: peroxisome proliferator activating receptor-gamma. 2003 , 6, 153-9	12
1681	Induction of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma during nitric oxide-induced apoptotic PC12 cell death. 2003 , 1010, 648-58	8
1680	Effects of conjugated linoleic acid on growth and cytokine expression in Jurkat T cells. 2003 , 90, 195-201	35
1679	N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. 2003 , 38, 343-52	407
1678	Anti-inflammatory properties of lipid oxidation products. 2003 , 81, 613-26	67
1677	Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators. 2003 , 7, 27-32	29
1676	The function of nuclear receptors in bone tissues. 2003 , 21, 323-36	5

1675	The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. 2003 , 17, 218-28	18
1674	Insulin as an anti-inflammatory and antiatherosclerotic hormone. 2003 , Suppl 4, S13-20	39
1673	15-Deoxy-delta 12,14-prostaglandin J2 inhibits the expression of granulocyte-macrophage colony-stimulating factor in endothelial cells stimulated with lipopolysaccharide. 2003 , 71, 293-9	9
1672	Cytokines, prostaglandins and parturition--a review. 2003 , 24 Suppl A, S33-46	447
1671	The potential contributions of chronic inflammation to lung carcinogenesis. 2003 , 5, 46-62	152
1670	Effect of 15-deoxy-delta 12,14-prostaglandin J2 on acute lung injury induced by lipopolysaccharide in mice. 2003 , 481, 261-9	16
1669	Opposing mechanisms of NADPH-cytochrome P450 oxidoreductase regulation by peroxisome proliferators. 2003 , 65, 949-59	22
1668	New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging. 2003 , 91, 17A-26A	18
1667	The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock. 2003 , 476, 257-8	19
1666	Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. 2003 , 71, 1-22	97
1665	Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. 2003 , 97, 35-53	51
1664	Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. 2003 , 142, 29-34	66
1663	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo. 2003 , 187, 80-8	41
1662	Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. 2003 , 7, 207-22	149
1661	TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. 2003 , 41, 3-14	56
1660	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-IIigand rosiglitazone. 2003 , 38, 1008-1017	568
1659	Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. 2003 , 89, 38-47	51
1658	Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice. 2003 , 90, 347-60	12

1657	Control of inflammatory diseases by pathogens: lipids and the immune system. 2003 , 33, 2953-63	41
1656	Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro. 2003 , 71, 246-55	26
1655	Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. 2003 , 71, 315-25	129
1654	Effects of peroxisome proliferator-activated receptor gamma ligands ciglitazone and 15-deoxy-delta 12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability. 2003 , 72, 747-55	26
1653	Involvement of c-jun N-terminal kinase activation in 15-deoxy-delta12,14-prostaglandin J2-and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells. 2003 , 37, 16-24	32
1652	Lipid Metabolism and Signaling in Zebrafish. 203-221	
1651	Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. 2003 , 48, 231-9	68
1650	Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. 2003 , 48, 3544-56	128
1649	Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis. 2003 , 86, 183-9	42
1648	Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. 2003 , 85, 690-6	83
1647	Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARGamma) in murine primary astrocytes and neurons. 2003 , 86, 907-16	43
1646	15-deoxy-delta12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. 2003 , 87, 742-51	39
1645	Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E2 synthesis. 2003 , 87, 1193-203	61
1644	Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. 2004 , 88, 494-501	299
1643	Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands. 2003 , 121, 757-64	23
1642	Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. 2003 , 121, 1104-17	91
1641	Rosiglitazone (PPARGamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. 2003 , 5, 45-50	54
1640	Effect of rebamipide on prostaglandin receptors-mediated increase of inflammatory cytokine production by macrophages. 2003 , 18 Suppl 1, 113-8	10

1639	PPARgamma and metabolism: insights from the study of human genetic variants. 2003 , 59, 267-77	61
1638	PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. 2003 , 94, 338-43	57
1637	Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. 2003 , 254, 597-604	74
1636	The cyclopentenone prostaglandin 15-deoxy-delta(12,14)- PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. 2003 , 138, 678-88	81
1635	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. 2003 , 139, 163-71	120
1634	Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. 2003 , 140, 366-76	81
1633	15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. 2003 , 83, 1529-39	36
1632	Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. 2003 , 83, 1715-21	97
1631	Mild hypothermia inhibits nuclear factor-kappaB translocation in experimental stroke. 2003 , 23, 589-98	111
1630	Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. 2003 , 5, 224-30	253
1629	Pioglitazone, a Specific Ligand of the Peroxisome Proliferator-Activated Receptor Gamma Reduces Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rat. 2003 , 38, 468-476	43
1628	A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. 2003 , 544, 181-96	173
1627	Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. 2003 , 79 Suppl 1, 763-9	36
1626	Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. 2003 , 124, 1265-76	329
1625	Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. 2003 , 166, 129-35	132
1624	Degree of oxidation of low density lipoprotein affects expression of CD36 and PPARgamma, but not cytokine production, by human monocyte-macrophages. 2003 , 168, 271-82	22
1623	Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones. 2003 , 169, 235-43	7
1622	Oxidised LDL decreases VEGFR-1 expression in human monocyte-derived macrophages. 2003 , 169, 259-67	8

1621	Apoptosis in human oral squamous cell carcinomas is induced by 15-deoxy-delta 12,14-prostaglandin J2 but not by troglitazone. 2003 , 82, 802-6	13
1620	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. 2003 , 42, 5429-37	66
1619	Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. 2003 , 352, 203-6	192
1618	Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. 2003 , 418, 186-96	85
1617	The vascular biology of atherosclerosis. 2003 , 115 Suppl 8A, 55S-61S	46
1616	Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). 2003 , 146, 613-20	89
1615	Regulation and differential expression of the c-maf gene in differentiating cultured cells. 2003 , 310, 318-26	21
1614	NF-kappa B-binding activity in an animal diet-induced overweightness model and the impact of subsequent energy restriction. 2003 , 311, 533-9	15
1613	Hematopoietic prostaglandin D synthase is expressed in microglia in the developing postnatal mouse brain. 2003 , 42, 263-74	53
1612	Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. 2003 , 9, 213-9	969
1611	Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. 2003 , 38, 434-40	102
1610	Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. 2003 , 550, 190-4	66
1609	2-Cyclopenten-1-one and prostaglandin J2 reduce restenosis after balloon angioplasty in rats: role of NF-kappaB. 2003 , 553, 21-7	15
1608	Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase. 2003 , 553, 419-22	14
1607	Reconstitution of lethally irradiated mice by cells isolated from adipose tissue. 2003 , 301, 1016-22	177
1606	15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. 2003 , 302, 415-20	59
1605	PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. 2003 , 303, 782-7	34
1604	Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. 2003 , 305, 557-65	65

1603	Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. 2003 , 308, 505-10	48
1602	Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. 2003 , 332, 61-7	23
1601	The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. 2003 , 171, 211-8	50
1600	Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. 2003 , 62, 1-8	25
1599	Hypothermia suppresses inducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells. 2003 , 110, 63-75	41
1598	Effect of endotoxin treatment on the expression of cyclooxygenase-2 and prostaglandin synthases in spinal cord, dorsal root ganglia, and skin of rats. 2003 , 116, 1043-52	27
1597	Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?. 2003 , 90, 133-40	30
1596	Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. 2003 , 5, 67-73	91
1595	A novel PGD(2) receptor expressed in eosinophils. 2003 , 69, 179-85	21
1594	Effect of 15-deoxy-delta12,14-prostaglandin J2 on IL-1beta-induced expression of epithelial neutrophil-activating protein-78 in human endothelial cells. 2003 , 69, 323-7	8
1593	Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. 2003 , 39, 1296-301	30
1592	PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. 2003 , 19, 329-39	78
1591	Activation of protein kinase C by phorbol esters in human macrophages reduces the metabolism of modified LDL by down-regulation of scavenger receptor activity. 2003 , 35, 1127-43	13
1590	Novel prostaglandin D(2)-derived activators of peroxisome proliferator-activated receptor-gamma are formed in macrophage cell cultures. 2003 , 1631, 35-41	11
1589	Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor in mice. 2003 ,	1
1588	Thioredoxin as a molecular target of cyclopentenone prostaglandins. 2003 , 278, 26046-54	136
1587	Animal Cell Technology: Basic & Applied Aspects. 2003 ,	1
1586	The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. 2003 , 88, 2412-21	148

1585	Signal Transduction by Reactive Oxygen and Nitrogen Species: Pathways and Chemical Principles. 2003,	16
1584	Molecular mechanisms underlying suppression of lymphocyte responses by nonsteroidal antiinflammatory drugs. 2003, 60, 1071-83	9
1583	Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. 2003, 20, 101-13	79
1582	Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. 2003, 112, 1821-1830	4446
1581	Obesity is associated with macrophage accumulation in adipose tissue. 2003, 112, 1796-1808	6264
1580	Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. 2003, 37 Suppl 2, S47-51	32
1579	Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. 2003, 63, 983-92	108
1578	Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. 2003, 278, 23270-7	176
1577	Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. 2003, 177, 207-14	20
1576	Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta 12,14-prostaglandin J2. 2003, 278, 19325-30	173
1575	Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. 2003, 198, 411-21	222
1574	Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from I κ B α -kinase inhibition and cell death induction. 2003, 17, 1099-101	26
1573	PPAR γ inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. 2003, 42, 844-50	72
1572	15-Deoxy-Delta12,14-prostaglandin J2 regulates endogenous Cot MAPK kinase 1 activity induced by lipopolysaccharide. 2003, 278, 52124-30	23
1571	Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. 2003, 278, 28181-92	147
1570	Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics. 2003, 60 Suppl 3, 51-5	2
1569	Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-delta12,14-prostaglandin J2. 2003, 63, 607-16	55
1568	Early stimulation and late inhibition of peroxisome proliferator-activated receptor gamma (PPAR gamma) gene expression by transforming growth factor beta in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads. 2003, 370, 1019-25	69

1567	Suppression of macrophage inflammatory responses by PPARs. 2003 , 100, 6295-6	30
1566	Preadipocyte conversion to macrophage. Evidence of plasticity. 2003 , 278, 9850-5	370
1565	Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. 2003 , 278, 10443-9	255
1564	Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2. 2003 , 278, 51251-60	118
1563	Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. 2003 , 278, 5828-36	132
1562	Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. 2003 , 42, 737-43	132
1561	Inhibition of IFN-gamma-mediated inducible nitric oxide synthase induction by the peroxisome proliferator-activated receptor gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, involves inhibition of the upstream Janus kinase/STAT1 signaling pathway. 2003 , 171, 979-88	56
1560	Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. 2003 , 278, 51340-6	73
1559	15-deoxy-delta(12,14)-prostaglandin J2 inhibits IFN-gamma-induced galectin-9 expression in cultured human umbilical vein endothelial cells. 2003 , 131, 57-61	18
1558	Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. 2003 , 58, 778-83	58
1557	Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. 2003 , 26, 2493-9	258
1556	Immunomodulation by polyunsaturated fatty acids: mechanisms and effects. 2003 , 132, 310-21	148
1555	Anti-inflammatory activity of 15-deoxy-delta12,14-PGJ2 and 2-cyclopenten-1-one: role of the heat shock response. 2003 , 64, 85-93	53
1554	A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. 2003 , 23, 289-94	85
1553	Activation of peroxisome proliferator-activated receptor gamma and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins. 2003 , 23, 475-82	62
1552	Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. 2003 , 171, 5743-50	93
1551	Therapeutic potential of thiazolidinediones as anticancer agents. 2003 , 12, 1925-37	68
1550	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. 2003 , 278, 13975-83	98

1549	Peroxisome proliferator-activated receptor gamma and ligands inhibit surfactant protein B gene expression in the lung. 2003 , 278, 36841-7	16
1548	Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. 2003 , 64, 355-64	48
1547	Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. 2003 , 42, 664-8	114
1546	15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. 2003 , 304, 349-55	72
1545	Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. 2003 , 307, 987-94	69
1544	PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. 2003 , 44, 1224-31	46
1543	The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms. 2003 , 170, 4578-92	28
1542	Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. 2003 , 171, 6827-37	176
1541	Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. 2003 , 170, 5295-301	78
1540	Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. 2003 , 170, 1043-51	80
1539	Potential of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. 2003 , 23, 1196-208	40
1538	Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. 2003 , 278, 45485-91	183
1537	15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. 2003 , 278, 14747-52	173
1536	Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARGamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy. 2003 , 5, 733-9	19
1535	Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. 2003 , 23, 52-7	262
1534	Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. 2003 , 108, 1994-9	65
1533	Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. 2003 , 64, 1169-79	60
1532	PPARs and atherosclerosis. 2003 , 33, 543-560	

1531	PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. 2003 , 100, 6712-7	366
1530	Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. 2003 , 16, 517-33	180
1529	Macrophage cholesterol transport: a critical player in foam cell formation. 2003 , 35, 146-55	57
1528	PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. 2003 , 23, 1461	
1527	Recent advances in peroxisome proliferator-activated receptor science. 2003 , 10, 267-80	89
1526	Analysis of small molecule metabolism in zebrafish. 2003 , 364, 408-26	11
1525	Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. 2003 , 23, 283-8	218
1524	Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. 2003 , 17, 1240-54	214
1523	PPARalpha agonist-induced rodent tumors: modes of action and human relevance. 2003 , 33, 655-780	479
1522	Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. 2003 , 29, 677-82	105
1521	Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. 2003 , 20, 56-62	27
1520	Lipid metabolism: inflammatory-immune responses in atherosclerosis. 2003 , 14, 337-9	4
1519	Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. 2003 , 14, 567-73	35
1518	The PPARgamma ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis. 2003 , 27, 58-66	33
1517	Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. 2003 , 14, 459-68	64
1516	Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. 2003 , 171, 5148-56	51
1515	Induction of epidermal fatty acid binding protein in intravascular monocytes of renal allografts. 2003 , 75, 685-8	5
1514	Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1beta in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation. 2003 , 23, 9233-44	106

1513	[Role of PPARgamma in inflammatory response related to mast cells]. 2003 , 122, 325-30	0
1512	Possible involvement of small oligomers of amyloid-beta peptides in 15-deoxy-delta 12,14 prostaglandin J2-sensitive microglial activation. 2003 , 91, 330-3	28
1511	Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). 2003 , 93, 347-55	36
1510	Peroxisome proliferator-activated receptors and the cardiovascular system. 2003 , 66, 157-88	35
1509	Inhibition of IFN-gamma -induced STAT1 activation by 15- deoxy-Delta 12,14-prostaglandin J2. 2003 , 284, E883-91	15
1508	Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. 2003 , 101, 545-51	193
1507	Diabetes mellitus and coronary artery disease: therapeutic considerations. 2003 , 5, 119-28	4
1506	Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. 2003 , 90, 611-9	23
1505	. 2003 ,	5
1504	PPARs: Nuclear Hormone Receptors Involved in the Control of Inflammation. 419-435	
1503	. 2003 ,	2
1502	PPARs in Atherosclerosis. 401-417	
1501	Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. 2003 , 133, 3058-64	63
1500	Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. 2003 , 77, 1220-8	67
1499	15-deoxy-delta 12,14-prostaglandin J2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells. 2003 , 285, H38-46	19
1498	Gene expression profiling of potential PPARgamma target genes in mouse aorta. 2004 , 18, 33-42	43
1497	[Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances.]. 2004 , 54, 448-64	17
1496	Eicosanoids and the Intestine. 423-429	

1495	Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes. 2004 , 5, 99-109	16
1494	Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. 2004 , 286, L613-9	57
1493	Mitochondrial Function in Cell Growth and Death. 2004 , 77-119	
1492	Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. 2004 , 2004, 156-166	72
1491	Angiotensin II, PPAR-gamma and atherosclerosis. 2004 , 9, 359-69	23
1490	Synergy between signal transducer and activator of transcription 3 and retinoic acid receptor-alpha in regulation of the surfactant protein B gene in the lung. 2004 , 18, 1520-32	34
1489	Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. 2004 , 94, 1168-78	431
1488	Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. 2004 , 25, 899-918	234
1487	Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. 2004 , 26, 497-505	17
1486	Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin J(2). 2004 , 24, 36-45	349
1485	Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. 2004 , 10, 695-700	62
1484	Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. 2004 , 30, 1-5	87
1483	Be fit or be sick: peroxisome proliferator-activated receptors are down the road. 2004 , 18, 1321-32	185
1482	Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. 2004 , 169, 195-200	140
1481	A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. 2004 , 311, 683-90	74
1480	Influence of peroxisome proliferator-activated receptor gamma activation by its endogenous ligand 15-deoxy Delta12,14 prostaglandin J2 on nitric oxide production in term placental tissues from diabetic women. 2004 , 10, 671-6	35
1479	Dietary lipids and immune function. 2004 , 349-393	
1478	Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. 2004 , 25, 530-6	46

1477	RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. 2004 , 10, 1508-20	25
1476	Protein thiol modification by 15-deoxy-Delta12,14-prostaglandin J2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes. 2004 , 66, 1349-58	75
1475	Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. 2004 , 279, 22057-65	86
1474	Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. 2004 , 43, 297-305	124
1473	Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. 2004 , 1, 76-81	16
1472	Evidence for a potent antiinflammatory effect of rosiglitazone. 2004 , 89, 2728-35	326
1471	Peroxisome proliferator-activated receptor gamma regulates eosinophil functions: a new therapeutic target for allergic airway inflammation. 2004 , 134 Suppl 1, 30-6	48
1470	Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. 2004 , 24, 230-9	129
1469	Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. 2004 , 279, 6883-92	107
1468	Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. 2004 , 279, 28411-8	41
1467	p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. 2004 , 279, 22138-44	49
1466	Reduction of atherosclerotic plaques by lysosomal acid lipase supplementation. 2004 , 24, 147-54	36
1465	Sensing environmental lipids by dendritic cell modulates its function. 2004 , 172, 54-60	48
1464	15-deoxy-Delta12,14-prostaglandin J2 inhibits glucocorticoid binding and signaling in macrophages through a peroxisome proliferator-activated receptor gamma-independent process. 2004 , 172, 7677-83	8
1463	15-deoxy-Delta12,14-prostaglandin J2 inhibits IFN-inducible protein 10/CXC chemokine ligand 10 expression in human microglia: mechanisms and implications. 2004 , 173, 3504-13	16
1462	The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. 2004 , 173, 5196-208	123
1461	Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer's disease. 2004 , 17, 225-31	31
1460	Peroxisome proliferator-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis associated with inhibition of self-sensitive T cells. 2004 , 43, 868-75	16

1459	Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. 2004 , 95, e45-55	84
1458	Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. 2004 , 44, 381-5	28
1457	Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. 2004 , 172, 5790-8	188
1456	Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. 2004 , 172, 7530-6	67
1455	Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. 2004 , 279, 16388-93	49
1454	Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin J2. 2004 ,	37
1453	Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. 2004 , 64, 5162-71	48
1452	15-deoxy-delta 12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. 2004 , 279, 21929-37	86
1451	Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. 2004 , 65, 309-18	32
1450	15-deoxy-delta12,14-prostaglandin J2-mediated ERK signaling inhibits gram-negative bacteria-induced RelA phosphorylation and interleukin-6 gene expression in intestinal epithelial cells through modulation of protein phosphatase 2A activity. 2004 , 279, 36103-11	25
1449	A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. 2004 , 101, 14461-6	149
1448	Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. 2004 , 279, 8300-15	81
1447	Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. 2004 , 53, 200-8	107
1446	Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. 2004 , 24, 607-12	27
1445	Synergistic anti-inflammatory activity of omega-3 lipid and rofecoxib pretreatment on macrophage proinflammatory cytokine production occurs via divergent NF-kappaB activation. 2004 , 28, 232-9; discussion 239-40	16
1444	Prostaglandin A2-mediated stabilization of p21 mRNA through an ERK-dependent pathway requiring the RNA-binding protein HuR. 2004 , 279, 49298-306	64
1443	Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. 2004 , 94, 609-16	340
1442	Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g. 2004 , 36, 534-44	19

1441	Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. 2004 , 23, 283-92	18
1440	PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. 2004 , 45, 2161-73	248
1439	1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility. 2004 , 42, 1-53	19
1438	Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control. 2004 , 64, 8135-8	27
1437	An inflammatory cascade leading to hyperresistinemia in humans. 2004 , 1, e45	361
1436	Lysosomal acid lipase deficiency causes respiratory inflammation and destruction in the lung. 2004 , 286, L801-7	73
1435	Hypoxia-reoxygenation enhances interleukin-8 production from U937 human monocytic cells. 2004 , 9, 365-9	3
1434	Molecular mechanisms of endotoxin tolerance. 2004 , 10, 71-84	348
1433	Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. 2004 , 24, 1259-65	95
1432	Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids. 2004 , 286, L808-16	60
1431	The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. 2004 , 61, 630-43	64
1430	Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists. 2004 , 58, 22-9	29
1429	The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. 2004 , 21, 1249-52	57
1428	Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. 2004 , 21, 1280-7	80
1427	Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. 2004 , 91, 521-36	185
1426	PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose. 2004 , 65, 961-71	11
1425	Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. 2004 , 65, 1647-53	53
1424	Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. 2004 , 65, 1664-75	72

1423	Multiple facets of macrophages in renal injury. 2004 , 66, 542-57	110
1422	Pioglitazone Prevents Acute Liver Injury Induced by Ethanol and Lipopolysaccharide Through the Suppression of Tumor Necrosis Factor- α . 2004 , 28, 139S-144S	7
1421	Abnormal TNF activity in Timp3 ^{-/-} mice leads to chronic hepatic inflammation and failure of liver regeneration. 2004 , 36, 969-77	251
1420	ComPPARtmentalizing NF-kappaB in the gut. 2004 , 5, 14-6	18
1419	Mindin the fort. 2004 , 5, 16-8	7
1418	The IKK NF-kappa B system: a treasure trove for drug development. 2004 , 3, 17-26	1125
1417	Inflammatory resolution: new opportunities for drug discovery. 2004 , 3, 401-16	596
1416	Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. 2004 , 5, 142-7	122
1415	Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. 2004 , 23, 100-8	177
1414	JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-O-tetradecanoylphorbol-13-acetate (TPA). 2004 , 90, 2017-24	23
1413	The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages. 2004 , 141, 1037-47	78
1412	<i>S. aureus</i> -dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta ^{12,14} - prostaglandin J ₂ (15d-PGJ ₂). 2004 , 90, 1163-72	37
1411	Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. 2004 , 199, 275-84	43
1410	Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. 2004 , 14, 8-12	64
1409	Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. 2004 , 148, 116-26	113
1408	15-deoxy-delta (12,14)-PGJ ₂ inhibits astrocyte IL-1 signaling: inhibition of NF-kappaB and MAP kinase pathways and suppression of cytokine and chemokine expression. 2004 , 153, 132-42	13
1407	Effect of administration of fish oil on aspects of cell-mediated immune response in periparturient dairy goats. 2004 , 55, 77-83	19
1406	Effect of nuclear factor-kappa B inhibitors and peroxisome proliferator-activated receptor-gamma ligands on PTHrP release from human fetal membranes. 2004 , 25, 699-704	14

1405	Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. 2004 , 73, 191-213	15
1404	15-deoxy-delta12,14-prostaglandin-J2 inhibits expression of eNOS in human endothelial cells. 2004 , 74, 11-28	10
1403	CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. 2004 , 41, 139-46	58
1402	Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. 2004 , 41, 187-95	33
1401	Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. 2004 , 483, 79-93	167
1400	Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. 2004 , 486, 233-5	21
1399	15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria. 2004 , 498, 295-301	28
1398	Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11. 2004 , 498, 257-65	10
1397	Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. 2004 , 39, 1095-100	50
1396	Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. 2004 , 94, 151-6	49
1395	Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins. 2004 , 37, 71-85	35
1394	Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way. 2004 , 67, 841-54	12
1393	Nuclear receptor signaling in macrophages. 2004 , 67, 201-12	79
1392	The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. 2004 , 67, 1259-67	24
1391	Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. 2004 , 67, 2141-65	56
1390	Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. 2004 , 1021, 140-5	62
1389	Peroxisome proliferator-activated receptor gamma; Its role in atherosclerosis and restenosis. 2004 , 5, 44-8	8
1388	Reciprocal expression of peroxisome proliferator-activated receptor-gamma and cyclooxygenase-2 in human term parturition. 2004 , 190, 809-16	37

1387	Inflammation in atherosclerosis and diabetes mellitus. 2004 , 5, 255-9	27
1386	What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?. 2004 , 27, IV11-6	15
1385	Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. 2004 , 20, 37-47	45
1384	Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. 2004 , 39, 461-8	31
1383	Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. 2004 , 296, 1-5	14
1382	Alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. 2004 , 296, 97-104	27
1381	Effects of insulin sensitizers on plaque vulnerability associated with elevated lipid content in atheroma in ApoE-knockout mice. 2004 , 41, 25-31	6
1380	Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway. 2004 , 24, 623-36	30
1379	PPAR-gamma in Cushing's disease. 2004 , 7, 265-9	20
1378	Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. 2004 , 30, 951-6	54
1377	15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. 2004 , 4, 6	35
1376	Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity. 2004 , 91, 1613-8	58
1375	Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. 2004 , 40, 376-85	76
1374	Decreased expression of peroxisome proliferator activated receptor gamma in cftr ^{-/-} mice. 2004 , 200, 235-44	62
1373	Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. 2004 , 20, 455-80	243
1372	Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. 2004 , 82, 976-85	41
1371	Novel medical approaches for the treatment of Cushing's disease. 2004 , 27, 591-5	7
1370	Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. 2004 , 27, 982-91	110

1369	Induction of reversible cysteine-targeted protein oxidation by an endogenous electrophile 15-deoxy-delta12,14-prostaglandin J2. 2004 , 17, 1313-22	47
1368	Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone. 2004 , 2, 137-42	11
1367	Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. 2004 , 279, 36093-102	143
1366	Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. 2004 , 127, 777-91	327
1365	The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. 2004 , 43, 464-73	87
1364	Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. 2004 , 113, 882-8	128
1363	Benzo[a]pyrene diol epoxide up-regulates COX-2 expression through NF-kappaB in rat astrocytes. 2004 , 151, 345-55	29
1362	Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?. 2004 , 13, 215-28	68
1361	Role of fibric acid derivatives in the management of risk factors for coronary heart disease. 2004 , 64, 2177-98	52
1360	PPARgamma, neuroinflammation, and disease. 2004 , 1, 5	32
1359	El ácido acetilsalicílico incrementa la expresión de CD36 en macrófagos THP-1 de forma independiente del receptor activado por proliferadores peroxisómicos gamma. 2004 , 16, 61-67	
1358	Dual role of oxidized LDL on the NF-kappaB signaling pathway. 2004 , 38, 541-51	116
1357	Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. 2004 , 27, 813-23	1001
1356	LXR-dependent gene expression is important for macrophage survival and the innate immune response. 2004 , 119, 299-309	434
1355	Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. 2004 , 113, 203-13	42
1354	IL-1 and LPS but not IL-6 inhibit differentiation and downregulate PPAR gamma in brown adipocytes. 2004 , 26, 9-15	26
1353	Inducible nitric oxide synthase activation by interleukin-17. 2004 , 15, 21-32	103
1352	Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. 2004 , 63, 19-26	10

1351	Prostanoids and prostanoid receptors in signal transduction. 2004 , 36, 1187-205	299
1350	15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-1beta-induced IKK enzymatic activity and IkkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway. 2004 , 572, 33-40	28
1349	Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. 2004 , 1673, 115-21	17
1348	Pravastatin up-regulates transforming growth factor-beta1 in THP-1 human macrophages: effect on scavenger receptor class A expression. 2004 , 314, 704-10	17
1347	15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-kappaB. 2004 , 314, 817-23	12
1346	Identification of gene polymorphism in lipocalin-type prostaglandin D synthase and its association with carotid atherosclerosis in Japanese hypertensive patients. 2004 , 322, 428-33	28
1345	Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. 2004 , 323, 782-8	42
1344	Role of PPARgamma in macrophage biology and atherosclerosis. 2004 , 15, 500-5	67
1343	Transcriptional regulation of genes for enzymes of the prostaglandin biosynthetic pathway. 2004 , 70, 115-35	24
1342	Conjugated linoleic acids: are they beneficial or detrimental to health?. 2004 , 43, 553-87	383
1341	Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. 2004 , 123, 131-45	475
1340	Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. 2004 , 164, 263-71	151
1339	Ciglitazone and 15d PGJ2 induce apoptosis in Jurkat and Raji cells. 2004 , 4, 1171-85	12
1338	The specific p38 mitogen-activated protein kinase pathway inhibitor FR167653 keeps insulinitis benign in nonobese diabetic mice. 2004 , 74, 1817-27	15
1337	Thiol antioxidant and thiol-reducing agents attenuate 15-deoxy-delta 12,14-prostaglandin J2-induced heme oxygenase-1 expression. 2004 , 74, 2451-63	25
1336	Review: Molecular mechanisms of endotoxin tolerance. 2004 , 10, 71-84	11
1335	Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. 2004 , 5, 419-29	377
1334	L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARalpha-independent expression. 2004 , 36, 2042-53	29

1333	Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. 2004 , 82 Suppl 3, 1008-13	107
1332	Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. 2004 , 25, 315-24	73
1331	Fatty acid binding proteins--the evolutionary crossroads of inflammatory and metabolic responses. 2004 , 134, 2464S-2468S	194
1330	Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. 2004 , 32, 457-66	45
1329	Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. 2004 , 29, 67-74	35
1328	Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. 2004 , 15, 955-60	32
1327	Peroxisome proliferator-activated receptor-gamma ligands: a pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndrome. 2004 , 32, 604-5	25
1326	The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. 2004 , 22, 555-61	48
1325	The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. 2004 , S37-46	191
1324	Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. 2004 , 32, 826-31	49
1323	Fatty acid-mediated inhibition of IL-12 production by murine macrophages is independent of PPARgamma. 2004 , 91, 733-9	14
1322	Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. 2004 , 44, 682-7	45
1321	Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. 2004 , 15, 877-81	20
1320	Effects of long-term intake of edible oils on hypertension and myocardial and aortic remodelling in spontaneously hypertensive rats. 2004 , 22, 921-9	29
1319	Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. 2004 , 104, 1361-8	175
1318	Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells. 2004 , 382, 83-91	24
1317	Lipid oxidation in atherogenesis: an overview. 2004 , 32, 134-8	64
1316	The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. 2004 , 107, 461-6	36

1315	15-Deoxy-delta(12,14)-prostaglandin J2 inhibits the IL-1beta-induced expression of granulocyte-macrophage colony-stimulating factor in BEAS-2B bronchial epithelial cells. 2004 , 202, 69-76	8
1314	Physiology and pharmacology of the prostaglandin J2 family. 2004 , 123, 34-40	5
1313	Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. 2004 , 96, 134-43	27
1312	Polyunsaturated fatty acids and inflammation. 2004 , 11, 38-45	2
1311	Heart failure, diabetes and the thiazolidinediones: an unfolding story. 2005 , 2, 159-161	
1310	The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. 2005 , 64, 797-805	59
1309	A pivotal role for PPR gamma in innate immune homeostasis?. 2005 , 40 Suppl 1, S9	
1308	Regulation of TRAIL-Induced Apoptosis by Transcriptional Factors. 2005 , 297-303	
1307	Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. 2005 , 33, 2309-16	99
1306	The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. 2005 , 16, 543-8	149
1305	Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. 2005 , 23, 393-9	120
1304	15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. 2005 , 24, 59-65	74
1303	Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. 2005 , 4, 386-90	16
1302	Recent Advances in Peroxisome Proliferator- Activated Receptor Science. 2005 , 2, 233-251	
1301	15-Deoxy-Delta12,14-prostaglandin J2 and peroxisome proliferator-activated receptor gamma (PPARGamma) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPARGamma agonist on nitridergic and lipid placental metabolism. 2005 , 17, 423-33	27
1300	Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor gamma in mast cells: its roles in proliferation and differentiation. 2005 , 97, 190-4	16
1299	PPARGamma as a therapeutic target for tumor angiogenesis and metastasis. 2005 , 4, 687-93	108
1298	Food components and immune function. 2005 , 16, 31-7	37

1297	Role of immunologic and inflammatory factors in the development of endometriosis: indications for treatment strategies. 2005 , 2, 623-639	16
1296	Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor gamma and cytokines in bone marrow-derived mesenchymal stem cells. 2005 , 97, 184-9	20
1295	Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. 2005 , 208, 249-58	261
1294	The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. 2005 , 12, 493-504	12
1293	Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. 2005 , 13, 317-30	22
1292	The role of phospholipases in lipid modification and atherosclerosis. 2005 , 5, 161-82	14
1291	Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. 2005 , 92, 895-903	49
1290	Novel determinants of plaque instability. 2005 , 3, 1962-75	34
1289	Bezafibrate suppresses rat antglomerular basement membrane crescentic glomerulonephritis. 2005 , 67, 1821-9	12
1288	The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. 2005 , 68, 529-36	38
1287	The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. 2005 , 22, 278-82	90
1286	Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. 2005 , 10 Suppl, S40-3	35
1285	Peroxisome proliferator-activated receptor gamma: the more the merrier?. 2005 , 35, 82-92; discussion 80	53
1284	'PPAR'ting ways with inflammation. 2005 , 6, 966-7	39
1283	Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. 2005 , 4, 977-87	619
1282	Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. 2005 , 29, 140S-145S	115
1281	The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. 2005 , 11, 231-43	83
1280	Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). 2005 , 44, 328-33	66

1279	A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. <i>Nature</i> , 2005 , 437, 759-63	50.4	1006
1278	Liver X receptor agonists inhibit tissue factor expression in macrophages. 2005 , 272, 1546-56		63
1277	Signal pathways underlying homocysteine-induced production of MCP-1 and IL-8 in cultured human whole blood. 2005 , 26, 85-91		22
1276	Turning down the system: counter-regulatory mechanisms in bone and adaptive immunity. 2005 , 208, 66-79		10
1275	Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. 2005 , 508, 255-65		36
1274	Inhibition of iNOS gene expression by quercetin is mediated by the inhibition of I κ B kinase, nuclear factor-kappa B and STAT1, and depends on heme oxygenase-1 induction in mouse BV-2 microglia. 2005 , 521, 9-20		191
1273	Ciglitazone inhibits the antigen-induced leukotrienes production independently of PPARgamma in RBL-2H3 mast cells. 2005 , 521, 21-8		10
1272	Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. 2005 , 40, 599-604		39
1271	Identification and organ expression of peroxisome proliferator activated receptors in brown trout (<i>Salmo trutta f. fario</i>). 2005 , 1731, 88-94		52
1270	Pro-inflammatory properties for thiazolidinediones. 2005 , 69, 255-65		23
1269	Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. 2005 , 70, 177-88		233
1268	Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. 2005 , 1034, 139-46		13
1267	Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. 2005 , 46, 713-9		60
1266	Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. 2005 , 5, 1856-67		55
1265	Insulin alters nuclear factor-lambdaB and peroxisome proliferator-activated receptor-gamma protein expression induced by glycated bovine serum albumin in vascular smooth-muscle cells. 2005 , 145, 144-50		12
1264	An aqueous extract of the popular Chinese nutraceutical Kwei Ling Ko (Tortoise shell-Rhizome jelly) activates the PPARgamma pathway and down-regulates the NFkappaB activity. 2005 , 12, 748-59		7
1263	Effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of retinoic acid-inducible gene-I in endothelial cells stimulated with lipopolysaccharide. 2005 , 78, 46-54		2
1262	Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. 2005 , 161, 113-22		140

1261	PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. 2005 , 167, 99-107	50
1260	Tactics for vascular protection after acute ischemic stroke. 2005 , 25, 387-95	28
1259	A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. 2005 , 35, 3064-73	103
1258	Troglitazone and liver injury: in search of answers. 2005 , 41, 237-46	99
1257	Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. 2005 , 41, 1329-38	64
1256	Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism. 2005 , 52, 94-104	46
1255	Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. 2005 , 52, 479-87	80
1254	Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. 2005 , 52, 759-69	22
1253	Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. 2005 , 80, 66-74	42
1252	Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. 2005 , 81, 403-11	115
1251	The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats. 2005 , 180, 513-22	28
1250	Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. 2005 , 54, 464-70	75
1249	A structure-activity study for the inhibition of metalloproteinase-9 activity and gene expression by analogues of gallic acid. 2005 , 62, 2896-903	19
1248	Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma. 2005 , 29, 422-8	33
1247	Rôle des récepteurs nucléaires PPAR et ROR dans les cellules articulaires de la polyarthrite rhumatoïde. 2005 , 72, 331-336	
1246	Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. 2005 , 100, 263-9	25
1245	Immunohistochemical distribution of activated nuclear factor kappaB and peroxisome proliferator-activated receptors in carbon tetrachloride-induced chronic liver injury in rats. 2005 , 123, 585-93	36
1244	Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. 2005 , 23, 275-9	64

1243	Alzheimer's associated inflammation, potential drug targets and future therapies. 2005 , 112, 429-53	82
1242	Inflammation and conjugated linoleic acid: mechanisms of action and implications for human health. 2005 , 61, 483-94	48
1241	Thiazolidinediones and cardiovascular disease. 2005 , 7, 115-20	5
1240	Diabetes in Japan. 2005 , 5, 226-9	23
1239	Global analysis of gene expression in gastric ischemia-reperfusion: a future therapeutic direction for mucosal protective drugs. 2005 , 50 Suppl 1, S45-55	13
1238	PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. 2005 , 30, 1369-75	31
1237	The gene expression profile of extraskeletal myxoid chondrosarcoma. 2005 , 206, 433-44	58
1236	Molecular targets of dietary polyphenols with anti-inflammatory properties. 2005 , 46, 585-96	227
1235	Erratum. 2005 , 74, 173-173	
1234	Regulatory Role of the COX-2 Pathway in the Nrf2-Mediated Anti-Inflammatory Response. 2005 , 37, 9-18	8
1233	. 2005 ,	6
1232	Transcriptional regulation of labour-associated genes. 2005 , 76-108	1
1231	Multi-site therapeutic modalities for inflammatory bowel diseases [mechanisms of action. 2003 , 523-551	
1230	Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. 2005 , 93, 8-16	49
1229	Peroxisome proliferator-activated receptors and cardiovascular remodeling. 2005 , 288, H1037-43	92
1228	Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. 2005 , 44, 983-8	41
1227	Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. 2005 , 280, 29728-42	81
1226	Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. 2005 , 67, 1620-8	52

1225	Peroxisome proliferator-activated receptors and their relevance to dermatology. 2005 , 85, 194-202	30
1224	Pharmacological properties of nimesulide. 2005 , 133-244	1
1223	Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells. 2005 , 67, 134-41	23
1222	Retinoids potentiate peroxisome proliferator-activated receptor gamma action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. 2005 , 67, 1935-43	43
1221	Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway. 2005 , 3, 119-128	1
1220	The role of alterations in arachidonic acid metabolism and nitric oxide homeostasis in rat models of diabetes during early pregnancy. 2005 , 11, 1327-42	43
1219	PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. 2005 , 288, H1314-23	45
1218	Macrophage differentiation to foam cells. 2005 , 11, 3061-72	207
1217	15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. 2005 , 25, 710-6	15
1216	Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. 2005 , 280, 35562-70	79
1215	Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. 2005 , 68, 1568-75	78
1214	Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. 2005 , 46, 372-9	44
1213	Significance of anti-inflammatory effects of PPARgamma agonists?. 2006 , 55, 1067-9	12
1212	COX-2 and prostaglandins in atherosclerosis. 2005 , 14, 756-9	10
1211	Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. 2005 , 2, 226-31	110
1210	Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. 2005 , 46, 11-20	153
1209	Activator protein-1 mediates shear stress-induced prostaglandin d synthase gene expression in vascular endothelial cells. 2005 , 25, 970-5	31
1208	CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism. 2005 , 174, 4060-9	50

1207	Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. 2005 , 65, 6189-98	62
1206	Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. 2005 , 312, 69-76	42
1205	Thiazolidinediones and inflammation. 2005 , 14, 794-7	46
1204	Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. 2005 , 146, 3301-8	39
1203	Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. 2005 , 25, 225-34	125
1202	Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. 2005 , 84, 240-4	9
1201	PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. 2005 , 19, 1033-5	107
1200	Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells. 2005 , 73, 527-35	67
1199	Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. 2005 , 280, 2550-61	73
1198	Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. 2005 , 146, 85-92	79
1197	The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. 2005 , 19, 1120-2	118
1196	PPARs as targets for metabolic and cardiovascular diseases. 2005 , 5, 741-53	34
1195	15-Deoxy-{delta}12,14-prostaglandin j2 inhibits interleukin-1{beta}-induced nuclear factor-{kappa}b in human amnion and myometrial cells: mechanisms and implications. 2005 , 90, 3534-43	51
1194	Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. 2005 , 54, 1543-51	53
1193	Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. 2005 , 102, 9406-11	286
1192	Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. 2005 , 171, 1260-6	101
1191	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. 2005 , 201, 1205-15	361
1190	Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. 2005 , 65, 772-81	157

1189	15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes. 2005 , 37, 179-85	17
1188	Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. 2005 , 25, 1647-53	159
1187	Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. 2005 , 175, 4948-55	94
1186	Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. 2005 , 54, 2787-94	84
1185	Activation of peripheral blood CD14+ monocytes occurs in diabetes. 2005 , 54, 2779-86	103
1184	PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. 2005 , 25, 1897-902	63
1183	Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. 2005 , 2, 37-41	34
1182	Catalase and PPARgamma2 genotype and risk of systemic lupus erythematosus in Koreans. 2005 , 14, 351-5	13
1181	Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. 2005 , 128, 1442-53	455
1180	Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. 2005 , 54, 2305-13	300
1179	Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. 2006 , 55, 1104-13	141
1178	Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade. 2005 , 91, 1203-8	28
1177	Peroxyntrites and impaired modulation of nitric oxide concentrations in embryos from diabetic rats during early organogenesis. 2005 , 130, 695-703	35
1176	Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. 2005 , 25, 8240-9	362
1175	Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. 2005 , 42, 509-16	19
1174	The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. 2005 , 280, 12888-95	280
1173	Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B. 2005 , 68, 169-78	30
1172	17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. 2005 , 25, 2957-68	314

1171	Role of resistin in obesity, insulin resistance and Type II diabetes. 2005 , 109, 243-56	201
1170	Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. 2005 , 25, 1903-9	111
1169	Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. 2005 , 36, 1189-94	59
1168	Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. 2005 , 20, 1057-65	48
1167	Receptores activados por proliferadores peroxisómicos tipo gamma en el síndrome metabólico: ¿amigos o enemigos?. 2005 , 17, 59-69	
1166	Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. 2005 , 182, 105-11	28
1165	A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. 2005 , 182, 71-7	29
1164	Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation. 2005 , 310, 196-204	13
1163	An inverse relationship between peroxisome proliferator-activated receptor gamma and allergic airway inflammation in an allergen challenge model. 2005 , 95, 468-73	34
1162	Flavones suppress the expression of the high-affinity IgE receptor FcepsilonRI in human basophilic KU812 cells. 2005 , 53, 1812-7	35
1161	Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. 2005 , 19, 1592-601	171
1160	A novel PPAR response element in the murine iNOS promoter. 2005 , 42, 1303-10	37
1159	Arachidonic acid cascade in endothelial pathobiology. 2005 , 69, 107-27	92
1158	Impaired expression of PPAR gamma protein contributes to the exaggerated growth of vascular smooth muscle cells in spontaneously hypertensive rats. 2005 , 77, 3037-48	14
1157	Endogenous prostaglandin D(2) synthesis decreases vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. 2005 , 78, 22-9	8
1156	Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. 2005 , 78, 389-97	110
1155	5-(3,5-Di-tert-butyl-4-hydroxybenzylidene) thiazolidine-2,4-dione modulates peroxisome proliferators-activated receptor gamma in 3T3-L1 adipocytes: roles as a PPARgamma ligand. 2005 , 242, 96-102	8
1154	Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. 2005 , 330, 737-45	25

1153	The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. 2005 , 333, 455-62	18
1152	Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. 2005 , 334, 30-7	42
1151	Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. 2005 , 336, 215-22	288
1150	Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. 2005 , 336, 909-17	233
1149	Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. 2005 , 122, 707-21	542
1148	The many faces of PPARgamma. 2005 , 123, 993-9	1114
1147	15d-PGJ2: the anti-inflammatory prostaglandin?. 2005 , 114, 100-9	260
1146	Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell?. 2005 , 1, 223-30	109
1145	SUMOylation and PPARgamma: wrestling with inflammatory signaling. 2005 , 2, 273-5	15
1144	Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. 2005 , 68, 104-10	23
1143	Hormone regulation of microglial cell activation: relevance to multiple sclerosis. 2005 , 48, 322-7	30
1142	New insights into COX-2 biology and inhibition. 2005 , 48, 352-9	90
1141	Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. 2005 , 80, 435-42	52
1140	Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes. 2005 , 81, 65-70	15
1139	Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. 2005 , 191, 331-6	172
1138	Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. 2005 , 194, 267-78	42
1137	Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. 2005 , 579, 4503-12	46
1136	Expression of macrophage-selective markers in human and rodent adipocytes. 2005 , 579, 5631-4	123

1135	Neutral lipids and peroxisome proliferator-activated receptor- γ control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice. 2005 , 167, 813-21	55
1134	Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. 2005 , 166, 721-8	62
1133	15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. 2005 , 72, 363-72	32
1132	The effect of PPAR γ ligands on the adipose tissue in insulin resistance. 2005 , 73, 65-75	94
1131	15d-Deoxy-Delta12,14-prostaglandin J2 modulates collagen type I synthesis in human hepatic stellate cells by inducing oxidative stress. 2005 , 73, 361-7	6
1130	Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. 2005 , 38, 257-65	44
1129	Study of a new PPAR γ 2 promoter polymorphism and haplotype analysis in a French population. 2005 , 85, 140-8	22
1128	PPARs: therapeutic targets for metabolic disease. 2005 , 26, 244-51	563
1127	Agonists of peroxisome proliferator-activated receptor-gamma attenuate the A β -mediated impairment of LTP in the hippocampus in vitro. 2005 , 49, 359-66	35
1126	Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. 2005 , 130, 685-96	240
1125	Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis. 2005 , 6, 132	10
1124	Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. 2005 , 3, 41	135
1123	PPARs and Their Emerging Role in Vascular Biology, Inflammation, and Atherosclerosis. 2005 , 93-105	
1122	Neuroinflammation: a potential therapeutic target. 2005 , 9, 887-900	82
1121	Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. 2005 , 57, 885-94	92
1120	Experimental autoimmune encephalomyelitis: A heterogeneous group of animal models to study human multiple sclerosis. 2005 , 2, 127-134	6
1119	An overview on biological mechanisms of PPARs. 2005 , 51, 85-94	498
1118	Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion. 2005 , 52, 100-8	27

1117	PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. 2005 , 7, 294-301	85
1116	A Nuclear Receptor Atlas: macrophage activation. 2005 , 19, 2466-77	190
1115	Atherosclerosis: Diet and Drugs. 2005 ,	2
1114	Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis. 2005 , 6, 1455-61	7
1113	Death Receptors in Cancer Therapy. 2005 ,	3
1112	The synthetic PPARgamma agonist troglitazone inhibits IL-5-induced CD69 upregulation and eosinophil-derived neurotoxin release from eosinophils. 2005 , 74, 169-73	17
1111	Diabetes and Cardiovascular Disease. 2005 ,	6
1110	Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2. 2005 , 7, R1325-37	46
1109	Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. 2006 , 5, 1	109
1108	THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. 2006 , 8, R7	36
1107	Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. 2006 , 8, 851-61	40
1106	Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. 2006 , 147, 4463-75	88
1105	Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis. 2006 , 20, 121-35	13
1104	Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease. 2006 , 20, 231-41	35
1103	Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. 2006 , 6, 15-40	20
1102	Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. 2006 , 6, 231-42	26
1101	Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. 2006 , 17, 1633-43	67
1100	Antioxidants and Cardiovascular Disease. 2006 ,	3

1099	Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. 2006 , 15, 1453-68	11
1098	Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system. 2006 , 26, 679-92	20
1097	The molecular inflammatory process in aging. 2006 , 8, 572-81	333
1096	Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. 2006 , 32, 229-35	20
1095	The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. 2006 , 22 Suppl B, 12B-17B	24
1094	What has ageing to do with periodontal health and disease?. 2006 , 56, 240-9	24
1093	Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. 2006 , 35, 561-74, ix	22
1092	Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. 2006 , 12, 4200-8	31
1091	Endothelial dysfunction and its role in diabetic vascular disease. 2006 , 35, 551-60, viii-ix	42
1090	Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. 2006 , 131, 1943-70	60
1089	Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. 2006 , 49, 4072-84	38
1088	Vascular protection in brain ischemia. 2006 , 21 Suppl 2, 21-9	34
1087	Inflammatory modulation of PPAR gamma expression and activity. 2006 , 118, 276-83	19
1086	Susceptibility to cholesterol gallstone formation: evidence that LITH genes also encode immune-related factors. 2006 , 1761, 1133-47	11
1085	Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. 2006 , 340, 1078-84	51
1084	Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. 2006 , 340, 1111-8	130
1083	Fucoidan induces nitric oxide production via p38 mitogen-activated protein kinase and NF-kappaB-dependent signaling pathways through macrophage scavenger receptors. 2006 , 343, 286-94	112
1082	Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2. 2006 , 351, 198-203	40

1081	Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. 2006 , 38, 766-81	51
1080	Peroxisome proliferator-activated receptors and acute lung injury. 2006 , 6, 263-70	20
1079	PPARs and other nuclear receptors in inflammation. 2006 , 6, 421-7	108
1078	Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. 2006 , 46, 1-39	64
1077	Rosiglitazone inhibits endothelial proliferation and angiogenesis. 2006 , 78, 1520-8	29
1076	15-Deoxy-Delta(12,14)-prostaglandin J(2) suppresses IL-6-induced STAT3 phosphorylation via electrophilic reactivity in endothelial cells. 2006 , 78, 3035-42	13
1075	The pleiotropic function of PPAR gamma in the placenta. 2006 , 249, 10-5	80
1074	PPARgamma as a therapeutic target in central nervous system diseases. 2006 , 49, 136-44	92
1073	Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. 2006 , 49, 183-9	80
1072	Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. 2006 , 49, 170-82	159
1071	Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. 2006 , 211, 487-501	271
1070	Carbon monoxide orchestrates a protective response through PPARgamma. 2006 , 24, 601-10	131
1069	Pathological effects of the mushroom toxin alpha-amanitin on BALB/c mice. 2006 , 27, 3047-52	17
1068	From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. 2006 , 45, 120-59	564
1067	Inflammation and immune regulation by 12/15-lipoxygenases. 2006 , 45, 334-56	295
1066	Systemic inflammation induces COX-2 mediated prostaglandin D2 biosynthesis in mice spinal cord. 2006 , 50, 165-73	15
1065	Lipoxygenase-derived eicosanoids are involved in the inhibitory effect of Crotalus durissus terrificus venom or crotoxin on rat macrophage phagocytosis. 2006 , 47, 313-21	31
1064	Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-prostaglandin J2 by augmenting GSH and activating MAPK. 2006 , 47, 5098-105	53

1063	Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity. 2006 , 136, 690-4	29
1062	Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma. 2006 , 136, 695-9	7
1061	Peroxisome proliferator-activated receptors and shock state. 2006 , 6, 1770-82	8
1060	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS. 2006 , 327-332	
1059	Mechanisms and Consequences of Intestinal Inflammation. 2006 , 1115-1135	
1058	Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. 2006 , 136, 700-3	39
1057	Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. 2006 , 3, e287	249
1056	Inflammation et immunité: implications dans l'obésité et le diabète de type 2. 2006 , 13, 343-351	3
1055	Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. 2006 , 6, 908-17	79
1054	Peroxisome proliferator-activated receptor- β and lipodystrophy. 2006 , 1, 455-462	1
1053	Immune Modulation by the Intestinal Microbiota. 2006 , 93-122	
1052	Comparative toxicity of fatty acids on a macrophage cell line (J774). 2006 , 111, 307-17	78
1051	Peroxisome proliferator-activated receptor gamma (PPAR γ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. 2006 , 108, 525-35	98
1050	Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. 2006 , 136, 2813-9	48
1049	Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. 2006 , 83, 475S-483S	88
1048	Chapter 2 PPAR α a key therapeutic target in the metabolic syndrome Unique insights derived from the study of human genetic variants. 2006 , 5, 15-41	
1047	Angiotensin-converting enzyme genetic variation and lung injury: are we genetically predisposed to develop acute respiratory distress syndrome?. 2006 , 34, 1261-2	3
1046	Erythropoietin: a role in intensive care beyond erythropoiesis?. 2006 , 34, 1281-2	

1045	Does hyperventilation cause secondary brain injury?. 2006 , 34, 1284-5	4
1044	Caring for the critically ill in developing countries--our collective challenge. 2006 , 34, 1288-9	13
1043	Vasopressin and relativity: on the matter of deficiency and sensitivity. 2006 , 34, 1275-7	7
1042	Body habitus should not considerably affect the interpretation of hemodynamic measurements: huge news?. 2006 , 34, 1289-90	1
1041	PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. 2006 , 5, 1008-14	44
1040	COX-2 and atherosclerosis. 2006 , 47 Suppl 1, S26-36	55
1039	Pioglitazone Improves Left Ventricular Diastolic Function in Patients With Essential Hypertension. 2006 , 2006, 395-398	
1038	Adrenocortical insufficiency: an early step in the pathogenesis of severe acute pancreatitis and development of necrosis? Do we have a new treatment option?. 2006 , 34, 1269-70	10
1037	Omega-3 fatty acids-supplemented parenteral nutrition in the critically ill: another step forward on the "great journey"?. 2006 , 34, 1253-5	7
1036	Heatstroke: facing the threat. 2006 , 34, 1272-3	4
1035	Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. 2006 , 48, 299-305	21
1034	Implementation of an evidence-based "standard operating procedure" and outcome in septic shock: what a sepsis pilot must consider before taking flight with your next patient. 2006 , 34, 1247	8
1033	Intensive care triage--the hardest rationing decision of them all. 2006 , 34, 1250-1	30
1032	Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. 2006 , 17, 510-8	52
1031	Biological evaluation of perioperative cardiac stress: a two-way approach. 2006 , 34, 1259-60	
1030	Artificial neural networks and power of breathing: new approaches, expanded utility?. 2006 , 34, 1267-8	1
1029	Synergistic effect of peroxisome proliferator activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages. 2006 , 26, 146-53	27
1028	Critical care's great leap forward?. 2006 , 34, 1262-3	3

1027	On the road to discovering protective endogenous peroxisome proliferator-activator receptor-gamma ligands for endotoxemia: are we there yet?. 2006 , 34, 1277-9	3
1026	Whole-body hypothermia: another option in smoke inhalation management?. 2006 , 34, 1280-1	
1025	Cardiogenic shock: giving the heart a break. 2006 , 34, 1248-9	
1024	Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. 2006 , 17, 763-9	21
1023	Extracorporeal membrane oxygenation for cardiac arrest: when to use it, and what are the outcomes?. 2006 , 34, 1285-6	10
1022	Potassium channels and septic shock. 2006 , 34, 1255-7	14
1021	Substitute decisions about genetic testing in critical care research: a glimpse behind the curtain. 2006 , 34, 1257-9	3
1020	Antifungal prophylaxis in the intensive care unit: who should get it?. 2006 , 34, 1286-7	12
1019	Is erythropoietin the key to optimize wound healing?. 2006 , 34, 1279-80	3
1018	Applying the evidence: multiple urgent therapies for patients with sepsis. 2006 , 34, 1264-5	3
1017	Acute lung injury and nutritional support. 2006 , 34, 1265-7	8
1016	Statin use and mortality in the bacteremic critically ill patient. 2006 , 34, 1270-2	3
1015	Adenosine A2A receptor activation: another potential therapy for trauma and hemorrhagic shock. 2006 , 34, 1273-5	20
1014	Hypotensive resuscitation with hypertonic saline: less may not be more!. 2006 , 34, 1283	
1013	The paradoxical effect of obesity on outcome in critically ill patients. 2006 , 34, 1251-3	21
1012	The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. 2006 , 34, 1874-82	145
1011	Chronic pancreatitis. 2006 , 22, 487-97	18
1010	Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators. 2006 , 26, 262-70	49

1009	[The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)]. 2006 , 200, 121-31	11
1008	Bacillus Calmette-Guifin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. 2006 , 17, 269	0
1007	Mechanisms of Inflammation: Neutrophils. 2006 , 248-268	
1006	Receptor Ck-dependent signaling regulates hTERT gene transcription. 2006 , 7, 2	11
1005	Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?. 2006 , 41, 23-34	33
1004	Phytochemicals of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. 2006 , 15, 66-73	38
1003	Altered PPARgamma expression and activation after transient focal ischemia in rats. 2006 , 24, 1653-63	120
1002	PPARs: transcription factors controlling lipid and lipoprotein metabolism. 2002 , 967, 7-18	115
1001	Mitochondria, oxidative damage, and inflammation in Parkinson's disease. 2003 , 991, 120-31	383
1000	The role of glial reaction and inflammation in Parkinson's disease. 2003 , 991, 214-28	344
999	Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. 2005 , 15, 149-58	49
998	Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. 2006 , 97, 435-48	164
997	15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway. 2006 , 99, 1389-1402	27
996	Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. 2006 , 20, 429-47	95
995	PPAR-gamma-mediated regulation of normal and malignant B lineage cells. 2000 , 905, 97-109	43
994	Proinflammatory signals upregulate COX-2 and increase PGE2 production in biphenotypic B/macrophage cells. 2000 , 905, 294-6	5
993	Effects of 15-deoxy-delta 12,14-PGJ2 on B lineage cells. 2000 , 905, 322-5	5
992	PPARgamma phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation. 2006 , 27, 1146-52	30

991	PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. 2006 , 65, 389-95	34
990	Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. 2006 , 62, 391-402	23
989	Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands. 2006 , 63, 330-7	38
988	Combinatorial roles of nuclear receptors in inflammation and immunity. 2006 , 6, 44-55	336
987	Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. 2006 , 13, 1533-40	70
986	Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. 2006 , 26, 218-29	93
985	Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. 2006 , 26, 433-45	58
984	15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. 2006 , 26, 811-20	201
983	Peroxisome proliferator-activated receptor gamma in malignant diseases. 2006 , 58, 1-14	101
982	Positioning prostanoids of the D and J series in the immunopathogenic scheme. 2006 , 102, 121-31	69
981	Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. 2006 , 39, 109-14	27
980	Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis. 2006 , 10, 1120-30	15
979	Recent findings concerning thiazolidinediones in the treatment of diabetes. 2006 , 15, 243-50	71
978	Polymer-assisted solution-phase synthesis and neurite-outgrowth-promoting activity of 15-deoxy-delta(12,14)-PGJ2 derivatives. 2006 , 1, 669-77	16
977	Highly efficient total synthesis of 12-PGJ2, 15-deoxy-12,14-PGJ2, and their analogues. 2006 , 62, 3329-3343	45
976	Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. 2006 , 44, 65-71	21
975	Influence of ciglitazone on HepG2 cells growth in vitro and in vivo and its mechanisms. 2006 , 5, 169-172	
974	Catalase and PPARgamma2 genotype and risk of rheumatoid arthritis in Koreans. 2006 , 26, 388-92	20

973	Attenuation of experimental colonic injury by thiazolidinedione agents. 2006 , 55, 10-5	19
972	Is omega-3 key to unlocking inflammation in obesity?. 2006 , 49, 1999-2001	29
971	BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. 2006 , 49, 2350-8	30
970	Inflammation and diabetic nephropathy. 2006 , 6, 463-8	144
969	Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism. 2006 , 26, 36-9	11
968	Vascular effects of TZDs: new implications. 2006 , 45, 3-18	42
967	TGF-beta inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-gamma). 2006 , 6, 1809-19	2
966	Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. 2006 , 530, 70-80	242
965	Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. 2006 , 533, 101-9	98
964	Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. 2006 , 41, 590-9	64
963	Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. 2006 , 1759, 32-43	39
962	Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. 2006 , 71, 646-56	77
961	Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. 2006 , 71, 1308-23	21
960	15-deoxy-Delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors. 2006 , 72, 1516-28	134
959	Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. 2006 , 1073-1074, 460-9	73
958	Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. 2006 , 1096, 196-203	71
957	The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. 2006 , 20, 336-42	33
956	Methylmercury causes oxidative stress and cytotoxicity in microglia: attenuation by 15-deoxy-delta 12, 14-prostaglandin J2. 2006 , 171, 17-28	48

955	Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. 2006 , 176, 95-105	83
954	PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2. 2006 , 178, 76-86	47
953	Low and high levels of alpha-tocopherol exert opposite effects on IL-2 possibly through the modulation of PPAR-gamma, I kappa B alpha, and apoptotic pathway in activated splenocytes. 2006 , 22, 433-40	18
952	Peroxisome proliferator-activated receptors and inflammation. 2006 , 110, 371-85	273
951	Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy. 2006 , 110, 57-70	36
950	15-Deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. 2006 , 27, 1060-72	45
949	PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. 2006 , 80, 165-74	52
948	Solid-phase synthesis and biological activity of a combinatorial cross-conjugated dienone library. 2006 , 12, 1368-76	15
947	New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator-activated receptor- α . 2006 , 67, 687-697	4
946	Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: its potential role in peritoneal cavity local defense. 2006 , 26, 602-11	18
945	Quantitative characterization of 15-deoxy-delta(12,14)-prostaglandin J2 in regulating EGFP/Smad2 translocation in CHO cells through PPARgamma/TGFbeta/Smad2 pathway. 2006 , 18, 143-50	2
944	The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model. 2006 , 21, 3008-13	12
943	Emerging drugs in endometriosis. 2006 , 11, 503-24	32
942	Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. 2006 , 91, 546-54	122
941	Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. 2006 , 91, 3553-8	70
940	Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. 2006 , 72, 881-7	151
939	PPARgamma activity in the vessel wall: anti-atherogenic properties. 2006 , 13, 3227-38	21
938	Role of PPAR in cardiovascular diseases. 2006 , 1, 193-209	29

937	PPAR-gamma agonists decrease hyperhomocysteinemia and cardiac dysfunction: new hope for ailing diabetic hearts?. 2006 , 291, H26-8	4
936	Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. 2006 , 291, L84-90	44
935	Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. 2006 , 12, 3509-19	37
934	Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. 2006 , 70, 446-56	77
933	Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. 2006 , 290, L797-805	137
932	Differential induction of PPAR-gamma by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel. 2006 , 290, G616-23	58
931	New Strategies in Evaluation of Therapeutic Efficacy in Fibromyalgia Syndrome. 2006 , 12, 67-71	11
930	Novel targets for antiinflammatory and antiarthritic agents. 2006 , 12, 2437-54	37
929	Diabetic pregnancies: the challenge of developing in a pro-inflammatory environment. 2006 , 13, 2127-38	74
928	Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. 2006 , 290, F600-5	60
927	Cell biology and lipoproteins in atherosclerosis. 2006 , 6, 439-56	51
926	Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. 2006 , 55, 1020-9	48
925	PPAR-gamma agonists as regulators of microglial activation and brain inflammation. 2006 , 12, 93-109	166
924	The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). 2006 , 90, 269-95	217
923	Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. 2006 , 66, 4001-10	73
922	Peroxisome proliferator-activated receptor gamma agonists in renal disease. 2006 , 154, 613-21	55
921	Pioglitazone prevents acute and chronic cardiac allograft rejection. 2006 , 113, 2613-22	46
920	Troglitazone regulates peroxisome proliferator-activated receptors and inducible nitric oxide synthase in murine ovarian macrophages. 2006 , 74, 153-60	22

919	15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. 2006 , 26, 481-7	113
918	Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. 2006 , 281, 38376-84	240
917	Pioglitazone induces apoptosis of macrophages in human adipose tissue. 2006 , 47, 2080-8	55
916	GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice. 2006 , 26, 2337-44	64
915	Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. 2006 , 26, 28-40	104
914	Epithelial cell PPAR[gamma] contributes to normal lung maturation. 2006 , 20, 1507-9	85
913	Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. 2006 , 70, 101-11	132
912	Low-density lipoprotein modified by macrophage-derived lysosomal hydrolases induces expression and secretion of IL-8 via p38 MAPK and NF-kappaB by human monocyte-derived macrophages. 2006 , 26, 2504-9	16
911	Adipokines and the signaling role of adipose tissue in inflammation and obesity. 2006 , 1, 81-89	15
910	Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. 2006 , 98, 192-9	107
909	Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: Modulation of T cell differentiation. 2006 , 147, 4410-8	53
908	Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. 2006 , 20, 786-94	159
907	Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. 2006 , 6, 1313-25	22
906	The Diabetic Kidney. 2006 ,	1
905	Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-gamma2 gene polymorphisms. 2006 , 96, 965-72	55
904	Arachidonic acid-derived eicosanoids in rheumatoid arthritis: implications and future targets. 2006 , 1, 323-330	3
903	Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). 2006 , 116, 30-40	12
902	PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. 2006 , 26, 808-13	57

901	Human T cell cytokine responses are dependent on multidrug resistance protein-1. 2006 , 18, 485-93	23
900	Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. 2006 , 103, 3781-6	279
899	A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. 2006 , 281, 33982-96	60
898	Nrf2-mediated induction of cytoprotective enzymes by 15-deoxy-Delta12,14-prostaglandin J2 is attenuated by alkenal/one oxidoreductase. 2006 , 281, 26245-52	24
897	Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. 2006 , 317, 37-43	80
896	Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. 2006 , 20, 1405-28	728
895	The etiology of hypertension in the metabolic syndrome part three: the regulation and dysregulation of blood pressure. 2006 , 4, 321-48	6
894	Dietary conjugated linoleic acid enhances spleen PPAR-gamma mRNA expression in broiler chicks. 2006 , 47, 726-33	9
893	Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. 2006 , 20, 1162-75	162
892	Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. 2006 , 177, 5248-57	67
891	Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. 2006 , 177, 3737-45	31
890	Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. 2006 , 103, 2346-51	46
889	International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. 2006 , 58, 726-41	749
888	Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. 2006 , 13, 58-62	39
887	Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. 2006 , 103, 5179-84	116
886	The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. 2006 , 177, 5068-76	75
885	Anti-inflammatory mechanisms of phenanthroindolizidine alkaloids. 2006 , 69, 749-58	67
884	Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. 2007 , 27, 2276-83	333

883	Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. 2007 , 179, 6263-72	43
882	9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. 2007 , 178, 6130-9	53
881	Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. 2007 , 179, 313-21	52
880	Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function. 2007 , 178, 4362-72	32
879	Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. 2007 , 178, 2940-9	138
878	Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12,14-PGJ2. 2007 , 104, 20979-84	202
877	The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. 2007 , 282, 17964-17973	143
876	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. 2007 , 7, 1405-21	63
875	Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. 2007 , 16, 1561-72	26
874	Anti-inflammatory and antidiabetic roles of PPARgamma. 2007 , 286, 183-96; discussion 196-203	26
873	Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development. 2007 , 2007, 91240	18
872	PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis. 2007 , 293, G319-26	20
871	Innate immune system regulation of nuclear hormone receptors in metabolic diseases. 2007 , 82, 187-95	17
870	Catalase potentiates retinoic acid-induced THP-1 monocyte differentiation into macrophage through inhibition of peroxisome proliferator-activated receptor gamma. 2007 , 81, 1568-76	27
869	RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury. 2007 , 2007, 29275	24
868	Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-gamma on Fc-gamma Receptor-Mediated Phagocytosis by Alveolar Macrophages. 2007 , 2007, 52546	18
867	PPARs, Obesity, and Inflammation. 2007 , 2007, 95974	170
866	Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. 2007 , 4, 159-64	87

865	Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. 2007 , 293, C75-86	61
864	PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation. 2007 , 292, E1052-61	15
863	Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. 2007 , 116, 2182-90	46
862	Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. 2007 , 115, 518-33	261
861	PPARs and diabetes-associated atherosclerosis. 2007 , 13, 2736-41	8
860	Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. 2007 , 2007, 14983	34
859	Peroxisome proliferator-activated receptors and acute lung injury. 2007 , 2007, 63745	19
858	Genetic manipulations of PPARs: effects on obesity and metabolic disease. 2007 , 2007, 12781	25
857	Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. 2007 , 5, 35-46	47
856	Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells. 2007 , 22, 1041-51	34
855	The metabolic syndrome and stroke: potential treatment approaches. 2007 , 38, 2196-203	55
854	PPAR ligands: are they potential agents for cardiovascular disorders?. 2007 , 80, 1-10	53
853	Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. 2007 , 80, 57-64	17
852	PGJ2 inhibition of LPS-induced inflammatory mediator expression from rat alveolar macrophages. 2007 , 70, 1967-76	5
851	The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. 2007 , 21, 1756-68	31
850	Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. 2007 , 7, 93-7	4
849	Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. 2007 , 56, 1865-71	51
848	Resistin- and Obesity-associated metabolic diseases. 2007 , 39, 710-6	134

847	Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. 2007 , 23, 2849-55	19
846	The effect of rosiglitazone on orthostatic tolerance during heat exposure in individuals with type II diabetes. 2007 , 9, 377-86	15
845	The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. 2007 , 1, 7-26	17
844	Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. 2007 , 56, 524-33	41
843	Complex roles of cyclo-oxygenase 2 in hepatitis. 2007 , 56, 903-4	8
842	Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes. 2007 , 72, 1246-57	11
841	Endogenous lipid mediators in the resolution of airway inflammation. 2007 , 30, 980-92	64
840	The endothelium and vascular inflammation in diabetes. 2007 , 4, 84-8	188
839	Regulation of CD8+ T lymphocyte effector function and macrophage inflammatory cytokine production by retinoic acid receptor gamma. 2007 , 178, 2113-21	43
838	Constitutive expression of prostaglandin-endoperoxide synthase 2 by somatic and spermatogenic cells is responsible for prostaglandin E2 production in the adult rat testis. 2007 , 76, 759-68	39
837	Adipocyte enhancer-binding protein-1 promotes macrophage inflammatory responsiveness by up-regulating NF-kappaB via IkappaBalpha negative regulation. 2007 , 18, 930-42	40
836	Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. 2007 , 178, 2122-31	99
835	Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. 2007 , 21, 1895-908	89
834	15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors. 2007 , 178, 4039-50	14
833	Open questions in oesophageal adenocarcinogenesis. 2007 , 56, 897-8	5
832	PPARs in alveolar macrophage biology. 2007 , 2007, 23812	14
831	Potential role for peroxisome proliferator-activated receptor gamma in regulating luteal lifespan in the rat. 2007 , 133, 187-96	3
830	The Functions of PPARs in Aging and Longevity. 2007 , 2007, 39654	26

829	PPARs and Adipose Cell Plasticity. 2007 , 2007, 68202	9
828	'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. 2007 , 2007, 83593	20
827	Peroxisome proliferator-activated receptors in lung cancer. 2007 , 2007, 90289	16
826	Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. 2007 , 81, 372-82	45
825	Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. 2007 , 67, 881-9	52
824	Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. 2007 , 30, 203-11	30
823	Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. 2007 , 27, 1115-22	32
822	S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects. 2007 , 56, 2797-808	42
821	Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. 2007 , 282, 5356-66	40
820	Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. 2007 , 282, 31085-93	152
819	Fatty acids isolated from Toxoplasma gondii reduce glycosylphosphatidylinositol-induced tumor necrosis factor alpha production through inhibition of the NF-kappaB signaling pathway. 2007 , 75, 2886-93	18
818	Peroxisome proliferator-activated receptor ligands inhibit the growth of human ovarian cancer. 2007 , 18, 833	3
817	Peroxisome proliferated-activated receptor ligand, Pioglitazone, does not prevent hepatic fibrosis in mice. 2007 ,	4
816	Oxidative stress and transcriptional regulation in Alzheimer disease. 2007 , 21, 276-91	115
815	Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats. 2007 , 84, 517-26	10
814	Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. 2007 , 179, 7478-87	40
813	Use of mouse models to evaluate roles of nuclear receptors and their ligands in the pathogenesis and treatment of atherosclerosis. 2007 , 8, 1273-87	1
812	Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice. 2007 , 8, 982-95	11

811	THE PPARgamma ligand 15d-PGJ2 modulates macrophage activation after injury in a murine trauma model. 2007 , 28, 186-91	14
810	Trans-10, cis-12-conjugated linoleic acid increases phagocytosis of porcine peripheral blood polymorphonuclear cells in vitro. 2007 , 97, 117-25	26
809	Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. 2007 , 76, 103-12	50
808	The two faces of the 15-lipoxygenase in atherosclerosis. 2007 , 77, 67-77	130
807	Vascular effects of PPARgamma activators - from bench to bedside. 2007 , 46, 283-96	19
806	A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. 2007 , 52, 1616-23	39
805	The choroid plexus response to peripheral inflammatory stimulus. 2007 , 144, 424-30	41
804	PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. 2007 , 154, 718-24	27
803	Diabetes mellitus and macrovascular disease: mechanisms and mediators. 2007 , 120, S12-7	167
802	Peroxisome proliferator-activated receptor gamma agonist action of 3-methyl-1,2-cyclopentanedione. 2007 , 1770, 1612-9	6
801	PPARgamma in immunity and inflammation: cell types and diseases. 2007 , 1771, 1014-30	115
800	PPARs and molecular mechanisms of transrepression. 2007 , 1771, 926-35	369
799	Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. 2007 , 1771, 1117-24	30
798	15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) mediates repression of TNF-alpha by decreasing levels of acetylated histone H3 and H4 at its promoter. 2007 , 359, 88-93	10
797	Non-steroidal anti-inflammatory drugs in Parkinson's disease. 2007 , 205, 295-312	170
796	The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. 2007 , 205, 396-406	95
795	Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?. 2007 , 206, 172-8	24
794	PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. 2007 , 88, 1108-19	67

793	Effects of dietary thia fatty acids on lipid composition, morphology and macrophage function of Atlantic salmon (<i>Salmo salar</i> L.) kidney. 2007 , 148, 103-11	15
792	Macrophage polarization and insulin resistance: PPARgamma in control. 2007 , 6, 96-8	94
791	Upregulation of tumor necrosis factor-alpha expression by trans10-cis12 conjugated linoleic acid enhances phagocytosis of RAW macrophages via a peroxisome proliferator-activated receptor gamma-dependent pathway. 2007 , 37, 227-35	21
790	Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. 2007 , 39, 1260-75	69
789	PPAR agonists modulate human osteoclast formation and activity in vitro. 2007 , 40, 149-59	70
788	PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. 2007 , 41, 562-74	54
787	Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. 2007 , 46, 115-23	31
786	Serum Levels of IL-1 β , IL-6, TGF- β , and MMP-9 in Patients Undergoing Carotid Artery Stenting and Regulation of MMP-9 in a New In Vitro Model of THP-1 Cells Activated by Stenting. 2015 , 2015, 956082	12
785	Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment. 2015 , 2015, 515248	30
784	Macrophage takeover and the host-bacilli interplay during tuberculosis. 2015 , 10, 853-72	33
783	The Role of Inflammation in Alzheimer's Disease. 2015 , 313-336	1
782	The role of PPAR-gamma receptor in pruritus. 2015 , 762, 322-5	5
781	The role of 15-LOX-1 in colitis and colitis-associated colorectal cancer. 2015 , 64, 661-9	12
780	miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer. 2015 , 34, 3088-96	36
779	Intestinal steroidogenesis. 2015 , 103, 64-71	22
778	Molecular cloning, characterization and expression analysis of PPAR gamma in the orange-spotted grouper (<i>Epinephelus coioides</i>) after the <i>Vibrio alginolyticus</i> challenge. 2015 , 43, 310-24	36
777	PPAR γ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. 2015 , 8, 1031-46	75
776	The multifaceted factor peroxisome proliferator-activated receptor γ (PPAR γ) in metabolism, immunity, and cancer. 2015 , 38, 302-12	48

775	The effect of PPAR- α agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions. 2015 , 42, 85-91	4
774	Hyper-inflammation and skin destruction mediated by rosiglitazone activation of macrophages in IL-6 deficiency. 2015 , 135, 389-399	10
773	Inhibition of Lipopolysaccharide (LPS)-induced inflammatory responses by selenium in bovine mammary epithelial cells in primary culture. 2015 , 38, 152-8	5
772	A soybean and fish oil mixture with different n-6/n-3 PUFA ratios modulates the inflammatory reaction in mice with dextran sulfate sodium-induced acute colitis. 2015 , 34, 1018-24	22
771	Polyphenols in Regulation of Redox Signaling and Inflammation During Cardiovascular Diseases. 2015 , 72, 485-94	7
770	Hepatocyte-Specific Expression of Human Lysosome Acid Lipase Corrects Liver Inflammation and Tumor Metastasis in <i>lal(-/-)</i> Mice. 2015 , 185, 2379-89	27
769	New nanocomposite-graphene pastes based stochastic microsensors. 2015 , 5, 66185-66191	8
768	Acid sphingomyelinase (aSMase) deficiency leads to abnormal microglia behavior and disturbed retinal function. 2015 , 464, 434-40	9
767	Vasa vasorum in atherosclerosis and clinical significance. 2015 , 16, 11574-608	78
766	Botanical oils enriched in n-6 and n-3 FADS2 products are equally effective in preventing atherosclerosis and fatty liver. 2015 , 56, 1191-205	18
765	Pro-inflammatory effect of fibrinogen on vascular smooth muscle cells by regulating the expression of β -catenin. 2015 , 3, 513-518	7
764	Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. 2015 , 235, 1-9	48
763	Prostacyclin protects vascular integrity via PPAR/ α -1 pathway. 2015 , 118-119, 19-27	23
762	Identification and characterisation of a prototype for a new class of competitive PPAR α antagonists. 2015 , 755, 16-26	4
761	Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. 2015 , 67, 901-6	24
760	A mathematical model of insulin resistance in Parkinson's disease. 2015 , 56, 84-97	9
759	The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. 2015 , 8, 7	73
758	Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity. 2015 , 39, 638-45	12

757	Host Response to Orthopedic Implants (Metals and Plastics). 2015 , 315-373	3
756	A new and openly accessible database of tests on piles driven in sands. 2015 , 5, 12-20	13
755	Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line. 2015 , 66, 293-9	33
754	Immunology and Psychiatry. 2015 ,	3
753	Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk. 2015 , 7, 87-101	41
752	MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis. 2015 , 12, 361-74	77
751	New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice. 2015 , 71, 174-80	6
750	Vascular endothelial cell Toll-like receptor pathways in sepsis. 2015 , 21, 827-46	126
749	Possible involvement of 15-deoxy-(12,14)-prostaglandin J2 in the development of leptin resistance. 2015 , 133, 343-51	10
748	A canonical correlation analysis-based dynamic bayesian network prior to infer gene regulatory networks from multiple types of biological data. 2015 , 22, 289-99	16
747	Airway epithelial cell PPAR γ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice. 2015 , 309, L293-304	35
746	Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. 2015 , 243, 107-19	44
745	Novel phosphorylation of PPAR δ ameliorates obesity-induced adipose tissue inflammation and improves insulin sensitivity. 2015 , 27, 2488-95	16
744	Pleiotropic role of PPAR δ in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF- κ B. 2015 , 21, 357-66	73
743	Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. 2015 , 74, 295-304	44
742	PPAR δ activation by Tityus serrulatus venom regulates lipid body formation and lipid mediator production. 2015 , 93, 90-7	25
741	Macrophages in diabetic gastroparesis--the missing link?. 2015 , 27, 7-18	36
740	PPAR δ dependent anti-tumor and immunomodulatory actions of pioglitazone. 2015 , 12, 308-16	6

739	Endocannabinoids in synaptic plasticity and neuroprotection. 2015 , 21, 152-68	67
738	Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan. 2015 , 72, 123-30	29
737	Pharmacokinetic properties of MH84, a β -secretase modulator with PPAR α agonistic activity. 2015 , 102, 417-24	6
736	Design, synthesis and evaluation of PPAR gamma binding activity of 2-thioxo-4-thiazolidinone derivatives. 2015 , 26, 63-68	16
735	Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. 2015 , 51, 661-71	30
734	Dietary Fats and Inflammation. 2016 , 635-665	0
733	Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway. 2016 , 10, 3591-3597	19
732	Role of PPAR γ ; in the nutritional and pharmacological actions of carotenoids. 2016 , 13	2
731	Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. 2016 , 17,	29
730	Protective Effect of PPAR Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats. 2016 , 2016, 1952561	17
729	Gamma-Glutamylcysteine Ethyl Ester Protects against Cyclophosphamide-Induced Liver Injury and Hematologic Alterations via Upregulation of PPAR and Attenuation of Oxidative Stress, Inflammation, and Apoptosis. 2016 , 2016, 4016209	39
728	PPARs and Mitochondrial Metabolism: From NAFLD to HCC. 2016 , 2016, 7403230	49
727	CD97/ADGRE5 Inhibits LPS Induced NF- κ B Activation through PPAR- γ Upregulation in Macrophages. 2016 , 2016, 1605948	2
726	15-Deoxy- Δ Prostaglandin J Modifies Components of the Proteasome and Inhibits Inflammatory Responses in Human Endothelial Cells. 2016 , 7, 459	10
725	Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPAR α Expression and/or Its Transcriptional Activity. 2016 , 21,	49
724	Perfluorooctanesulfonate Mediates Renal Tubular Cell Apoptosis through PPAR γ Inactivation. 2016 , 11, e0155190	28
723	Phytochemicals Mediate the Expression and Activity of OCTN2 as Activators of the PPAR α /RXR β Pathway. 2016 , 7, 189	12
722	Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy. 2016 , 57, 1494-9	6

721	The regulation of inflammation by oxidized phospholipids. 2016 , 46, 1818-25	50
720	Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype. 2016 , 68, 127-42	3
719	PPAR α agonists regulate bidirectional transport of amyloid- β across the blood-brain barrier and hippocampus plasticity in db/db mice. 2016 , 173, 372-85	24
718	Cinnamomum camphora Seed Kernel Oil Ameliorates Oxidative Stress and Inflammation in Diet-Induced Obese Rats. 2016 , 81, H1295-300	16
717	Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). 2016 , 16, 12	28
716	Scavenger Receptors. 2016 , 727-740	1
715	Effect of Curcumin on Growth Factors and Their Receptors, Ion Channels, and Transporters in the Visceral Organs and the Brain. 2016 , 183-208	
714	Marine oils: Complex, confusing, confounded?. 2016 , 5, 3-10	10
713	Anti-osteoarthritic activity of Bungarus fasciatus venom fraction BF-F47 involving molecular markers in the rats. 2016 , 118, 43-6	3
712	Pharmacology of Ischemia-Reperfusion. Translational Research Considerations. 2016 , 29, 234-49	9
711	Biphasic activation of nuclear factor-kappa B in chondrocyte death induced by interleukin-1beta: The expression of inducible nitric oxide synthase and phagocyte-type NADPH oxidase through immediate and monocarboxylate transporter-1-mediated late-phase activation of nuclear factor-kappa B. 2016 , 58, 39-44	1
710	PPAR δ affects nitric oxide in human umbilical vein endothelial cells exposed to Porphyromonas gingivalis. 2016 , 68, 116-22	2
709	Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice. 2016 , 115, 85-93	11
708	Anti-Inflammatory Effects of Cajaninstilbene Acid and Its Derivatives. 2016 , 64, 2893-900	39
707	An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis. 2016 , 39, 1253-67	36
706	Quercetin metabolites inhibit MMP-2 expression in A549 lung cancer cells by PPAR δ -associated mechanisms. 2016 , 33, 45-53	33
705	PER1 prevents excessive innate immune response during endotoxin-induced liver injury through regulation of macrophage recruitment in mice. 2016 , 7, e2176	34
704	Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. 2016 , 310, G526-38	20

703	Effect of High Glucose Concentration on Human Preadipocytes and Their Response to Macrophage-Conditioned Medium. 2016 , 40, 411-418	8
702	Peroxisome Proliferator-activated Receptor- γ Activation Augments the β -Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β -Cell Death in Non-obese Diabetic Mice. 2016 , 291, 22524-22533	15
701	Berberine and Its Role in Chronic Disease. 2016 , 928, 27-45	106
700	Regulation of IFN- γ Expression. 2016 , 941, 1-19	24
699	Oral administration of Lentinus edodes β -glucans ameliorates DSS-induced ulcerative colitis in mice via MAPK-Elk-1 and MAPK-PPAR γ pathways. 2016 , 7, 4614-4627	42
698	Effects of ruminic acid rich conjugated linoleic acid supplementation on cognitive function and handgrip performance in older men and women. 2016 , 84, 1-11	4
697	MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation. 2016 , 20, 1898-907	42
696	SCISSOR-Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol. 2016 , 6, e010651	13
695	Parkinson Disease and Pioglitazone: Could Traumatic Brain Injury Catch a Lift?. 2016 , 95, 580-581	0
694	Lipid Mediators in Inflammation. 2016 , 4,	69
693	The Role of Selenoproteins in Resolution of Inflammation. 2016 , 499-510	4
692	Is Adequate Selenium Important for Healthy Human Pregnancy?. 2016 , 353-364	3
691	A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPAR γ Gene Expression in Experimental Autoimmune Encephalomyelitis. 2016 , 60, 498-508	5
690	Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. 2016 , 12, 594-604	150
689	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. 2016 , 39 Suppl 2, S244-52	134
688	Activation of PPAR γ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization. 2016 , 9, 61-76	77
687	DNMT1-PPAR γ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. 2016 , 6, 30053	64
686	Upregulation of MKP-7 in response to rosiglitazone treatment ameliorates lipopolysaccharide-induced destabilization of SIRT1 by inactivating JNK. 2016 , 114, 47-55	12

685	PPAR- α agonist pioglitazone regulates dendritic cells immunogenicity mediated by DC-SIGN via the MAPK and NF- κ B pathways. 2016 , 41, 24-34	10
684	Isoliquiritigenin Attenuates Adipose Tissue Inflammation in vitro and Adipose Tissue Fibrosis through Inhibition of Innate Immune Responses in Mice. 2016 , 6, 23097	56
683	N-(2-Bromo-4-fluorophenyl)-3-(3,4-dihydroxyphenyl)-acrylamide (CPAM), a small catecholic amide as an antioxidant, anti diabetic and antibacterial compound. 2016 , 6, 104632-104641	2
682	Statistical ensemble of gene regulatory networks of macrophage differentiation. 2016 , 17, 506	13
681	Peroxisome proliferator-activated receptor Pro12Ala polymorphism and the risks of gestational diabetes mellitus: An updated meta-analysis of 12 studies. 2016 , 95, e5090	2
680	PPAR δ s a therapeutic target to rescue mitochondrial function in neurological disease. 2016 , 100, 153-163	111
679	The role of endogenous opioid peptides in the antinociceptive effect of 15-deoxy(Δ 2,14)-prostaglandin J2 in the temporomandibular joint. 2016 , 110, 27-34	11
678	Modulation of the Tumor Metastatic Microenvironment and Multiple Signal Pathways by <i>Prunella vulgaris</i> in Human Hepatocellular Carcinoma. 2016 , 44, 835-49	15
677	Identifying Factors of Microparticles Modified with Arginine Derivatives That Induce Phenotypic Shifts in Macrophages. 2016 , 2, 946-953	3
676	MiR-146a modulates macrophage polarization by inhibiting Notch1 pathway in RAW264.7 macrophages. 2016 , 32, 46-54	80
675	PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling. 2016 , 95, 357-68	17
674	Mast cell activation disease and the modern epidemic of chronic inflammatory disease. 2016 , 174, 33-59	19
673	Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer. 2016 , 20, 843-58	22
672	An overview of early drug development for endometriosis. 2016 , 25, 227-47	6
671	Adipocyte Dysfunction, Inflammation, and Insulin Resistance in Obesity. 2016 , 61-80	
670	Icariside II protects against cerebral ischemia-reperfusion injury in rats via nuclear factor- κ B inhibition and peroxisome proliferator-activated receptor up-regulation. 2016 , 96, 56-61	35
669	Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection. 2016 , 34, 37-48	20
668	Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung. 2016 , 137, 833-43	42

667	Peroxisome proliferator-activated receptor gamma expression in peripheral monocytes from rheumatoid arthritis patients. 2016 , 38, 141-146	0
666	Macrophage Phenotype and Function in Different Stages of Atherosclerosis. 2016 , 118, 653-67	493
665	An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is Attenuated by Rosiglitazone Treatment. 2016 , 196, 2476-2491	105
664	Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. 2016 , 113, 2288-93	40
663	Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. 2016 , 34, 1-15	20
662	Circadian Clocks: Role in Health and Disease. 2016 ,	5
661	Cerebral Innate Immunity. 2016 , 361-386	
660	Therapeutic Potentials of Curcumin for Alzheimer Disease. 2016 ,	8
659	Hormetic and anti-inflammatory properties of oxidized phospholipids. 2016 , 49, 78-90	33
658	Celecoxib, a COX-2 inhibitor, synergistically potentiates the anti-inflammatory activity of docosahexaenoic acid in macrophage cell line. 2016 , 38, 153-61	6
657	Facile Construction of pH- and Redox-Responsive Micelles from a Biodegradable Poly(β -hydroxyl amine) for Drug Delivery. 2016 , 17, 291-300	76
656	Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by Rosiglitazone. 2016 , 196, 1044-59	55
655	Assessment of therapeutic options for reducing alkali burn-induced corneal neovascularization and inflammation. 2016 , 61, 101-12	19
654	Interaction between peroxisome proliferator-activated receptor gamma and smoking on cardiovascular disease. 2016 , 153, 28-32	6
653	Macrophage polarization: the link between inflammation and related diseases. 2016 , 65, 1-11	89
652	Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury. 2017 , 34, 414-422	32
651	Palmitoleic acid reduces the inflammation in LPS-stimulated macrophages by inhibition of NF κ B, independently of PPARs. 2017 , 44, 566-575	34
650	A Comparison of the Anti-Inflammatory Effects of Cis-9, Trans-11 Conjugated Linoleic Acid to Celecoxib in the Collagen-Induced Arthritis Model. 2017 , 52, 151-159	14

649	PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation. 2017 , 92, 2046-2069	48
648	A single-stranded DNA aptamer against mannose-capped lipoarabinomannan enhances anti-tuberculosis activity of macrophages through downregulation of lipid-sensing nuclear receptor peroxisome proliferator-activated receptor α expression. 2017 , 61, 92-102	14
647	Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?. 2017 , 153, 100-120	47
646	Interleukin-18-induced cell adhesion molecule expression is associated with feedback regulation by PPAR α and NF- κ B in Apo E $^{-/-}$ mice. 2017 , 428, 119-128	16
645	Targeting endothelial metaflammation to counteract diabetes cardiovascular risk: Current and perspective therapeutic options. 2017 , 120, 226-241	16
644	Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression. 2017 , 27, 2776-2780	7
643	Hesperetin derivative-14 alleviates inflammation by activating PPAR α in mice with CCl $_4$ -induced acute liver injury and LPS-treated RAW264.7 cells. 2017 , 274, 51-63	23
642	Role of Peroxisome Proliferator-Activated Receptors in Inflammation and Angiogenesis. 2017 , 417-456	
641	Hypertension-Causing Mutation in Peroxisome Proliferator-Activated Receptor α Impairs Nuclear Export of Nuclear Factor- κ B p65 in Vascular Smooth Muscle. 2017 , 70, 174-182	20
640	Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. 2017 , 355, 200-211	20
639	Hydrogen Sulfide Confers Lung Protection During Mechanical Ventilation via Cyclooxygenase 2, 15-deoxy Δ 2,14-Prostaglandin J $_2$, and Peroxisome Proliferator-Activated Receptor Gamma. 2017 , 45, e849-e857	6
638	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. 2017 , 169, 750-765.e17	29
637	Peroxisome proliferator-activated receptor- α agonists attenuate biofilm formation by. 2017 , 31, 3608-3621	17
636	Pathophysiology of Aortic Stenosis and Mitral Regurgitation. 2017 , 7, 799-818	12
635	Peroxisome proliferator-activated receptor α agonism attenuates endotoxaemia-induced muscle protein loss and lactate accumulation in rats. 2017 , 131, 1437-1447	11
634	Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain - a case control study. 2017 , 16, 112	16
633	Quantitative targeted metabolomics for 15d-deoxy- Δ 2, 14-PGJ $_2$ (15d-PGJ $_2$) by MALDI-MS. 2017 , 22, 100-106	2
632	Collagen Membrane and Immune Response in Guided Bone Regeneration: Recent Progress and Perspectives. 2017 , 23, 421-435	69

631	In vivo activation of invariant natural killer T cells induces systemic and local alterations in T-cell subsets prior to preterm birth. 2017 , 189, 211-225	29
630	Concurrent suppression of NF- κ B, p38 MAPK and reactive oxygen species formation underlies the effect of a novel compound isolated from Curcuma comosa Roxb. in LPS-activated microglia. 2017 , 69, 917-924	6
629	15-Deoxy- Δ^12 -Prostaglandin J Exerts Proresolving Effects Through Nuclear Factor E2-Related Factor 2-Induced Expression of CD36 and Heme Oxygenase-1. 2017 , 27, 1412-1431	19
628	PPAR α activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice. 2017 , 43, 53-61	31
627	The neuroprotective role of rosiglitazone in advanced glycation end product treated human neural stem cells is PPAR γ -dependent. 2017 , 92, 121-133	10
626	ERV1 Overexpression in Myeloid Cells Protects against High Fat Diet Induced Obesity and Glucose Intolerance. 2017 , 7, 12848	25
625	Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice. 2017 , 187, 2232-2245	31
624	Functional diversity of macrophages in vascular biology and disease. 2017 , 99, 13-22	10
623	Psoriasis. 2017 , 81-124	3
622	Propane-2-sulfonic acid octadec-9-enyl-amide, a novel PPAR δ dual agonist, protects against ischemia-induced brain damage in mice by inhibiting inflammatory responses. 2017 , 66, 289-301	25
621	Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis. 2017 , 49, 661-677	12
620	Sex-specific regulation of immune responses by PPARs. 2017 , 49, e364	41
619	Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters. 2017 , 27, 30-34	0
618	Evidence for a Role of Nerve Injury in Painful Intervertebral Disc Degeneration: A Cross-Sectional Proteomic Analysis of Human Cerebrospinal Fluid. 2017 , 18, 1253-1269	13
617	Gut microbiome, metabolome, and allergic diseases. 2017 , 66, 523-528	50
616	Effects of prostaglandin lipid mediators on agonist-induced lung endothelial permeability and inflammation. 2017 , 313, L710-L721	20
615	Cyclopentenone-containing oxidized phospholipids and their isoprostanes as pro-resolving mediators of inflammation. 2017 , 1862, 382-392	18
614	The contributions of lung macrophage and monocyte heterogeneity to influenza pathogenesis. 2017 , 95, 225-235	41

613	PPAR γ regulates inflammatory reaction by inhibiting the MAPK/NF- κ B pathway in C2C12 skeletal muscle cells. 2017 , 73, 49-57	24
612	Protective effects of bezafibrate against elaidic acid-induced accumulation of lipid droplets in monocytic cells. 2017 , 65, 20-30	3
611	Yixinshu ameliorates hippocampus abnormality induced by heart failure via the PPAR δ signaling pathway. 2017 , 7, 53415-53421	0
610	Possible role of PPAR α in the negative regulation of ovulatory cascade and luteal development in rats. 2017 , 79, 1043-1051	5
609	Lipid Mediators in Inflammation. 2017 , 343-366	1
608	Deficient Adipogenesis of Scleroderma Patient and Healthy African American Monocytes. 2017 , 8, 174	8
607	The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR- γ Agonist. 2017 , 15,	27
606	Prostaglandins, Leukotrienes, and Related Compounds. 2017 , 366-383.e3	1
605	Dietary and Microbial Metabolites in the Regulation of Host Immunity. 2017 , 8, 2171	67
604	Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. 2017 , 9, 129	108
603	PPAR and Its Role in Cardiovascular Diseases. 2017 , 2017, 6404638	47
602	PPAR Agonists for the Prevention and Treatment of Lung Cancer. 2017 , 2017, 8252796	33
601	Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients. 2017 , 2017, 5032708	5
600	15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury. 2017 , 12, e0176106	19
599	Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. 2017 , 16, 134	62
598	A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. 2018 , 24, 558-572	159
597	Visceral Adipose Tissue Immune Homeostasis Is Regulated by the Crosstalk between Adipocytes and Dendritic Cell Subsets. 2018 , 27, 588-601.e4	73
596	PPAR γ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF. 2018 , 6, 723-732	14

595	Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting inflammation and promoting autophagy via PPAR- δ -mediated NF- κ B and AMPK/mTOR signaling. 2018 , 59, 197-208	27
594	Apoptotic cells trigger the ABCA1/STAT6 pathway leading to PPAR- δ expression and activation in macrophages. 2018 , 103, 885-895	11
593	Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis. 2018 , 198, 350-360	35
592	Macrophages and lipid metabolism. 2018 , 330, 27-42	159
591	Dietary Curcumin Intervention Targets Mouse White Adipose Tissue Inflammation and Brown Adipose Tissue UCP1 Expression. 2018 , 26, 547-558	46
590	Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2 α . 2018 , 9, 559	95
589	Hematoma clearance as a therapeutic target in intracerebral hemorrhage: From macro to micro. 2018 , 38, 741-745	36
588	An Integrated View of Immunometabolism. 2018 , 172, 22-40	203
587	Gene Therapy. 2018 , 301-317	
586	Diverse roles of mitochondria in ischemic stroke. 2018 , 16, 263-275	165
585	Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor α . 2018 , 33, 524-532	32
584	Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. 2018 , 175, 113-124	30
583	Obesity-induced changes in lipid mediators persist after weight loss. 2018 , 42, 728-736	18
582	Milk lipid regulation at the maternal-offspring interface. 2018 , 81, 141-148	7
581	Peroxisome proliferator-activated receptor γ (PPAR γ): A master gatekeeper in CNS injury and repair. 2018 , 163-164, 27-58	99
580	Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. 2018 , 38, 121-132	150
579	Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An F-FDG-PET/CT in vivo imaging study. 2018 , 43, 733-740	8
578	A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. 2018 , 63, 22-29	48

577	Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis. 2018 , 38, 783-795	41
576	Neuroinflammation produced by heavy alcohol intake is due to loops of interactions between Toll-like 4 and TNF receptors, peroxisome proliferator-activated receptors and the central melanocortin system: A novel hypothesis and new therapeutic avenues. 2018 , 128, 401-407	18
575	The ex vivo toll-like receptor 7 tolerance induction in donor lymphocytes prevents murine acute graft-versus-host disease. 2018 , 20, 149-164	3
574	Murine models of sleep apnea: functional implications of altered macrophage polarity and epigenetic modifications in adipose and vascular tissues. 2018 , 84, 44-55	18
573	Gene Regulatory Network Modeling of Macrophage Differentiation Corroborates the Continuum Hypothesis of Polarization States. 2018 , 9, 1659	51
572	Effects of selected triorganotin compounds on transcriptional activity of vitamin D3 receptor and peroxisome proliferator-activated receptor gamma. 2018 , 37, 589-596	1
571	Chlorogenic Acid Functions as a Novel Agonist of PPAR2 during the Differentiation of Mouse 3T3-L1 Preadipocytes. 2018 , 2018, 8594767	15
570	Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. 2018 , 2, 209-215	52
569	Effects of Flavored Nonalcoholic Beverages on Transcriptional Activities of Nuclear and Steroid Hormone Receptors: Proof of Concept for Novel Reporter Cell Line PAZ-PPARg. 2018 , 66, 12066-12078	2
568	Epidermal Fatty Acid-Binding Protein: A Novel Marker in the Diagnosis of Dry Eye Disease in Sjögren Syndrome. 2018 , 19,	9
567	Anti-inflammatory and anti-oxidant mechanisms of an MMP-8 inhibitor in lipoteichoic acid-stimulated rat primary astrocytes: involvement of NF- κ B, Nrf2, and PPAR- β signaling pathways. 2018 , 15, 326	22
566	Metabolic regulation of infection and inflammation. 2018 , 112, 1-11	11
565	C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD). 2018 , 13, e0207371	18
564	Tumor suppressor RARRES1- A novel regulator of fatty acid metabolism in epithelial cells. 2018 , 13, e0208756	11
563	Structural/Functional Matches and Divergences of Phytoprostanes and Phytofurans with Bioactive Human Oxylipins. 2018 , 7,	20
562	Ethanol and unsaturated dietary fat induce unique patterns of hepatic β and β PUFA oxylipins in a mouse model of alcoholic liver disease. 2018 , 13, e0204119	14
561	Astaxanthin Inhibits Mitochondrial Dysfunction and Interleukin-8 Expression in β -Infected Gastric Epithelial Cells. 2018 , 10,	33
560	Modulators of inflammation in Bronchopulmonary Dysplasia. 2018 , 42, 459-470	46

559	The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond. 2018 , 9, 1093	16
558	Stereoselective Synthesis of the Isomers of Notoincisol A: Assignment of the Absolute Configuration of this Natural Product and Biological Evaluation. 2018 , 81, 2419-2428	0
557	Signaling Mechanisms of Selective PPAR Modulators in Alzheimer's Disease. 2018 , 2018, 2010675	34
556	Selenium and Inflammatory Mediators. 2018 , 137-156	2
555	Serum PPAR α level and PPAR γ gene polymorphism as well as severity and prognosis of brain injury in patients with arteriosclerotic cerebral infarction. 2018 , 16, 4058-4062	3
554	Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver. 2018 , 8, 15331	8
553	15d-PGJ-loaded nanocapsules ameliorate experimental gout arthritis by reducing pain and inflammation in a PPAR-gamma-sensitive manner in mice. 2018 , 8, 13979	29
552	Targeting Peroxisome Proliferator-Activated Receptor α to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. 2018 , 17, 2732-2745	18
551	Cannabidiol prevents haloperidol-induced vacuol chewing movements and inflammatory changes in mice via PPAR δ receptors. 2018 , 74, 241-251	34
550	Peroxisome proliferator-activated receptor α (PPAR α) induces the gene expression of integrin β to promote macrophage M2 polarization. 2018 , 293, 16572-16582	31
549	Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPAR α Agonist Treatment Approaches. 2018 , 19,	23
548	PPAR δ in innate and adaptive lung immunity. 2018 , 104, 737-741	22
547	Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPAR. 2018 , 2018, 6079101	16
546	Modulation of hyperglycemia and dyslipidemia in experimental type 2 diabetes by gallic acid and p-coumaric acid: The role of adipocytokines and PPAR α 2018 , 105, 1091-1097	45
545	Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer. 2018 , 37, 289-315	9
544	Beneficial Effects of the Peroxisome Proliferator-Activated Receptor β Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. 2018 , 188, 1608-1624	8
543	PPAR-gamma activation is associated with reduced liver ischemia-reperfusion injury and altered tissue-resident macrophages polarization in a mouse model. 2018 , 13, e0195212	26
542	PPAR δ is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis. 2018 , 14, e1007100	35

541	Emerging Principles of Gene Expression Programs and Their Regulation. 2018 , 71, 389-397	43
540	Peroxisome Proliferator-Activated Receptor γ Is Essential for the Resolution of Staphylococcus aureus Skin Infections. 2018 , 24, 261-270.e4	17
539	First comprehensive analysis of lysine acetylation in Alvinocaris longirostris from the deep-sea hydrothermal vents. 2018 , 19, 352	10
538	The Activin A-Peroxisome Proliferator-Activated Receptor Gamma Axis Contributes to the Transcriptome of GM-CSF-Conditioned Human Macrophages. 2018 , 9, 31	11
537	Peroxisome Proliferator-Activated Receptor- γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids. 2018 , 9, 893	64
536	PPAR γ is a nexus controlling alternative activation of macrophages via glutamine metabolism. 2018 , 32, 1035-1044	51
535	Role of Nutrition in Alcoholic Liver Disease: Summary of the Symposium at the ESBRA 2017 Congress. 2018 , 8,	10
534	PPAR γ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas. 2018 , 19,	15
533	Gastrointestinal Exposome for Food Functionality and Safety. 2018 , 409-437	
532	Z-ligustilide and anti-inflammatory prostaglandins have common biological properties in macrophages and leukocytes. 2018 , 15, 4	3
531	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPAR γ /PTEN/mTOR signaling pathway. 2018 , 18, 407	18
530	HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. 2018 , 60, 179-188	1
529	Role of GPx3 in PPAR γ -induced protection against COPD-associated oxidative stress. 2018 , 126, 350-357	15
528	The protective role of glutamine on enteropathy induced by high dose of soybean meal in turbot, <i>Scophthalmus maximus</i> L.. 2018 , 497, 510-519	26
527	Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction. 2018 , 8, 12321	50
526	The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. 2018 , 157, 122-133	38
525	Fucosterol Protects against Concanavalin A-Induced Acute Liver Injury: Focus on P38 MAPK/NF-B Pathway Activity. 2018 , 2018, 2824139	18
524	The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine. 2018 , 9, 782	61

523	Breed-specific differences in the immune response to lipopolysaccharide in ewes. 2018 , 96, 4220-4228	9
522	Handbook of Nutrition and Pregnancy. 2018 ,	4
521	A bile acid derivative with PPAR γ -mediated anti-inflammatory activity. 2018 , 137, 40-46	2
520	Interplay between the renin-angiotensin system, the canonical WNT/ β -catenin pathway and PPAR α in hypertension. 2018 , 20, 62	16
519	Role of Tocotrienols in Chemosensitization of Cancer. 2018 , 77-97	0
518	Deletion of PPAR γ in lung macrophages provides an immunoprotective response against M. tuberculosis infection in mice. 2018 , 111, 170-177	28
517	An in vitro test system for compounds that modulate human inflammatory macrophage polarization. 2018 , 833, 328-338	20
516	Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models. 2019 , 115, 419-431	42
515	Physical Exercise Affects Adipose Tissue Profile and Prevents Arterial Thrombosis in Val66Met Mice. 2019 , 8,	10
514	Vitamin D-vitamin D receptor axis suppresses pulmonary emphysema by maintaining alveolar macrophage homeostasis and function. 2019 , 45, 563-577	12
513	Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPAR α and SUR agonists. 2019 , 91, 103115	39
512	Transcriptome Analysis of Landrace Pig Subcutaneous Preadipocytes during Adipogenic Differentiation. 2019 , 10,	9
511	Suppressive role of PPAR γ in the IgE-dependent activation of mast cells. 2020 , 32, 143-150	1
510	Docosahexaenoic Acid Suppresses Silica-Induced Inflammasome Activation and IL-1 Cytokine Release by Interfering With Priming Signal. 2019 , 10, 2130	13
509	Metabolic Programming of Macrophages: Implications in the Pathogenesis of Granulomatous Disease. 2019 , 10, 2265	28
508	Emodin ameliorates metabolic and antioxidant capacity inhibited by dietary oxidized fish oil through PPARs and Nrf2-Keap1 signaling in Wuchang bream (<i>Megalobrama amblycephala</i>). 2019 , 94, 842-851	22
507	15-Deoxy- Δ -prostaglandin J ameliorates dextran sulfate sodium-induced colitis in mice through heme oxygenase-1 induction. 2019 , 677, 108183	3
506	Microbial Metabolites Determine Host Health and the Status of Some Diseases. 2019 , 20,	40

505	Impact of fatty acid binding protein 5-deficiency on COPD exacerbations and cigarette smoke-induced inflammatory response to bacterial infection. 2019 , 8, 7	9
504	15-Deoxy- Δ Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR- γ : Function and Mechanism. 2019 , 2019, 7242030	41
503	Molecular determinants for the polarization of macrophage and osteoclast. 2019 , 41, 551-563	28
502	An adenosine derivative (IFC-305) reduced the risk of radiation-induced intestinal toxicity in the treatment of colon cancer by suppressing the methylation of PPAR- α promoter. 2019 , 118, 109202	3
501	Crth2 receptor signaling down-regulates lipopolysaccharide-induced NF- κ B activation in murine macrophages changes in intracellular calcium. 2019 , 33, 12838-12852	5
500	Treatment of β -Infected Mice with Apoptotic Cells Attenuates Lyme Arthritis via PPAR- α 2019 , 202, 1798-1806	2
499	Symposium review: Immunological detection of the bovine conceptus during early pregnancy. 2019 , 102, 3766-3777	17
498	Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. 2019 , 20,	12
497	Effects of PPAR- α agonist, pioglitazone on brain tissues oxidative damage and learning and memory impairment in juvenile hypothyroid rats. 2019 , 129, 1024-1038	9
496	2,4-Thiazolidinedione in Well-Fed Lactating Dairy Goats: II. Response to Intra-Mammary Infection. 2019 , 6,	3
495	Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/ β -catenin pathway and PPAR- α 2019 , 133, 36-46	19
494	An Algal Metabolite-Based PPAR- α Agonist Displayed Anti-Inflammatory Effect via Inhibition of the NF- κ B Pathway. 2019 , 17,	5
493	Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ) Suppresses Inflammation and Bacterial Clearance during Influenza-Bacterial Super-Infection. 2019 , 11,	15
492	Molecular Mechanisms of Zinc as a Pro-Antioxidant Mediator: Clinical Therapeutic Implications. 2019 , 8,	56
491	Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPAR- α 2019 , 286, 30-39	9
490	Nuclear receptors, cholesterol homeostasis and the immune system. 2019 , 191, 105364	11
489	Rheinic acid ameliorates radiation-induced acute enteritis in rats through PPAR- γ /NF- κ B. 2019 , 41, 909-917	9
488	Transcriptional control of macrophage polarisation in type 2 diabetes. 2019 , 41, 515-529	12

487	Endothelial PPAR α s Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK. 2019 , 36, 583-601	19
486	Mycobacterium tuberculosis and macrophage nuclear receptors: What we do and don't know. 2019 , 116S, S98-S106	8
485	Macrophage nuclear receptors: Emerging key players in infectious diseases. 2019 , 15, e1007585	28
484	Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. 2019 , 9, 3574	13
483	The Molecular Mechanism of Transforming Growth Factor- β Signaling for Intestinal Fibrosis: A Mini-Review. 2019 , 10, 162	30
482	M2 Macrophages as a Potential Target for Antiatherosclerosis Treatment. 2019 , 2019, 6724903	53
481	Resveratrol attenuates the pathogenic and inflammatory properties of Porphyromonas gingivalis. 2019 , 34, 118-130	13
480	Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. 2019 , 23, 4063-4075	49
479	Oxylipid profiles of dairy cattle vary throughout the transition into early mammary gland involution. 2019 , 102, 2481-2491	5
478	Perivascular adipose tissue modulates carotid plaque formation induced by disturbed flow in mice. 2019 , 70, 927-936.e4	8
477	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. 2019 , 20,	8
476	Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. 2019 , 9, 19603	15
475	Composition and Potential Health Benefits of Pomegranate: A Review. 2019 , 25, 1817-1827	34
474	Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-biotics in Inflammatory Bowel Disease. 2019 , 10, 2754	64
473	Fighting Type-2 Diabetes: Present and Future Perspectives. 2019 , 26, 1891-1907	10
472	Transcriptomics analysis reveals candidate genes and pathways for susceptibility or resistance to Singapore grouper iridovirus in orange-spotted grouper (Epinephelus coioides). 2019 , 90, 70-79	10
471	Redox Biology of Peroxisome Proliferator-Activated Receptor- γ in Pulmonary Hypertension. 2019 , 31, 874-897	9
470	IRF5 Is Required for Bacterial Clearance in Human M1-Polarized Macrophages, and Immune-Mediated Disease Risk Variants Modulate This Outcome. 2019 , 202, 920-930	12

469	Coding Molecular Determinants of Thyroid Cancer Development and Progression. 2019 , 48, 37-59	12
468	(all-E)- and (5Z)-Lycopene Display Similar Biological Effects on Adipocytes. 2019 , 63, e1800788	21
467	Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR- δ agonists and anti-inflammatory COX-2 selective inhibitors. 2019 , 82, 86-99	49
466	Neuroprotective effects of MHY908, a PPAR- δ dual agonist, in a MPTP-induced Parkinson's disease model. 2019 , 1704, 47-58	12
465	Anti-inflammatory activity of rhein isolated from the flowers of <i>L.</i> and possible underlying mechanisms. 2019 , 26, 96-104	22
464	Panaxadiol saponins treatment caused the subtle variations in the global transcriptional state of Asiatic corn borer,. 2020 , 44, 123-134	1
463	Betulinic Acid-Azaprostanoid Hybrids: Synthesis and Pharmacological Evaluation as Anti-inflammatory Agents. 2020 , 19, 254-267	4
462	Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. 2020 , 22, 1-10	10
461	The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone. 2019 , 1-9	7
460	prebiotic potential of agricultural by-products on intestinal fermentation, gut barrier and inflammatory status of piglets. 2020 , 123, 293-307	13
459	Macrophage ontogeny in the control of adipose tissue biology. 2020 , 62, 1-8	10
458	Immunometabolic approaches to prevent, detect, and treat neonatal sepsis. 2020 , 87, 399-405	16
457	Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier. 2020 , 5, 1-11	3
456	Steroid receptor RNA activator affects the development of poststroke depression by regulating the peroxisome proliferator-activated receptor β signaling pathway. 2020 , 31, 48-56	0
455	Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. 2020 , 105,	18
454	<i>Clostridium butyricum</i> Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis. 2020 , 23, 100772	32
453	PPAR- β signalling as a key mediator of human hair follicle physiology and pathology. 2020 , 29, 312-321	11
452	Host inflammatory responses to intracellular invaders: Review study. 2020 , 240, 117084	9

451	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. 2019 , 9,	47
450	Matrix Metalloproteinase-12 Is Required for Granuloma Progression. 2020 , 11, 553949	5
449	The function of peroxisome proliferator-activated receptors PPAR- α and PPAR- γ in Mycobacterium leprae-induced foam cell formation in host macrophages. 2020 , 14, e0008850	7
448	Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. 2020 , 22, J3-J20	11
447	Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. 2020 , 53, 101-116	4
446	Lipid Metabolism in Regulation of Macrophage Functions. 2020 , 30, 979-989	39
445	Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J) for effective treatment and reduction in the death toll. 2020 , 143, 110080	2
444	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. 2020 , 9,	28
443	Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease. 2020 , 10,	11
442	Treatment of intracerebral hemorrhage: Current approaches and future directions. 2020 , 416, 117020	9
441	Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm. 2020 , 12,	6
440	Association study of rs1801282 PPARG gene polymorphism and immune cells and cytokine levels in a Spanish pregnant women cohort and their offspring. 2020 , 27, 101	0
439	LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC. 2020 , 18, 452	3
438	Redox Regulation of PPAR in Polarized Macrophages. 2020 , 2020, 8253831	5
437	Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity. 2020 , 9,	18
436	Mechanisms of action, chemical characteristics, and model systems of obesogens. 2020 , 2, 6	10
435	PPARs and Angiogenesis-Implications in Pathology. 2020 , 21,	17
434	Reciprocal interference between the NRF2 and LPS signaling pathways on the immune-metabolic phenotype of peritoneal macrophages. 2020 , 8, e00638	4

433	Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2. 2020 , 217,	23
432	ssRNA Virus and Host Lipid Rearrangements: Is There a Role for Lipid Droplets in SARS-CoV-2 Infection?. 2020 , 7, 578964	16
431	Temperate Propolis Has Anti-Inflammatory Effects and Is a Potent Inhibitor of Nitric Oxide Formation in Macrophages. 2020 , 10,	1
430	Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. 2020 , 11, 1842	14
429	Impaired mitochondrial function of alveolar macrophages in carbon nanotube-induced chronic pulmonary granulomatous disease. 2020 , 445, 152598	8
428	Differential Host Pro-Inflammatory Response to Mycobacterial Cell Wall Lipids Regulated by the Operon. 2020 , 11, 1848	2
427	A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol. 2020 , 34, 14083-14092	7
426	Impaired Neonatal Immunity and Infection Resistance Following Fetal Growth Restriction in Preterm Pigs. 2020 , 11, 1808	7
425	Protracted rosiglitazone treatment exacerbates inflammation in white adipose tissues of adipocyte-specific Nfe2l1 knockout mice. 2020 , 146, 111836	3
424	Pharmacological (or Synthetic) and Nutritional Agonists of PPAR- β s Candidates for Cytokine Storm Modulation in COVID-19 Disease. 2020 , 25,	63
423	In vitro and in vivo Antiallergic Effects of Taurine on Allergic Rhinitis. 2020 , 181, 404-416	3
422	Regulation of Tumor Immunity by Lysophosphatidic Acid. 2020 , 12,	14
421	Expression of Peroxisome Proliferator-activated Receptor- β in the Kidneys of Cats with Chronic Kidney Disease. 2020 , 176, 81-85	
420	Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. 2020 , 11, 730	27
419	Airway Remodeling in Asthma. 2020 , 7, 191	69
418	Effects of cannabis oil extract on immune response gene expression in human small airway epithelial cells (HSAEpC): implications for chronic obstructive pulmonary disease (COPD). 2020 , 2, 5	7
417	Extensive Changes in Transcriptomic "Fingerprints" and Immunological Cells in the Large Organs of Patients Dying of Acute Septic Shock and Multiple Organ Failure Caused by. 2020 , 10, 42	2
416	Mechanisms of Macrophage Polarization in Insulin Signaling and Sensitivity. 2020 , 11, 62	36

415	Dexmedetomidine preconditioning alleviated murine liver ischemia and reperfusion injury by promoting macrophage M2 activation via PPAR γ /STAT3 signaling. 2020 , 82, 106363	12
414	16HBE Cell Lipid Mediator Responses to Mono and Co-Infections with Respiratory Pathogens. 2020 , 10,	3
413	MicroRNA-155 Implication in M1 Polarization and the Impact in Inflammatory Diseases. 2020 , 11, 625	8
412	PPAR and Its Agonists in Chronic Kidney Disease. 2020 , 2020, 2917474	9
411	Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. 2020 , 16, 255-274	38
410	Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. 2020 , 143, 104994	8
409	FABP7 upregulation induces a neurotoxic phenotype in astrocytes. 2020 , 68, 2693-2704	7
408	Regulation of inflammation in diabetes: From genetics to epigenomics evidence. 2020 , 41, 101041	12
407	Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials. 2020 , 133, 444-451	3
406	Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. 2020 , 17, 30	43
405	Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPAR γ Ligands as a Potential Target in Breast Cancer. 2020 , 9,	20
404	Anti-inflammatory effects of an optimized PPAR γ agonist via NF- κ B pathway inhibition. 2020 , 96, 103611	6
403	Omega-3 Versus Omega-6 Polyunsaturated Fatty Acids in the Prevention and Treatment of Inflammatory Skin Diseases. 2020 , 21,	65
402	Prostaglandins as the Agents That Modulate the Course of Brain Disorders. 2020 , 10, 1-13	10
401	Unraveling the Hierarchy of and Factors That Determine the DNA Binding by Peroxisome Proliferator-Activated Receptor α 2020 , 40,	3
400	Poloxamer micellar system for intra-articular injection of 15-deoxy--prostaglandin J with improved bioavailability and anti-inflammatory properties in the temporomandibular joint of rats. 2020 , 583, 119383	4
399	l-Thyroxine and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR α 2020 , 63, 6727-6740	12
398	Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor α Activation Aggravates Murine Immune-Mediated Hepatitis. 2020 , 21,	2

397	Identification of Crucial Genetic Factors, Such as PPAR α that Regulate the Pathogenesis of Fatty Liver Disease in Dairy Cows Is Imperative for the Sustainable Development of Dairy Industry. 2020 , 10,	7
396	Cell-intrinsic metabolic regulation of mononuclear phagocyte activation: Findings from the tip of the iceberg. 2020 , 295, 54-67	20
395	NF- κ B signaling regulates the formation of proliferating Müller glia-derived progenitor cells in the avian retina. 2020 , 147,	15
394	An in-silico approach: identification of PPAR δ agonists from seaweeds for the management of Alzheimer's Disease. 2021 , 39, 2210-2229	5
393	The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI). 2021 , 218, 107684	7
392	Dexmedetomidine inhibits LPS-induced inflammatory responses through peroxisome proliferator-activated receptor gamma (PPAR γ) activation following binding to β 2 adrenoceptors. 2021 , 892, 173733	0
391	Pathological changes of frozen shoulder in rat model and the therapeutic effect of PPAR δ agonist. 2021 , 39, 891-901	2
390	Use of Nanotechnology to Improve 15d-PGJ2 Immunomodulatory Activities. 2021 , 503-518	1
389	Interdependence of Anti-Inflammatory and Antioxidant Properties of Squalene-Implication for Cardiovascular Health. 2021 , 11,	4
388	Effects of dried natto diet on the transcript levels of the peroxisome proliferator-activated receptor- α coactivator-1 β and -1 γ and nuclear receptor corepressor 1 genes in laying hens. 2021 , 92, e13522	
387	Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/ β -Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. 2021 , 10,	11
386	Epigenetic Regulation of Kupffer Cell Function in Health and Disease. 2020 , 11, 609618	5
385	Design of Novel PPAR Agonist for Neurodegenerative Disease. 2021 , 249-270	
384	PPAR γ /NF- κ B and TGF- β 1/Smad pathway are involved in the anti-fibrotic effects of levo-tetrahydropalmatine on liver fibrosis. 2021 , 25, 1645-1660	12
383	Thiazolidine Derivatives Attenuate Carrageenan-Induced Inflammatory Pain in Mice. 2021 , 15, 369-384	2
382	Protein Lipoxidation: Basic Concepts and Emerging Roles. 2021 , 10,	8
381	Convallatoxin Promotes M2 Macrophage Polarization to Attenuate Atherosclerosis Through PPAR α Integrin β 1 Signaling Pathway. 2021 , 15, 803-812	6
380	15-Deoxy- Δ^2 -Prostaglandin J Promotes Resolution of Experimentally Induced Colitis. 2021 , 12, 615803	2

379	Regulation of Intestinal Inflammation by Dietary Fats. 2020 , 11, 604989	9
378	Nuclear Receptors as Multiple Regulators of NLRP3 Inflammasome Function. 2021 , 12, 630569	11
377	A-family anti-inflammatory cyclopentenone prostaglandins: A novel class of non-statin inhibitors of HMG-CoA reductase. 2021 , 182, 37-50	0
376	Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways. 2021 , 185, 114433	9
375	A convenient approach to synthesize substituted 5-Arylidene-3-m-tolyl thiazolidine-2, 4-diones by using morpholine as a catalyst and its theoretical study. 2021 , 16, e0247619	
374	Chronic tissue inflammation and metabolic disease. 2021 , 35, 307-328	28
373	Peroxisome-Proliferator Activator Receptor β in Mouse Model with Meningoencephalitis Caused by <i>Angiostrongylus cantonensis</i> . 2021 , 107, 205-213	1
372	The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases. 2021 , 12, 664871	12
371	IL-17-induced inflammation modulates the mPGES-1/PPAR- β pathway in monocytes/macrophages. 2021 ,	4
370	PPAR β Prevents Neuropathic Pain by Down-Regulating CX3CR1 and Attenuating M1 Activation of Microglia in the Spinal Cord of Rats Using a Sciatic Chronic Constriction Injury Model. 2021 , 15, 620525	5
369	The Emerging Role of COX-2, 15-LOX and PPAR β in Metabolic Diseases and Cancer: An Introduction to Novel Multi-target Directed Ligands (MTDLs). 2021 , 28, 2260-2300	5
368	Lithium and Atypical Antipsychotics: The Possible WNT/ β Pathway Target in Glaucoma. 2021 , 9,	2
367	Maternal hypercholesterolemia exacerbates atherosclerosis lesions in female offspring through potentiating macrophage polarization toward an inflammatory M1 phenotype. 2021 , 90, 108575	0
366	Resident and elicited murine macrophages differ in expression of their glycomes and glycan-binding proteins. 2021 , 28, 567-582.e4	4
365	Pparg drives luminal differentiation and luminal tumor formation in the urothelium.	
364	Role of the Peroxisome Proliferator Activated Receptors in Hypertension. 2021 , 128, 1021-1039	8
363	The antidiabetic drug troglitazone protects against PrP (106-126)-induced neurotoxicity via the PPAR β autophagy pathway in neuronal cells. 2021 , 23,	2
362	Interplay of Opposing Effects of the WNT/ β -Catenin Pathway and PPAR β and Implications for SARS-CoV2 Treatment. 2021 , 12, 666693	14

361	Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?. 2021 , 12, 663203	4
360	Ursolic and Oleanolic Acids: Plant Metabolites with Neuroprotective Potential. 2021 , 22,	10
359	Cannabidiol and the Canonical WNT/ β -Catenin Pathway in Glaucoma. 2021 , 22,	3
358	Nuclear Hormone Receptor Medicinal Chemistry. 1-117	
357	Lithium: a potential therapeutic strategy in obsessive-compulsive disorder by targeting the canonical WNT/ β pathway. 2021 , 11, 204	1
356	Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/ β -catenin pathway. 2021 ,	2
355	Potential role of cannabidiol in Parkinson's disease by targeting the WNT/ β -catenin pathway, oxidative stress and inflammation. 2021 , 13, 10796-10813	3
354	Absence of TNF Leads to Alternative Activation in Peritoneal Macrophages in Experimental <i>Listeria Monocytogenes</i> Infection. 2021 , 1-18	1
353	The Glitazone Class of Drugs as Carbonic Anhydrase Inhibitors-A Spin-Off Discovery from Fragment Screening. 2021 , 26,	1
352	EPA's pleiotropic mechanisms of action: a narrative review. 2021 , 133, 651-664	5
351	Obesity and aging: Molecular mechanisms and therapeutic approaches. 2021 , 67, 101268	15
350	Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF- κ B and in a PPAR β -dependent manner. 2021 , 22, 743	1
349	Skin damage caused by scale loss modifies the intestine of chronically stressed gilthead sea bream (<i>Sparus aurata</i> , L.). 2021 , 118, 103989	2
348	Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury. 2021 , 101, 1210-1224	1
347	PPAR β Agonists: Emergent Therapy in Endometriosis. 2021 , 14,	1
346	Japanese Encephalitis Virus Infected Human Monocyte-Derived Dendritic Cells Activate a Transcriptional Network Leading to an Antiviral Inflammatory Response. 2021 , 12, 638694	3
345	Reassessment of Pioglitazone for Alzheimer's Disease. 2021 , 15, 666958	5
344	Aspirin using was associated with slower cognitive decline in patients with Alzheimer's disease. 2021 , 16, e0252969	2

343	Immunometabolic regulation of adipose tissue resident immune cells. 2021 , 58, 44-51	0
342	Triclosan affects the expression of nitric oxide synthases (NOSs), peroxisome proliferator-activated receptor gamma (PPAR γ), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) in mouse neocortical neurons in vitro. 2021 , 73, 105143	4
341	PPAR α agonists promote the resolution of myelofibrosis in preclinical models. 2021 , 131,	0
340	Aberrant Mitochondrial Dynamics: An Emerging Pathogenic Driver of Abdominal Aortic Aneurysm. 2021 , 2021, 6615400	2
339	Roles of Eicosanoids in Regulating Inflammation and Neutrophil Migration as an Innate Host Response to Bacterial Infections. 2021 , 89, e0009521	6
338	Cyclopentenone Prostaglandins: Biologically Active Lipid Mediators Targeting Inflammation. 2021 , 12, 640374	3
337	Bioactive Lipid Mediators in the Initiation and Resolution of Inflammation after Spinal Cord Injury. 2021 , 466, 273-297	6
336	Effects of fatty acid nitroalkanes on signal transduction pathways and airway macrophage activation. 2021 , 27, 353-364	1
335	Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. 2021 , 1	6
334	Effects of hydroalcoholic extract of <i>Berberis integerrima</i> on the clinical signs, hs-CRP, TNF α and ESR in active rheumatoid arthritis patients. 2021 , 28, 100444	0
333	PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPAR α /DNMT1 Interactions in the Genome. 2021 , 13,	1
332	Untargeted Metabolic Profiling of Extracellular Vesicles of SARS-CoV-2-Infected Patients Shows Presence of Potent Anti-Inflammatory Metabolites. 2021 , 22,	2
331	PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPAR α 2021 , 162,	4
330	Depicting the Effects of Astragaloside IV on AD-Like Phenotypes: A Systematic and Experimental Investigation. 2021 , 2021, 1020614	2
329	Xenoextracellular matrix-rosiglitazone complex-mediated immune evasion promotes xenogenic bioengineered root regeneration by altering M1/M2 macrophage polarization. 2021 , 276, 121066	2
328	Signal Transduction and Molecular Regulation in Fatty Liver Disease. 2021 , 35, 689-717	5
327	Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways. 2021 , 11, 2950-2965	1
326	Metabolic Hormones Modulate Macrophage Inflammatory Responses. 2021 , 13,	1

325	Ferulic acid: A review of its pharmacology, pharmacokinetics and derivatives. 2021 , 284, 119921	19
324	PPAR α receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. 2021 , 111, 110367	0
323	Nuclear receptors in liver fibrosis. 2021 , 1867, 166235	4
322	Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPAR α 2021 , 22,	6
321	Amorfrutins Relieve Neuropathic Pain through the PPAR/CCL2 Axis in CCI Rats. 2021 , 2021, 8894752	1
320	Nuclear Receptor Ligands in Flavivirus Infection Control. 2021 , 483-502	
319	Thiazolidinediones as PPAR Agonists.	1
318	Combination Therapy in Type 2 Diabetes.	2
317	NO Synthesis and NOS Regulation. 2003 , 119-154	2
316	Lipoproteins and Oxidation. 2006 , 17-48	3
315	Modulation of macrophage function and metabolism. 2005 , 665-95	5
314	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A β 2-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD). 2007 , 167-193	1
313	Polyunsaturated Fatty Acids and Prostate Cancer Metastasis. 2008 , 63-85	2
312	Lipid A-mediated tolerance and cancer therapy. 2010 , 667, 81-99	7
311	Soluble Epoxide Hydrolase as a Stroke Target. 2012 , 277-294	1
310	Endotoxin in Human Disease and its Endogenous Control. 2000 , 114-130	1
309	Selenium and Adverse Health Conditions of Human Pregnancy. 2011 , 531-544	2
308	Peroxisome Proliferator-Activated Receptors and Inflammation. 2013 , 221-233	1

307	The Role of PPAR γ in Stroke. 2014 , 301-320	2
306	Novel eicosanoid activators of PPAR gamma formed by RAW 264.7 macrophage cultures. 2002 , 507, 343-9	2
305	Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis. 2002 , 25-34	1
304	The Oxidative Modification Hypothesis of Atherogenesis. 2000 , 49-74	13
303	Oxidation-Sensitive Transcription and Gene Expression in Atherosclerosis. 2000 , 135-154	3
302	PPARs: nuclear receptors for fatty acids, eicosanoids, and xenobiotics. 1999 , 469, 231-6	23
301	Polarized Activation of Macrophages. 2014 , 37-57	2
300	Techniques used to study regulation of cyclooxygenase-2 promoter sites. 2010 , 644, 11-20	1
299	Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. 2003 , 60, 93-132	20
298	The involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer's disease. 2001 , 173-195	2
297	Overview of HO-1 in inflammatory pathologies. 1999 , 55-91	8
296	The Role of Carbon Monoxide as a Gasotransmitter in Cardiovascular and Metabolic Regulation. 2012 , 37-70	9
295	Nuclear Receptors as Regulators of Macrophage Homeostasis and Function. 2003 , 209-225	1
294	Transcription Factors That Regulate Macrophage Development and Function. 2003 , 11-40	3
293	Inhibition of pristane-induced peritoneal plasmacytoma formation. 1999 , 246, 351-61; discussion 361-2	2
292	PPARs and Atherosclerosis. 2000 , 88-95	1
291	What Is New About Eosinophil Activation in Asthma and Allergic Disease. 2009 , 95-107	1
290	Formation and Function of Lipid Droplets in Inflammation and Cancer. 2013 , 139-165	1

289	Tools to Interfere with NF- κ B Activation. 2003 , 199-219	1
288	Regulation of the Expression of Nitric Oxide Synthase Isoforms. 2000 , 105-128	15
287	Digestive System 2. 2000 , 432-544	5
286	Prostaglandins, Leukotrienes, and Related Compounds. 2009 , 343-356	1
285	Prostaglandins, Leukotrienes, and Related Compounds. 2013 , 340-357	3
284	PPAR γ -mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice. 2020 , 117, 104674	15
283	PPARadigms and PPARadoxes: expanding roles for PPAR γ in the control of lipid metabolism. 2002 , 43, 177-186	176
282	Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR γ 2000 , 41, 688-696	183
281	Ligand activation of peroxisome proliferator-activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.	5
280	UPR modulation of host immunity by <i>Pseudomonas aeruginosa</i> in cystic fibrosis. 2020 , 134, 1911-1934	5
279	Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy. 2020 , 34, 4283-4292	2
278	PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. 1999 , 33, 798-806	173
277	Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. 2000 , 35, 749-57	31
276	Chemokines and atherosclerosis. 1998 , 9, 397-405	113
275	Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. 1998 , 9, 425-32	86
274	Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. 2004 , 28, 139S-144S	16
273	Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells. 2007 , 28, 722-726	21
272	Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. 2008 , 30, 142-52	26

271	MicroRNA-511-3p mediated modulation of the peroxisome proliferator-activated receptor gamma (PPAR γ) controls LPS-induced inflammatory responses in human monocyte derived DCs.	1
270	NF- κ B signaling regulates the formation of proliferating Müller glia-derived progenitor cells in the avian retina.	2
269	Compromised neuroimmune status in rats with experimental colitis. 2003 , 548, 929-39	9
268	The Modulatory Effect of 15d-PGJ2 in Dendritic Cells. 2014 , 1,	2
267	Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. 1999 , 67, 3488-93	66
266	Expression of Peroxisome Proliferator-Activated Receptor- γ in Vascular Smooth Muscle Cells Is Upregulated in Cystic Medial Degeneration of Annuloaortic Ectasia in Marfan Syndrome. 2002 , 106,	1
265	PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. 2002 , 110, 923-932	237
264	Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. 2000 , 106, 523-31	687
263	Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache. 2000 , 106, 629-31	56
262	Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. 2001 , 108, 1667-75	85
261	Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. 2001 , 108, 15-23	201
260	PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. 2002 , 110, 923-32	145
259	PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. 2003 , 111, 1381-8	55
258	Biosynthesis of 15-deoxy-delta ^{12,14} -PGJ2 and the ligation of PPAR γ . 2003 , 112, 945-55	119
257	Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR α , β / δ , and γ . 2004 , 114, 1564-76	442
256	Obesity is associated with macrophage accumulation in adipose tissue. 2003 , 112, 1796-808	3535
255	Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. 2003 , 112, 1821-30	2477
254	Increased CD36 protein as a response to defective insulin signaling in macrophages. 2004 , 113, 764-73	159

253	PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. 2004 , 113, 846-55	365
252	PPAR δ receptor ligands: novel therapy for pituitary adenomas. 2003 , 111, 1381-1388	116
251	Biosynthesis of 15-deoxy- $\Delta^{12,14}$ -PGJ ₂ and the ligation of PPAR δ 2003 , 112, 945-955	281
250	PPAR δ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. 2004 , 113, 846-855	638
249	PPARs in atherosclerosis: the clot thickens. 2004 , 114, 1538-40	34
248	Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. 2006 , 116, 59-69	311
247	Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. 2007 , 117, 1658-69	380
246	DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. 2010 , 120, 756-67	153
245	Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. 1999 , 103, 1489-98	1256
244	A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. 1999 , 104, 383-9	602
243	15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. 2000 , 106, 189-97	311
242	Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization. 2020 , 11, 424	25
241	Differential effects of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ and a peroxisome proliferator-activated receptor δ agonist on macrophage activation. 2001 , 69, 631-638	7
240	The role of PPARs in inflammation and immunity. 2002 , 71, 388-400	63
239	Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor- δ counter-regulatory activity by IFN- γ 2002 , 71, 677-685	24
238	Polyunsaturated Fatty Acids and Regulation of Gene Expression. 2007 , 727-739	1
237	Anti-Oxidant Modulation in Immune Function. 2005 , 97-122	1
236	Activated and inactivated PPARs δ modulate experimentally induced colitis in rats. 2011 , 17, BR116-24	5

235	Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. 2003 , 26, 929-36	36
234	Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. 2008 , 3, e3950	57
233	Curcumin alleviates matrix metalloproteinase-3 and -9 activities during eradication of <i>Helicobacter pylori</i> infection in cultured cells and mice. 2011 , 6, e16306	55
232	Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. 2011 , 6, e19115	40
231	Dietary eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor- α 2011 , 6, e24031	32
230	15-Deoxy- Δ^14 -prostaglandin J ₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. 2011 , 6, e25541	6
229	PPAR α agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. 2012 , 7, e50500	40
228	The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. 2013 , 8, e54472	66
227	Predictive computational modeling of the mucosal immune responses during <i>Helicobacter pylori</i> infection. 2013 , 8, e73365	45
226	The novel PPAR β dual agonist MHY 966 modulates UVB-induced skin inflammation by inhibiting NF- κ B activity. 2013 , 8, e76820	25
225	Commensal <i>Streptococcus salivarius</i> Modulates PPAR γ Transcriptional Activity in Human Intestinal Epithelial Cells. 2015 , 10, e0125371	32
224	Non-Esterified Fatty Acids Profiling in Rheumatoid Arthritis: Associations with Clinical Features and Th1 Response. 2016 , 11, e0159573	26
223	Is spaceflight-induced immune dysfunction linked to systemic changes in metabolism?. 2017 , 12, e0174174	35
222	Coordinated balance of Rac1 and RhoA plays key roles in determining phagocytic appetite. 2017 , 12, e0174603	25
221	The peroxisome proliferator-activated receptor gamma (PPAR γ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness. 2020 , 15, e0242427	3
220	Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both. 2015 , 7, 613-9	0
219	Role of ceruloplasmin as a low grade chronic inflammatory marker and activated innate immune system in pathogenesis of diabetes mellitus. 2018 , 5, 148-153	0
218	Role of immunologic and inflammatory factors in the development of endometriosis: indications for treatment strategies. 2005 , 2, 623-639	1

217	Regulation of Proinflammatory Enzymes by Peroxisome Proliferator-Activated Receptor Gamma in Astroglia Infected with Toxoplasma gondii. 2020 , 106, 564-571	3
216	Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells. 1999 , 10, 943-52	52
215	Cyclopentenone prostaglandins inhibit cytokine-induced nf-kappab activation and chemokine production by human mesangial cells. 2001 , 12, 1659-1667	28
214	Telmisartan inhibits hyperalgesia and inflammatory progression in a diabetic neuropathic pain model of Wistar rats. 2015 , 20, 115-23	14
213	Peroxisome Proliferator Activated Receptors and The Metabolic Syndrome. 2009 , 1, 4	1
212	Asiatic acid protects against hepatic ischemia/reperfusion injury by inactivation of Kupffer cells via PPAR/NLRP3 inflammasome signaling pathway. 2017 , 8, 86339-86355	29
211	Critical role of PPAR in myeloid-derived suppressor cell-stimulated cancer cell proliferation and metastasis. 2016 , 7, 1529-43	29
210	Identification of the microRNA networks contributing to macrophage differentiation and function. 2016 , 7, 28806-20	9
209	The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. 2006 , 3, 31-8	10
208	New insights into acquired endocrine resistance of breast cancer. 2019 , 2, 198-209	19
207	Macrophage: A Key Therapeutic Target in Atherosclerosis?. 2019 , 25, 3165-3174	13
206	Peroxisome Proliferator-Activated Receptor Expression in Murine Models and Humans with Age-related Macular Degeneration. 2009 , 2, 141-148	30
205	Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor [(PPAR)] Agonists. 2011 , 4, 120-124	9
204	Curcumin inhibits APOE4-induced injury by activating peroxisome proliferator-activated receptor-[(PPAR)] in SH-SY5Y cells. 2020 , 23, 1576-1583	1
203	Anti-tumor effects of prostaglandin D2 and its metabolites, 15-deoxy-12, 14-PGJ2, by peroxisome proliferator-activated receptor (PPAR) dependent and -independent pathways.. 2011 , 31, 189-195	2
202	Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. 2008 , 13, 1813-26	293
201	Gastric peroxisome proliferator activator receptor-[(PPAR)] expression and cytoprotective actions of its ligands against ischemia-reperfusion injury in rats. 2011 , 48, 170-7	5
200	Pyridinecarboxylic Acid Derivative Stimulates Pro-Angiogenic Mediators by PI3K/AKT/mTOR and Inhibits Reactive Nitrogen and Oxygen Species and NF-B Activation Through a PPAR-Dependent Pathway in -Infected Macrophages. 2019 , 10, 2955	10

199	Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. 2009 , 15, 441-8	35
198	Effects of PPAR γ agonist pioglitazone on rat hepatic fibrosis. 2004 , 10, 1047-51	32
197	Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells. 2005 , 11, 4735-9	18
196	Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis. 2005 , 11, 6322-9	28
195	Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats. 2006 , 12, 6458-63	21
194	Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. 2007 , 13, 1983-8	19
193	(Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione protects rats from carbon tetrachloride-induced liver injury and fibrogenesis. 2012 , 18, 654-61	10
192	Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. 2016 , 22, 2533-44	39
191	15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. 2003 , 9, 2149-53	34
190	Synthesis of Novel Mannich Bases of Pioglitazone. 2013 , 6, 10-15	1
189	Sclerochorioretinal abnormalities in hypercholesterolemic rabbits treated with rosiglitazone. 2010 , 41, 562-71	3
188	Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma. 2018 , 26, 539-545	7
187	Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. 2017 , 12, 1256-1261	23
186	The effect of β -adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. 2011 , 49, 545-54	10
185	Insulin sensitizers and atherosclerosis. 2002 , 9, 276-9	5
184	Macrophage PPAR γ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. 2016 , 5,	25
183	Ciglitazone-a human PPAR γ agonist-disrupts dorsoventral patterning in zebrafish. 2019 , 7, e8054	6
182	Brain-derived neurotrophic factor and nitric oxide contribute to protective effects of rosiglitazone on learning and memory in hypothyroid rats. 2021 , 81, 218-232	0

- 181 The Role of PPAR- γ in Allergic Disease. **2021**, 21, 45 2
- 180 Pparg signaling controls bladder cancer subtype and immune exclusion. **2021**, 12, 6160 1
- 179 A role for peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists in counteracting the degeneration of cardiovascular grafts. **2021**, 2
- 178 The M2a Macrophage Phenotype Accompanies Pulmonary Granuloma Resolution in Knock-Out Mice Instilled with Multiwall Carbon Nanotubes. **2021**, 22, 2
- 177 Necrotizing Enterocolitis: LPS/TLR4-Induced Crosstalk Between Canonical TGF- β /Wnt/ β -Catenin Pathways and PPAR γ **2021**, 9, 713344 2
- 176 PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions. **2021**, 22, 0
- 175 Expression of cyclooxygenase-2 and prostaglandins by B-1 cells and B-CLL cells. **2000**, 252, 293-300 2
- 174 Glukose. **2001**, 605-805
- 173 Does Cyclooxygenase-2 Down-Regulate Gastric Inflammation?. **2001**, 86-89
- 172 Peroxisome Proliferator-Activated Receptors. **2001**, 363-388
- 171 Structures and Functions of the Nuclear Receptor Family, PPAR. **2001**, 1, 1049-1056,1046
- 170 Role of PPAR- γ in the Growth and Differentiation of Gastric and Colorectal Cancers. **2001**, 128-131
- 169 Nutrition and Adipocyte Gene Expression. **2001**, 25-48
- 168 Inflammatory Mechanisms in Alzheimer's Disease: β -Amyloid-Stimulated Proinflammatory Responses are Blocked by PPAR γ Agonists. **2002**, 163-168
- 167 Peroxisome Proliferator-Activated Receptors (PPARs).
- 166 Analysis of tissue-specific and PPAR γ -dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method. **2002**, 165-172
- 165 Peroxisome Proliferator Activator Receptor Gamma Agonists Inhibit the Development of Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Male Mice. **2002**, 143-148
- 164 Functions of PPAR Gamma in Macrophages and Atherosclerosis. **2002**, 9-16

- 163 PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall?. **2002**, 17-24
- 162 Fatty Acid Modulation of Atherosclerosis by Peroxisome Proliferator- Activated Receptors. **2002**, 7, 454-460
- 161 Multi-site therapeutic modalities for inflammatory bowel diseases [mechanisms of action. **2003**, 523-551
- 160 Negative Regulation of the Basophil Activation by Natural Ligands for Peroxisome Proliferator-Activated Receptors. **2003**, 369-374
- 159 Peroxisome Proliferator-Activated Receptor α and Hepatic Stellate Cell Activation. **2003**, 179-188 1
- 158 Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart. **2003**, 337-348
- 157 Thiazolidinediones in Cardiovascular Risk in Type 2 Diabetes Mellitus. **2003**, 193-203
- 156 Retinoids. **2003**, 316-348
- 155 Arachidonic Acid Metabolites. **2003**, 419-450
- 154 Treatment of Vulnerable Plaques. **2004**, 164-202
- 153 NASH. **2006**, 1031-1063 1
- 152 Type 1 and 2 Diabetes. **2006**, 305-319
- 151 Regulating the Master Regulator NF- κ B. **2006**, 195-221
- 150 Thiazolidinediones. **2007**, 135-157
- 149 Pioglitazone Modulates Plasma MMP-9 and TIMP-1 Activities in Spontaneously Hypertensive Hyperlipidemic Rats Fed a High-fat Diet Plus Sucrose Solution. **2008**, 20, 187-197
- 148 Nuclear Receptors in the Control of Lipid Metabolism. **2008**, 96-122
- 147 PPARs in Atherosclerosis. 401
- 146 Asthma and Allergic Diseases. **2009**, 709-728

- 145 Anti Allergic Effects of Lipophilic Dietary Flavones. **2009**, 9, 337-344
- 144 The Link Between Inflammation and Thrombosis. **2010**, 39-61
- 143 Insulin as Modulator of Adipose Inflammation. **2009**, 99-114
- 142 Hypoxia/Ischemia Signaling. **2010**, 529-542
- 141 The Impact of Redox State on Regulation of the High-Affinity IgE Receptor Expression. **2010**, 259-264
- 140 Selenium. **2010**, 411-448
- 139 Endogenous prostaglandin D₂ synthesis inhibits e-selectin generation in human umbilical vein endothelial cells. **2011**, 03, 304-311
- 138 The Effects of Highexpression and Knockdown Adipophilin in The Activity of ERK1/2 and Expression of PPAR γ and Lipid Accumulation in Cells*. **2012**, 38, 1132-1144
- 137 Dectin-1 Receptor Family. **2012**, 725-747
- 136 Inflammatory Diseases. **2012**, 495-525
- 135 Tocotrienols, Inflammation, and Cancer. **2012**, 209-224
- 134 Encyclopedia of Inflammatory Diseases. **2013**, 1-24
- 133 Differential Mechanisms of the Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonists on Bleomycin-Induced Lung Fibrosis. **2013**, 03, 31-38
- 132 Contribution of Dietary Fat in Neuroinflammation. **2014**, 75-109
- 131 Biological Impact of Type I Interferon Induction Pathways beyond Their Antivirus Activity. 155-175
- 130 Lipid metabolism. **1998**, 9, 503-5
- 129 Typ-2-Diabetes mellitus und genetische Defekte der β -Zell-Funktion. **1999**, 169-268
- 128 Lipids. 417-431

- 127 Protection by Glutamine After Ischemia/Reperfusion Injury. **2015**, 461-474
- 126 How Noncoding RNAs Contribute to Macrophage Polarization. **2015**, 59-84 1
- 125 [Mitochondrial dysfunction and compensatory mechanisms in liver cells during acute carbon tetrachloride-induced rat intoxication]. **2015**, 61, 731-6 1
- 124 Circadian Rhythms and the Circadian Clock in the Cardiovascular System. **2016**, 199-224
- 123 Compendium of Inflammatory Diseases. **2016**, 994-1016
- 122 Pharmacological Macrophage Attenuation by Imatinib Reverts Hepatic Steatosis and Inflammation in Obese Mice.
- 121 Postpartum Depression and the Role of Nutritional Factors. **2018**, 357-383 1
- 120 C/VDdb: a multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD).
- 119 Functional Foods for Treatment and Prevention of Obesity and Its Associated Disorders. **2019**, 93-124 0
- 118 Effects of Peroxisome Proliferator-Activated Receptor Ligand and Brown Seaweed Based Compound on Megakaryocyte. **2019**, 5, 1-7
- 117 Anti-NAFLD Effect of Djulis Hull and Its Major Compound, Rutin, in Mice with High-Fat Diet (HFD)-Induced Obesity. **2021**, 10, 0
- 116 Indomethacin, a non-steroidal anti-inflammatory drug, induces skin dryness via PPAR α in mice. **2021**, 1 1
- 115 Chapter 4:Nutritional Regulation of Inflammation in Obesity and Diabetes. **2020**, 71-93
- 114 PPAR α Agonists in Combination Cancer Therapies. **2020**, 20, 197-215 3
- 113 Resident and elicited macrophages differ in expression of their glycomes and lectins.
- 112 Phillyrin Prevents Neuroinflammation-Induced Blood-Brain Barrier Damage Following Traumatic Brain Injury Altering Microglial Polarization. **2021**, 12, 719823 5
- 111 PPAR- γ Ligands and Diabetic Nephropathy. **2006**, 289-304
- 110 Physiologic and Neurotoxic Properties of A β Peptides. **2007**, 179-197

109	Restoration of Immunocompetence in Aging and Other Inflammatory Disease States by Dehydroepiandrosterone-3βSulfate, an Activator of the Peroxisome Proliferator-Activated Receptor Alpha (PPARα)	
108	Heart failure, diabetes and the thiazolidinediones: an unfolding story. 2005 , 2, 159-161	
107	Antioxidant therapies for the management of atrial fibrillation. 2012 , 2, 298-307	17
106	Expression of peroxisome proliferator-activated receptor γ in rat retina during development. 2015 , 8, 52-6	1
105	Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. 2000 , 350 Pt 3, 829-37	9
104	Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease. 2001 , 86, 255-8	8
103	The possible role of peroxisome proliferator-activated receptor gamma in heart failure. 2004 , 9, 169-73	2
102	Thiazolidinediones and bone. 2007 , 4, 103-7	6
101	Peroxisome proliferator activated receptor-γ and traumatic brain injury. 2010 , 3, 283-92	21
100	An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model. 2013 , 19, 2135-50	21
99	The Role of Immunogenicity in Cardiovascular Disease. 2011 , 3, 1-29	10
98	Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis. 2015 , 8, 4332-43	4
97	Mannose prevents acute lung injury through mannose receptor pathway and contributes to regulate PPARα and TGF-β1 level. 2015 , 8, 6214-24	7
96	Effect of peroxisome proliferator-activated receptor β on inflammatory markers. 2015 , 11, 261-2	1
95	Effect of Pioglitazone on Perihematoma Edema in Intracerebral Hemorrhage Mouse Model by Regulating NLRP3 Expression and Energy Metabolism. 2020 , 63, 689-697	
94	CD226 knockout alleviates high-fat diet induced obesity by suppressing proinflammatory macrophage phenotype. 2021 , 19, 477	3
93	Robust temporal map of human in vitro myelopoiesis using single-cell genomics.	0
92	Inflammation and JNK's Role in Niacin-GPR109A Diminished Flushed Effect in Microglial and Neuronal Cells With Relevance to Schizophrenia.. 2021 , 12, 771144	1

91	Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment-From Mice to Men.. 2022 , 10,	1
90	The PPAR- β agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute <i>Pseudomonas aeruginosa</i> pneumonia.. 2022 , 207, 370-377	1
89	Effect of Pioglitazone on Perihematoma Edema in Intracerebral Hemorrhage Mouse Model by Regulating NLRP3 Expression and Energy Metabolism. 2020 , 63, 689-697	2
88	Osteoarthritis improvement effect of var. extract in relation to genotype.. 2022 ,	
87	Peroxisome Proliferator-Activated Receptor-Gamma Reduces ER Stress and Inflammation via Targeting NGBR Expression.. 2021 , 12, 817784	1
86	Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ Attenuates HO-Induced IL-6 Expression in Rat Brain Astrocytes.. 2022 , 40, 154	0
85	Functional Foods for Treatment and Prevention of Obesity and Its Associated Disorders. 2022 , 1100-1124	
84	MicroRNA-511-3p Mediated Modulation of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR γ) Controls LPS-Induced Inflammatory Responses in Human Monocyte Derived DCs. 2022 , 2, 104-117	
83	Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.. 2022 , 132,	2
82	Identification of Potential Candidate Genes From Co-Expression Module Analysis During Preadipocyte Differentiation in Landrace Pig.. 2021 , 12, 753725	0
81	Advancing the Adverse Outcome Pathway for PPAR β Inactivation Leading to Pulmonary Fibrosis Using Bradford-Hill Consideration and the Comparative Toxicogenomics Database.. 2022 ,	1
80	Omeprazole prevents stress induced gastric ulcer by direct inhibition of MMP-2/TIMP-3 interactions.. 2022 ,	2
79	Differentiation of human macrophages with anaphylatoxin C3a impairs alternative M2 polarization and decreases LPS-induced cytokine secretion.. 2022 ,	
78	Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.. 2022 , 20, 75	0
77	Recent advances in molecular genetics of cardiovascular disorders. Implications for atherosclerosis and diseases of cellular lipid metabolism. 1998 , 4, 152-60	2
76	Analysis of tissue-specific and PPAR α -dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method. 2002 , 239, 165-72	7
75	Adipose tissue. 2022 , 209-228	
74	Development of a new approach for the synthesis of (+)-15-deoxy- $\Delta^2,14$ -prostaglandin J2 methyl ester based on the [2+2]-cycloadduct of 5-trimethylsilylcyclopentadiene and dichloroketene. 2022 , 46, 6708-6714	

73	PPAR α Agonist Attenuates Vocal Fold Fibrosis in Rats via Regulation of Macrophage Activation.. 2022,	0
72	Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders.. 2022, 13, 865772	0
71	Cannabidiol and SARS-CoV-2 Infection.. 2022, 13, 870787	1
70	Fenofibrate Increases the Population of Non-Classical Monocytes in Asymptomatic Chagas Disease Patients and Modulates Inflammatory Cytokines in PBMC.. 2021, 11, 785166	0
69	Isoform-specific functions of PPAR β in gene regulation and metabolism.. 2022,	2
68	Epigenetics of Cutaneous T-Cell Lymphomas.. 2022, 23,	0
67	Activities and Molecular Mechanisms of Diterpenes, Diterpenoids, and Their Derivatives in Rheumatoid Arthritis.. 2022, 2022, 4787643	1
66	Protective effects of recombinant lactoferrin with different iron saturations on enteritis injury in young mice.. 2022,	2
65	Immunometabolic crosstalk during bacterial infection.. 2022, 7, 497-507	4
64	Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome.. 2022, 2022, 7137900	0
63	Synthesis and Structure-activity Relationship Study of 2,4-dioxothiazolidin-5-ylidene Derivatives for 15-hydroxyprostaglandin Dehydrogenase Inhibitory Activity, Prostaglandin E2 Release, and Wound Healing Effect. 2021, 26, 933-955	0
62	Parsing the Role of PPARs in Macrophage Processes.. 2021, 12, 783780	4
61	Deconstructing Adipose Tissue Heterogeneity One Cell at a Time.. 2022, 13, 847291	1
60	Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions.. 2022, 1	0
59	Macrophage programming is regulated by a cooperative interaction between fatty acid binding protein 5 and peroxisome proliferator-activated receptor α 2022, 36, e22300	0
58	Data_Sheet_1.pdf. 2020,	
57	Data_Sheet_1.docx. 2018,	
56	Table_1.PDF. 2018,	

55 Table_2.PDF. **2018**,

54 Data_Sheet_1.PDF. **2019**,

53 Image_1.TIF. **2019**,

52 Image_2.TIF. **2019**,

51 Table_1.docx. **2020**,

50 Data_Sheet_1.pdf. **2020**,

49 Data_Sheet_1.CSV. **2018**,

48 Data_Sheet_3.ZIP. **2018**,

47 Data_Sheet_4.ZIP. **2018**,

46 Table_1.xlsx. **2018**,

45 Lysosomal acid lipase: Roles in rare deficiency diseases, myeloid cell biology, innate immunity, and common neutral lipid diseases. **2022**, 639-673

44 New 1,2,3-Triazole-Tethered Thiazolidinedione Derivatives: Synthesis, Bioevaluation and Molecular Docking Study. 1-27

43 2,2',4,4'-Tetrabromodiphenyl Ether (PBDE 47) Selectively Stimulates Proatherogenic PPAR α Signatures in Human THP-1 Macrophages to Contribute to Foam Cell Formation.. **2022**,

42 Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. **2022**, 116084

41 Robust temporal map of human in vitro myelopoiesis using single-cell genomics. **2022**, 13,

1

40 The SUMO components in rheumatoid arthritis.

39 Nrf2 driven macrophage responses in diverse pathophysiological contexts: Disparate pieces from a shared molecular puzzle.

0

38 Allicin attenuated hepatic ischemia/reperfusion injury in mice by regulating PPAR α /RAK-M-TLR4 signal pathway.

1

- 37 Consumption of oils and anthocyanins may positively modulate PPAR- α expression in chronic non-communicable diseases: a systematic review. **2022**,
- 36 The Effect of PPARs on Macrophage Polarization and Progression on Parasite-Related Diseases. **2022**, 12, 6282-6290
- 35 Supplementation of Regular Diet With Medium-Chain Triglycerides for Procognitive Effects: A Narrative Review. 9, 2
- 34 Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs. **2022**, 30, 1153-1166 0
- 33 Regulation of PPAR- α activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease. **2022**, 14, 1365-1381
- 32 Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer. **2022**, 11, 2432 2
- 31 Does Childhood Obesity Trigger Neuroinflammation?. **2022**, 10, 1953 2
- 30 The relevance of selenium to viral disease with special reference to SARS-CoV-2 and COVID-19. 1-23 2
- 29 Maresin 1 enhances osteogenic potential of mesenchymal stem cells by modulating macrophage peroxisome proliferator-activated receptor- β mediated inflammation resolution. **2022**, 141, 213116 0
- 28 Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones. **2022**, 65, 101598 1
- 27 Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer. **2022**, 222, 562-572 2
- 26 The Role of Transcription Factor PPAR- γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells. **2022**, 23, 9708 1
- 25 SILAC-based quantitative proteomics to investigate the eicosanoid associated inflammatory response in activated macrophages. **2022**, 19, 0
- 24 [Therapeutic and preventive effects of apigenin in cerebral ischemia: a review. 0
- 23 Acetylation of PPAR- γ in macrophages promotes visceral fat degeneration in obesity. 0
- 22 Biosynthesis of prostaglandin 15dPGJ2 -glutathione and -cysteine conjugates in macrophages and mast cells via MGST3. **2022**, 100310 0
- 21 Innate Immune Memory in Monocytes and Macrophages: The Potential Therapeutic Strategies for Atherosclerosis. **2022**, 11, 4072 0
- 20 Natural compounds targeting nuclear receptors for effective cancer therapy. 3

- 19 Therapeutic modulation of JAK-STAT, mTOR, and PPAR- δ signaling in neurological dysfunctions. 0
- 18 Differential expression of nuclear hormone receptors by dendritic cell subsets in human vaginal mucosa and skin. 13, 0
- 17 Negative Regulation by Phosphatidylinositol 3-Kinase of Inducible Nitric Oxide Synthase Expression in Macrophages. **1999**, 162, 6184-6190 25
- 16 Negative Regulation by Protein Tyrosine Phosphatase of IFN- γ -Dependent Expression of Inducible Nitric Oxide Synthase. **1999**, 162, 6776-6783 4
- 15 Induction of Cyclooxygenase-2 on Activated T Lymphocytes: Regulation of T Cell Activation by Cyclooxygenase-2 Inhibitors. **1999**, 163, 111-119 27
- 14 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂ Inhibits the α_2 Integrin-Dependent Oxidative Burst: Involvement of a Mechanism Distinct from Peroxisome Proliferator-Activated Receptor α Ligand. **1999**, 163, 6187-6192 10
- 13 Dietary n-3 and n-6 polyunsaturated fatty acids differentially modulate the adiponectin and leptin mediated major signaling pathways in visceral and subcutaneous white adipose tissue in high fat diet induced obesity. **2022**, 0
- 12 Impact of PPAR-gamma activation on the durability of biological heart valve prostheses in hypercholesterolaemic rats. **2022**, 63, 0
- 11 The therapeutic role of microbial metabolites in human health and diseases. **2023**, 1-38 0
- 10 Physiological and pathophysiological roles of inositols. **2023**, 9-29 0
- 9 Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease. **2023**, 24, 2345 0
- 8 Inhibition of α_1 cR or IL17a Reduces T-Cell and Neutrophil Infiltration after Ischemia/Reperfusion Injury in Mouse Liver. **2023**, 12, 1751 0
- 7 CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPAR α Receptor. **2023**, 16, 593 0
- 6 PPAR- δ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. **2023**, 245, 108391 0
- 5 Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: a post-hoc study of the CONFIDENCE trial. 0
- 4 Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases. **2023**, 12, 650 0
- 3 The Antioxidant Properties of Lavandula multifida Extract Contribute to Its Beneficial Effects in High-Fat Diet-Induced Obesity in Mice. **2023**, 12, 832 0
- 2 Metabolic, structure-activity characteristics of conjugated linolenic acids and their mediated health benefits. 1-15 0

- 1 Antiobesity Effect of *Lacticaseibacillus paracasei* LM-141 on High-Fat Diet-Induced Rats through Alleviation of Inflammation and Insulin Resistance. **2023**, 2023, 1-14

o